triamcinolone acetonide profile

Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6436
CHEMBL ID	1504
CHEBI ID	71418
SCHEMBL ID	4689
MeSH ID	M0021897

Synonym
MLS002207192
AC-1239
MLS001148264
AB00383012-11
gtpl2867
aristogel
nsc-21916
wln: t f5 e5 b666 go io rv ahtttt&j a1 bf cq e1 fv1q h1 h1
triaceton
volon a 40
nsc21916
kenalone
pregna-1,20-dione, 9-fluoro-11.beta.,21-dihydroxy-16.alpha.,17-(isopropylidenedioxy)-
omcilon a
aristocort acetonide
solodelf
coupe-a
triamcincolone acetonide
9.alpha.-fluoro-11.beta.,4-pregnadiene,3,20-dione
pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
volon a
flutone
triamcinolone 16,17-acetonide
triam-injekt
pregna-1,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11.beta.,16.alpha.)-
adcortyl a
pregna-1,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone
tricinolon
aristoderm
9.alpha.-fluoro-16.alpha.-17.alpha.-isopropylidenedioxy-.delta.-1-hydrocortisone
9.alpha.-fluoro-16-hydroxyprednisolone acetonide
rineton
tramacin
(4as,4br,5s,6as,6bs,9ar,10as,10bs)-4b-fluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
vetalog
kenacort-a
9-alpha-fluoro-16-alpha-hydroxyprednisolone 16-alpha,17-alpha-acetonide
tricort-40
kenalog in orabase
triacet
triatex
kenalog-10
pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
triamsinolone acetonide
9-alpha-fluoro-11-beta,21-dihydroxy-16-alpha-isopropylidenedioxy-1,4-pregnadiene,3,20-dione
oracort
kenalog-40
kenalog-h
aristocort a
acetospan
flutex
nasacort hfa
triamcinolone acetonide [jan]
pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
9-alpha-fluoro-16-hydroxyprednisolone acetonide
trymex
pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
azmacort
ccris 5231
nasacort
nsc 21916
panolog ointment (veterinary)
triacort
vetalog (veterinary)
einecs 200-948-7
tri-nasal
triamcinolone acetonide in absorbase
9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
9-alpha-fluoro-11-beta,21-dihydroxy-16-alpha,17-alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
triderm
kenalog 40
9alpha-fluoro-16-hydroxyprednisolone acetonide
nasacort aq
9-alpha-fluoro-16-alpha-17-alpha-isopropyledenedioxyprednisolone
9alpha-fluoro-16alpha-17alpha-isopropyledenedioxyprednisolone
9-alpha-fluoro-16-alpha-17-alpha-isopropylidenedioxy-delta-1-hydrocortisone
brn 0060069
oralone
76-25-5
triamcinolone acetonide
C08183
NCGC00023193-04
azmacort (tn)
triamcinolone acetonide (jp17/usp)
nasacort (tn)
D00983
kenalog (tn)
MLS000028538 ,
smr000058335
acetonide, triamcinolone
9alpha-fluoro-11beta,21-dihydroxy-16alpha,17-isopropylidenedioxy-1,4-pregnadiene-3,20-dione
CHEMBL1504
fx006
chebi:71418 ,
BRD-K53790871-001-08-6
extracort
ftorocort
NCGC00023193-05
HMS3259A20
tri-adcortyl
NCGC00256560-01
dtxsid6021371 ,
dtxcid201371
tox21_303014
cas-76-25-5
NCGC00259344-01
tox21_201795
tox21_110885
HMS2232F22
zilretta
trianex
5-19-06-00568 (beilstein handbook reference)
asmacort [common misspelling of azmacort]
nasacort allergy 24 hour
triamcinolone acetonide [usp:inn:ban:jan]
triesence
trivaris
allernaze
unii-f446c597ka
f446c597ka ,
triamcinolone acetonide [who-dd]
triamcinolone acetonide [green book]
triamcinolone acetonide [mart.]
triamcinolone acetonide [mi]
fluocinolone acetonide impurity h
triamcinolone acetonide component of mytrex f
volonimat
triamcinolone acetonide [usp-rs]
triamcinolone hexacetonide impurity a [ep impurity]
triamcinolone acetonide [orange book]
xipere
triamcinolone acetonide component of mytrex a
cls1001
ledercort cream
triamcinolone acetonide [vandf]
cls-1001
triamcinolone acetonide component of mycolog
mykacet component triamcinolone acetonide
triamcinolone acetonide component of mykacet
triamcinolone acetonide [ep monograph]
mytrex a component triamcinolone acetonide
mytrex f component triamcinolone acetonide
triamcinolone acetonide [usp monograph]
mycolog component triamcinolone acetonide
AKOS015894871
9alpha-fluoro-11beta,21-dihydroxy-16alpha,17-isopropylidenedioxy-1,4-pregnadiene,3,20-dione
9alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
(4as,4br,5s,6as,6bs,9ar,10as,10bs)-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
9alpha-fluoro-16alpha-17alpha-isopropylidenedioxy-delta-1-hydrocortisone
9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione-16,17-acetonide
9alpha-fluoro-16alpha-hydroxyprednisolone 16alpha,17alpha-acetonide
HY-B0636
NC00591
SCHEMBL4689
NCGC00023193-06
tox21_110885_1
KS-5330
YNDXUCZADRHECN-JNQJZLCISA-N
Q-201855
AB00383012_12
OPERA_ID_232
triamcinolone (acetonide) ,
triamcinolone acetonide, united states pharmacopeia (usp) reference standard
triamcinolone acetonide, pharmaceutical secondary standard; certified reference material
triamcinolone acetonide, european pharmacopoeia (ep) reference standard
triamcinolone acetonide, analytical standard
triamcinolone acetonide for system suitability, european pharmacopoeia (ep) reference standard
1ta ,
(4as,4br,5s,6as,6bs,9ar,10as,10bs)-4b-fluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h,8h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
gppe ear oint
remiderm
pevaryl t.c.
audicort
silderm
aureocort
nystadermal
adcortyl in orabase
bdbm50248362
remotic
gppe ear dps cap
dimethyl2-(3-nitro-2-pyridyl)malonate
S1628
Q2211240
triamcinolone-acetonide
CCG-269068
kenalone, solodelf
A856341
triamcinolone acetonide; 76-25-5; azmacort; aristogel; nasacort;
triamcinolone acetonide 100 microg/ml in methanol
HY-B0636R
triamcinolone acetonide (standard)
CS-0695000
dg health nasal allergy
sila iii
medalone cream
foster and thrive 24 hour nasal allergy
triloan ii suik
(4as,4br,5s,6as,6bs,9ar,10as,10bs)-4b-fluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho(2',1':4,5)indeno(1,2-d)(1,3)dioxol-2-one
leader nasal allergy
triamcinolone acetonide ointment
triamcinolone acetonide cream .1%
nasal allergy
trivix lite
nasal allergy 24 hour
triamcinolone acetonide (usp:inn:ban:jan)
trianex 0.05%
up and up nasal allergy
triasil
good neighbor pharmacy 24 hour nasal allergy
good sense nasal allergy
pro-c-dure 5 kit
protherix
basic care nasal allergy
pediaderm ta
triamcinolone acetonide suspension
equaline nasal allergy
0.015% triamcinolone acetonide
health mart 24 hour nasal allergy
triamcinolone acetonide (usp monograph)
triamcinolone acetonide (mart.)
tritocin
topcare nasal allergy
triamcinolone acetonide nasal
kirkland signature aller cort
genesis topical spray
signature care nasal allergy
kenalog-80
triamcinolone acetonide (usp-rs)
triamcinolone acetonide ointment usp, 0.05%
vetalog parenteral
oramedy
readysharp triamcinolone
asmacort (common misspelling of azmacort)
24 hour nasal allergy
triamcinolone acetonide (ep monograph)
equate nasal allergy
nasacort allergy 24hr
triloan suik
pro-c-dure 6 kit
triamcinolone acetonide cream

Excerpt	Reference	Relevance
"Triamcinolone acetonide is a synthetic glucocorticoid used to treat numerous acute and chronic inflammatory conditions. "	( Dermal Discoloration Secondary to Triamcinolone Acetonide Injection Observed in Patients with Autoimmune Disorders. Madrigal, GJ; Wenz, JA; Wright, JA, 2021)	2.34
"Triamcinolone acetonide (TAA) is a corticosteroid used for treating AR."	( Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Efficacy Analysis of a Phase III Study Performed in Russia. Ilina, NI; Karaulov, AV; Lucio, L; Maslakov, A; Shartanova, N, )	2.3
"Triamcinolone acetonide is a glucocorticosteroid used in standard clinical practice for its anti-inflammatory properties. "	( Enigma of Intramuscular Triamcinolone Acetonide (Kenalog Maibach, H; Shahinfar, S, 2023)	2.66
"Triamcinolone acetonide (TA) is an effective drug widely (off-label) used in the treatment of several ocular diseases involving inflammation and angiogenic processes. "	( Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications. Benoit, JP; Formica, ML; Luna, JD; Palma, SD; Tártara, LI; Ullio Gamboa, GV, 2020)	3.44
"Triamcinolone acetonide (TA) is a therapeutic agent for DME, but since the detailed mechanism of action of TA is not known, part of its action was examined."	( Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells. Hara, H; Imai, S; Naito, A; Otsuka, T; Shimazawa, M, 2017)	2.62
"Triamcinolone acetonide (TA) is an alternative option for diabetic macular edema thanks to its cost-benefit ratio and unique delivery route. "	( Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: Retrospective comparative Analysis of an interventional case series. Byon, IS; Choi, BS; Lee, JE; Pak, KY; Park, SW, 2017)	2.12
"Triamcinolone acetonide is a slowly dissolving crystalline corticosteroid that is often used for this purpose because of its prolonged anti-inflammatory effect."	( A Common Procedure With an Uncommon Pathology: Triamcinolone Acetonide Eyelid Injection. Hatton, MP; Jakobiec, FA; Wolkow, N, )	1.11
"Triamcinolone acetonide (TAA) is a classical corticosteroid that reduces synovitis and alleviates pain, albeit transiently."	( Intra-articular injection of triamcinolone acetonide releasing biomaterial microspheres inhibits pain and inflammation in an acute arthritis model. Creemers, L; Eijkelkamp, N; Emans, P; Mihov, G; Rudnik-Jansen, I; Schrijver, K; Tellegen, A; Thies, J; Tryfonidou, M; Versteeg, S; Woike, N, 2019)	1.53
"Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and perennial AR (PAR) in different countries worldwide."	( Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial. Chernikova, M; Karaulov, AV; Nenasheva, N; Ovchinnikov, A; Vylegzhanina, T, 2019)	2.68
"Triamcinolone acetonide (TAA) is an effective and the most commonly used corticosteroid hormone for the treatment of hypertrophic scars (HSs). "	( Transdermal permeability of triamcinolone acetonide lipid nanoparticles. Ban, J; Chen, D; Chen, F; Qin, Z; Tan, Y; Wang, Y, 2019)	2.25
"Triamcinolone acetonide (TA) is a glucocorticoid (GC) widely used in sports medicine. "	( Additional studies on triamcinolone acetonide use and misuse in sports: Elimination profile after intranasal and high-dose intramuscular administrations. Alechaga, É; Coll, S; Matabosch, X; Monfort, N; Pérez-Mañá, C; Ventura, R, 2019)	2.27
"Triamcinolone acetonide (Kenacort) is a corticosteroid that can be administrated by subconjunctival injection, with an extended release for up to three months. "	( [Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases]. Bleriot, A; Couret, C; Le Meur, G; Lebranchu, P; Weber, M, 2014)	1.85
"Triamcinolone acetonide (TA) is a potent, intermediate-acting, steroid that has anti-inflammatory and anti-angiogenic activity. "	( Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Kambhampati, SP; Kannan, RM; Lutty, GA; Mastorakos, P; Mishra, MK; Oh, Y, 2015)	2.13
"Triamcinolone acetonide (TA) is a corticosteroid drug currently administered by intravitreal injection for a broad spectrum of inflammatory, edematous and angiogenic ocular diseases. "	( Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Araújo, J; Egea, MA; Garcia, ML; Nikolic, S; Souto, EB, 2011)	2.09
"Triamcinolone acetonide (TA) is a steroidal drug that has been widely administered intravitreally for retinal and choroidal conditions. "	( Drug safety evaluation of intravitreal triamcinolone acetonide. Di Giulio, A; Lanzetta, P; Sarao, V; Veritti, D, 2012)	2.09
"Triamcinolone acetonide (TA) is a corticosteroid that is used in the systemic and topical treatment of many inflammatory diseases. "	( Transdermal delivery system of triamcinolone acetonide from a gel using phonophoresis. Kim, DK; Kim, TY; Shin, SC; Yang, JH; Yun, MY, 2006)	2.06
"Triamcinolone acetonide appeared to be an as valuable therapy in minimizing inflammation after cataract surgery as steroid drops on days 7, 14 and 21 postoperatively, a significantly lower intraocular pressure was recorded in the group of patients administered a single injection of triamcinolone acetonide."	( [Triamcinolone acetonide in the treatment of inflammation after cataract surgery]. Iveković, R; Lacmanović Loncar, V; Mandić, Z; Musulin, T; Novak-Laus, K; Petric, I; Vatavuk, Z, 2006)	2.69
"Triamcinolone acetonide mouthrinse is an appropriate treatment for erosive OLP, in view of the high efficacy and low risk of fungal over-infection."	( Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. Blanco-Carrión, A; Diniz-Freitas, M; Gándara-Rey, J; Gándara-Vila, P; García-García, A; González-García, A, 2006)	3.22
"Triamcinolone acetonide (TCA) is a corticosteroid that is frequently used in the treatment of asthma. "	( Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. Barth, J; Derendorf, H; Erdmann, M; Galia, E; Hochhaus, G; Mollmann, H; Rohatagi, S; Sourgens, H, 1995)	1.99
"Triamcinolone acetonide is a synthetic glucocorticoid which has been formulated as both an aerosol and an aqueous metered-dose pump spray for nasal inhalation in the treatment of allergic rhinitis. "	( Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Faulds, D; Jeal, W, 1997)	3.18
"Triamcinolone acetonide is a glucocorticoid administered by oral inhalation in the management of asthma. "	( A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. Argenti, D; Heald, D; Shah, B, 1999)	1.98
"Triamcinolone acetonide (TACA) is a corticosteroid; it is used in the systemic and topical treatment of a variety of inflammatory conditions, including eczema and psoriasis. "	( The influence of hydrocolloid patch composition on the bioavailability of triamcinolone acetonide in humans. Brown, MB; Hollingsbee, DA; Ladenheim, D; Marriott, C; Martin, GP, 2000)	1.98
"Triamcinolone acetonide (TAA) is an anti-inflammatory steroid used for topical treatment of allergic rhinitis and asthma. "	( Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. Berridge, MS; Heald, DL; Lee, Z, 2000)	2
"Triamcinolone acetonide (TAA) is an effective and safe corticosteroid that is marketed as a metered-dose inhaler (MDI) with an integrated spacer (Azmacort) for the treatment of asthma."	( In vitro and in vivo techniques used in drug development for evaluation of dose delivery of inhaled corticosteroids. Banerji, DD; Chaikin, P; Deluccia, F; Gillen, MS; Rhodes, GR; Rohatagi, S, 2001)	1.03

Excerpt	Reference	Relevance
"Triamcinolone acetonide (TAC) has a potent teratogenic effect on various mammalian fetal tissues as well as a steroid effect on the lung. "	( Effect of triamcinolone acetonide on the development of the pulmonary airways in the fetal rat. Massoud, EA; Rotschild, A; Sekhon, HS; Solimano, A; Thurlbeck, WM, 1997)	2.14
"Triamcinolone acetonide (TA) has been shown to improve morphological and functional outcome in diabetic macular edema (DME) patients. "	( Effect of triamcinolone acetonide on retinal inflammation and angiogenesis induced by pericyte depletion in mouse. Arakawa, R; Masuda, T; Naito, A; Okabe, T; Otsuka, T; Suzuki, A; Takahashi, Y; Uemura, A, 2023)	2.76
"Triamcinolone acetonide has been used for ITS treatment in various clinical settings."	( Intratympanic Triamcinolone Acetonide as a Salvage Treatment for Idiopathic Sudden Sensorineural Hearing Loss. Andrianakis, A; Graupp, M; Holzmeister, C; Kiss, P; Moser, U; Tomazic, PV; Wolf, A, 2021)	1.7
"Triamcinolone acetonide (TAA) has been reformulated as an hydrofluoroalkane (HFA) aerosol for intranasal use in patients with seasonal allergic rhinitis (SAR). "	( Therapeutic equivalence of triamcinolone acetonide hydrofluoroalkane and chlorofluorocarbon nasal inhalers in patients with seasonal allergic rhinitis. Newman, KB; Schenkel, E, )	1.87
"Triamcinolone acetonide (TA) has been proposed as an adjuvant to pars plana vitrectomy with silicone oil for the surgical treatment of proliferative vitreoretinopathy and proliferative diabetic retinopathy. "	( The distribution, release kinetics, and biocompatibility of triamcinolone injected and dispersed in silicone oil. Bartz-Schmidt, KU; Heimann, H; Jaissle, GB; Kaczmarek, RT; Petermeier, K; Spitzer, MS; Szurman, P; Wong, D; Yoeruek, E, 2009)	1.8
"Triamcinolone acetonide has no inhibitory effect on macrophage infiltration or ICAM-1, Thy-1, or VEGF expression in CNV membranes in the early term. "	( Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Adam, A; Bartz-Schmidt, KU; Boeyden, V; Claes, C; Eckardt, C; Eckert, T; Grisanti, S; Kaiserling, E; Pertile, G; Scharioth, GB; Shinoda, K; Szurman, P; Tatar, O; Yoeruek, E, 2009)	2.08
"Triamcinolone acetonide (TA) has applications for the treatment of a large range of intraocular vascular diseases. "	( Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion. Cringle, SJ; McAllister, IL; McMenamin, PG; Mendis, KR; Morgan, WH; Vijayasekaran, S; Yu, DY, 2011)	2.18
"Triamcinolone acetonide (TA) has recently been used to treat diabetic macular edema (DME) but its effectiveness is limited."	( Pars plana vitrectomy with removal of posterior hyaloid face in treatment of refractory diabetic macular edema resistant to triamcinolone acetonide. Higuchi, A; Jo, N; Matsumura, M; Ogata, N; Wada, M, )	1.78
"Triamcinolone acetonide has been effectively used in ocular therapeutics for over 50 years. "	( Triamcinolone acetonide in ocular therapeutics. Dellacroce, JT; Heffez, J; Jermak, CM; Peyman, GA, )	3.02
"Triamcinolone acetonide (TAC) has a potent teratogenic effect on various mammalian fetal tissues as well as a steroid effect on the lung. "	( Effect of triamcinolone acetonide on the development of the pulmonary airways in the fetal rat. Massoud, EA; Rotschild, A; Sekhon, HS; Solimano, A; Thurlbeck, WM, 1997)	2.14

Excerpt	Reference	Relevance
"Triamcinolone acetonide induced increase in intraocular pressure may not be markedly associated with the dosage used."	( Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Derse, M; Jonas, JB; Papoulis, C; Schmitz-Valckenberg, P; Spandau, UH, 2005)	1.33
"The triamcinolone acetonide-induced increase in [125I]EGF binding capacity was dose-dependent between 10(-9) and 10(-6)M, and maximal binding was observed at 10(-6)M."	( Effect of glucocorticoid on epidermal growth factor receptor in human salivary gland adenocarcinoma cell line HSG. Kurokawa, R; Kyakumoto, S; Ota, M, 1990)	0.76

Excerpt	Reference	Relevance
"Triamcinolone acetonide treatment decreased steroid 5 alpha-reductase activity by 95% and also decreased the activities of steroid 3 alpha- and 3 beta-reductases by more than 90%."	( The effect of budesonide and triamcinolone acetonide on hepatic microsomal testosterone metabolism in the rat. Davies, DS; Edwards, RJ; Freeling, AB; Watson, D, 1992)	1.3
"Treatment with triamcinolone acetonide delivered by Med-Jet MBX is a safe, minimally painful and effective treatment for nail psoriasis."	( Treatment of nail psoriasis with intralesional triamcinolone acetonide using a needle-free jet injector: a prospective trial. Benohanian, A; Marcil, I; Nantel-Battista, M; Richer, V, )	0.74
"Treatment with triamcinolone acetonide is associated with increased tooth movement in rabbits via increased resorptive activity in the alveolar bone."	( Effect of corticosteroids on orthodontic tooth movement in a rabbit model. Abtahi, M; Giddon, D; Peel, S; Saghravania, N; Shafaee, H; Sohrabi, K, 2014)	0.76
"Treatment with triamcinolone acetonide was associated with a significantly greater increase in fasting serum glucose levels than other preparations (p = 0.006)."	( Effect of intranasal steroids on glucose and hemoglobin A1c levels in diabetic patients. Bachar, G; Hadar, T; Mizrachi, A; Vinker, S; Yaniv, E, )	0.47

Excerpt	Reference	Relevance
" Generally, after application of triamcinolone-acetonide fetal livers accumulated more lipids as toxic response to this glucocorticoid than the maternal organ; the degree of lipid accumulation was clearly dose-dependent in the fetuses."	( Analysis of hepatotoxicity in maternal and fetal rats after glucocorticoid administration by lipid histochemistry and thin layer chromatography. Frank, HG; Gossrau, R; Graf, R, 1989)	0.28
" The LD50 values of THS-201 both in mice and rats were estimated more than 5000 mg/kg at each route, and these are for above larger than those of TA or MPA."	( [Study on toxicity of halopredone acetate. (I) Acute toxicity study in mice and rats]. Ichinohe, M; Kaga, M; Okazaki, S; Shinpo, K; Sudo, J; Takeuchi, M; Tanabe, T; Tsuga, T, 1985)	0.27
" Mild-to-moderate adverse reactions (sore throat, hoarseness) were reported by six patients during the six-week phase and by ten patients during the 12-month phase."	( Efficacy and safety of triamcinolone acetonide aerosol in chronic asthma. Results of a multicenter, short-term controlled and long-term open study. Bernstein, IL; Chervinsky, P; Falliers, CJ, 1982)	0.57
" Aerosolized triamcinolone acetonide was therefore considered a safe and effective modality in the management of chronic asthma."	( Efficacy and safety of aerosolized triamcinolone acetonide in steroid-dependent and steroid-independent chronic asthmatic patients. Olivier, N, 1982)	0.91
" Among patients who reported adverse clinical experiences, most were considered unrelated or remotely related to therapy."	( Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis. Bronsky, E; Findlay, S; Pearlman, DS; Southern, DL; Storms, WW; Weakley, S; Welch, MJ, )	0.45
" There were no differences between the two treatment groups in the incidence of adverse events."	( Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Feiss, G; Furst, JA; LaForce, C; Munk, ZM; Simpson, B; Smith, JA, 1996)	0.6
" Adverse events were generally mild or moderate and consistent with long-term use and winter symptoms."	( Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Beaucher, WN; Feiss, G; Furst, JA; Kobayashi, RH; Koepke, JW; Ransom, JH; Rosen, JP; Simpson, B; Smith, JA, )	0.41
" Our findings indicate that TAA-HFA is a safe and effective replacement for the currently marketed CFC-containing product."	( Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. Banerji, D; Chervinsky, P; Jacobson, K; Kane, RE; Noonan, M; Uryniak, T, 1999)	0.54
" Seven patients discontinued because of adverse events and two because of ineffective asthma control."	( Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. Azmacort HFA Study Group. Banerji, D; Kane, RE; Nelson, HS; Petillo, J, 2000)	0.55
" In the intent-to-treat population (n = 92), there was no difference between treatment groups in the incidence of overall adverse events."	( Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Bousquet, J; Klossek, JM; Laliberté, F; Laliberté, MF; Mounedji, N, 2001)	0.61
" Adverse events, from mild to vision-threatening or life-threatening, were recorded as procedure-related or corticosteroid-related."	( Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Billson, FA; Chua, W; Gillies, MC; Hunyor, AB; Luo, W; Mitchell, P; Penfold, P; Simpson, JM; Zhu, M, 2004)	0.32
" There were no moderate or severe adverse events related to the surgical procedure in either group."	( Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Billson, FA; Chua, W; Gillies, MC; Hunyor, AB; Luo, W; Mitchell, P; Penfold, P; Simpson, JM; Zhu, M, 2004)	0.32
"Despite a significant adverse event profile, intravitreal triamcinolone is generally well tolerated by the human eye as long as patients are carefully followed up by their surgeon and treated appropriately, when necessary."	( Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Billson, FA; Chua, W; Gillies, MC; Hunyor, AB; Luo, W; Mitchell, P; Penfold, P; Simpson, JM; Zhu, M, 2004)	0.32
"The main outcome measures were improvement of best-corrected logarithm of the minimum angle of resolution visual acuity by 5 or more letters and incidence of moderate or severe adverse events."	( Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Gillies, MC; Simpson, JM; Sutter, FK, 2004)	0.32
"In the short term, intravitreal triamcinolone is an effective and relatively safe treatment for eyes with diabetic macular edema that have failed laser treatment."	( Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Gillies, MC; Simpson, JM; Sutter, FK, 2004)	0.32
" Adverse events were uncommon, with no difference between groups."	( Cost-effectiveness and safety of epidural steroids in the management of sciatica. Arden, N; Coglan, L; Price, C; Rogers, P, 2005)	0.33
"Triamcinolone acetonide is toxic to proliferating cells of retinal origin in vitro at doses normally used in clinical practice."	( Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Kenney, MC; Kuppermann, BD; Mungcal, JK; Narayanan, R; Seigel, GM, 2006)	2.16
"Intravitreal triamcinolone acetonide (TA) has been widely used as a therapeutic method for many ocular diseases, but a consensus on an appropriate safe therapeutic window of dosage for intravitreal injection, and whether vehicle of TA should be reduced or eliminated, has not yet been reached."	( Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Kai, W; Xiaoxin, L; Yanrong, J, 2006)	1.09
"To evaluate whether Triamcinolone acetonide (TA)-assisted pars plana vitrectomy for visualisation of posterior hyaloid during macular hole surgery has any adverse effects on macular hole closure rate and intraocular pressure (IOP)."	( Safety of Triamcinolone acetonide (TA)-assisted pars plana vitrectomy in macular hole surgery. Cheema, R; Gorman, C; Kampougeris, G; McPherson, R, 2007)	1.07
"Case series comparing outcomes and adverse effects in patients who had surgery for macular holes with ILM peel, with and without the use of TA-assisted vitrectomy."	( Safety of Triamcinolone acetonide (TA)-assisted pars plana vitrectomy in macular hole surgery. Cheema, R; Gorman, C; Kampougeris, G; McPherson, R, 2007)	0.74
"TA is safe and there is no contraindication for its use as an intraoperative aid to facilitate vitreous visualisation in macular hole surgery."	( Safety of Triamcinolone acetonide (TA)-assisted pars plana vitrectomy in macular hole surgery. Cheema, R; Gorman, C; Kampougeris, G; McPherson, R, 2007)	0.74
"Benzyl alcohol at concentrations modestly higher than what is present in commercial Kenalog is toxic to the rabbit eye."	( Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Bessho, K; Cheng, L; Davidson, MC; Freeman, WR; Koh, HJ; Morrison, VL, 2006)	0.33
" While non-adherent TA, if purified, appears to be safe in clinically used concentrations, direct physical contact with crystalline particles might cause a local, rapid-progressive cytotoxicity that involves the induction of the apoptotic cascade."	( Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Aisenbrey, S; Bartz-Schmidt, KU; Decker, P; Grisanti, S; Henke-Fahle, S; Jaissle, GB; Kaczmarek, R; Spitzer, MS; Szurman, P, 2006)	0.33
" After the treatment, each treatment modality was evaluated by the response rate, relapse rate, and side effect profile."	( A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Aiba, S; Kawamura, M; Kurosawa, M; Mizuashi, M; Nakagawa, S; Saito, M; Sasaki, Y, 2006)	0.33
" However, injections of 4 mg, 8 mg, and 20 mg of TA produced outer retina toxic effects."	( Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. D'Amico, DJ; Damico, FM; Viola, F; Young, LH; Yu, SY, )	0.41
" Patients recorded any adverse events (AEs) on daily diary cards."	( Safety and clinical relief over 1 year with triamcinolone acetonide hydrofluoroalkane-134a nasal aerosol in patients with perennial allergic rhinitis. Banerji, D; Faruqi, R; Garcia, J; Georges, G; Weber, R, )	0.39
" Because 1/10 -vTA appeared to be safe for up to 30 minutes of exposure, use of 1/10 dilutions of vehicle-removed TA is suggested to help surgeons visualize prolapsed vitreous during anterior vitrectomy in complicated cataract surgeries."	( Triamcinolone acetonide suspension toxicity to corneal endothelial cells. Chang, YS; Chen, MF; Tseng, SH; Tseng, SY; Wu, CL, 2006)	1.78
" Electroretinography tracings were normal, indicating no widespread toxic effect."	( Evaluation of the toxicity of subretinal triamcinolone acetonide in the rabbit. Cheng, L; Davidson, MC; Freeman, WR; Kozak, I; Mendez, T, 2006)	0.6
"Subretinal injection of TCA crystals can be toxic to the outer retina and retinal pigment epithelium."	( Evaluation of the toxicity of subretinal triamcinolone acetonide in the rabbit. Cheng, L; Davidson, MC; Freeman, WR; Kozak, I; Mendez, T, 2006)	0.6
" Intravitreal TA up to 30 mg does not seem to have acute toxic effects on the function (ERG) or the structure (LM, EM) of the retina of albino rabbits."	( Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Bayon, A; Montero, JA; Rueda, J; Ruiz-Moreno, JM; Vidal, M, 2007)	0.62
"To investigate the toxic effects of triamcinolone acetonide (TA) suspensions on human retinal pigment epithelial (RPE) cells."	( Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells. Chang, YS; Kuo, PY; Tseng, SH; Tseng, SY; Wu, CL, 2007)	0.96
"In the study center, the IVTA is extremely safe in patients without a history of glaucoma."	( Safety profile of intravitreal triamcinolone acetonide. Baath, J; Crichton, A; Ells, AL; Kherani, A; Williams, RG, 2007)	0.63
"A single intraoperative intravitreal injection of triamcinolone acetonide seemed to be a safe and efficacious route of steroid delivery during phacoemulsification in patients with chronic idiopathic anterior uveitis or intermediate uveitis and is recommended as a substitute for postoperative oral steroid administration."	( Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract. Dada, T; Dhawan, M; Garg, S; Mandal, S; Nair, S, 2007)	0.83
" The mechanism of these toxic events remains, however, poorly understood."	( Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Behar-Cohen, F; BenEzra, D; Gandolphe, C; Jeanny, JC; Savoldelli, M; Torriglia, A; Valamanesh, F, 2007)	0.34
" These toxic events were not associated with the anti-inflammatory activity of these compounds but depended on the hydro solubility of their formulation."	( Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Behar-Cohen, F; BenEzra, D; Gandolphe, C; Jeanny, JC; Savoldelli, M; Torriglia, A; Valamanesh, F, 2007)	0.34
" The most common adverse effect was increased intraocular pressure, with an increase of more than 15 mm Hg in 5 eyes (31%)."	( Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Andrews, R; Chang, JH; Comer, RM; Grigg, JR; Lightman, S; McCluskey, PJ; Sallam, A, 2008)	0.6
"To evaluate the toxic effects of two triamcinolone acetonide (TA) vehicles on rabbit retina at different volumes."	( A moephologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Li, Q; Liu, W; Mo, B; Wang, J; Wang, N; Yang, L; Zeng, H, 2008)	0.87
" The intensity of the toxic effects of different vehicles may differ."	( A moephologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Li, Q; Liu, W; Mo, B; Wang, J; Wang, N; Yang, L; Zeng, H, 2008)	0.6
"The half-life of commercially available TH in the vitreous is double that of TA, but the former is toxic to the retina in this rabbit model."	( Safety and pharmokinetics of triamcinolone hexacetonide in rabbit eyes. Abd-El-Barr, MM; Albini, TA; Carvounis, PE; Chevez-Barrios, P; He, F; Holz, ER; Manzano, RP; Wensel, TG; Wu, SM, 2008)	0.35
"0mg/mL, the concentration in commercial TA suspensions, was toxic within 5min on each assay for both human and rabbit RPE cells."	( In vitro benzyl alcohol cytotoxicity: implications for intravitreal use of triamcinolone acetonide. Chang, YS; Kuo, PY; Tseng, SH; Tseng, SY; Wu, CL, 2008)	0.58
" No evidence of TA toxic effect was noted on histopathology."	( Ocular distribution and toxicity of intravitreal injection of triamcinolone acetonide in normal equine eyes. Davis, JL; Gilger, BC; Salmon, JH; Yi, NY, 2008)	0.59
" PSTI of TA is an extremely safe procedure and can be repeatedly applied to an eye."	( Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. Byun, YS; Park, YH, 2009)	0.59
" Safety measures included reports of adverse events, morning serum cortisol levels before and after cosyntropin infusion, and growth as measured using office stadiometry."	( Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Georges, G; Nayak, A; Qaqundah, P; Weinstein, S, 2009)	0.66
" Adverse event rates were comparable between treatment groups."	( Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Georges, G; Nayak, A; Qaqundah, P; Weinstein, S, 2009)	0.66
"Intravitreal drug administration leads to high intraocular concentrations with potentially toxic effects on ocular tissues."	( Toxicity assessment of intravitreal triamcinolone and bevacizumab in a retinal explant mouse model using two-photon microscopy. Euler, T; Jonas, JB; Mittmann, W; Rensch, F; Schlichtenbrede, FC; Vom Hagen, F, 2009)	0.35
"2P microscopy in combination with SR101 staining allows fast morphologic assessment of living retinal explants and can be used to evaluate adverse effects on retinal viability of test substances."	( Toxicity assessment of intravitreal triamcinolone and bevacizumab in a retinal explant mouse model using two-photon microscopy. Euler, T; Jonas, JB; Mittmann, W; Rensch, F; Schlichtenbrede, FC; Vom Hagen, F, 2009)	0.35
"There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group."	( A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlu Blodi, BA; Chan, CK; Fisher, M; Gonzalez, VH; Ip, MS; Oden, NL; Scott, IU; Singerman, LJ; Tolentino, M; VanVeldhuisen, PC, 2009)	0.35
" However, this treatment is toxic for the retina because it induces a non-apoptotic, caspase-independent cell death related to paraptosis, mostly in the retinal pigmented epithelium cells and the Müller cells."	( On the retinal toxicity of intraocular glucocorticoids. Behar-Cohen, F; Torriglia, A; Valamanesh, F, 2010)	0.36
"1 mL (4 or 12 mg) intravitreal injection for human eye were found safe in guinea pig eyes."	( Further characterization of ocular safety profile of commercially available preserved and preservative-free triamcinolone acetonide. Chen, H; Cheng, L; Gu, X; Hou, J; Li, G; Li, Y; Luo, L; Qu, J; Shen, H; Zhang, Y, 2012)	0.59
" There was no evidence of toxic effects on the retina in either group based on ERG or histological analyses."	( Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes. Bonini-Filho, MA; Crispim, PT; Cunha, AS; Damico, FM; Haddad, A; Jorge, R; Maia-Filho, A; Messias, A; Oliveira, RC; Ribeiro, JA; Saliba, JB; Scott, IU; Siqueira, RC, 2012)	0.6
" No toxic reactions in the retina were observed in either group."	( Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes. Bonini-Filho, MA; Crispim, PT; Cunha, AS; Damico, FM; Haddad, A; Jorge, R; Maia-Filho, A; Messias, A; Oliveira, RC; Ribeiro, JA; Saliba, JB; Scott, IU; Siqueira, RC, 2012)	0.6
" Safety of steroidal products for intraocular use is essential because of their risk of ocular adverse events."	( Drug safety evaluation of intravitreal triamcinolone acetonide. Di Giulio, A; Lanzetta, P; Sarao, V; Veritti, D, 2012)	0.65
" It may imply an off-label use and it may be associated with ocular adverse events."	( Drug safety evaluation of intravitreal triamcinolone acetonide. Di Giulio, A; Lanzetta, P; Sarao, V; Veritti, D, 2012)	0.65
" In contrast, BBG and TA appear safe after subretinal injection."	( Toxicity profiles of subretinal indocyanine green, Brilliant Blue G, and triamcinolone acetonide: a comparative study. Ejstrup, R; Heegaard, S; Kiilgaard, JF; la Cour, M, 2012)	0.61
" Recent studies, which evaluated topical and systemic adverse events associated with ciclesonide (CIC), fluticasone furoate (FF), mometasone furoate (MF), triamcinolone acetonide, fluticasone propionate, budesonide, and beclomethasone dipropionate were summarized."	( Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Blaiss, MS, )	0.33
" TANS was well-tolerated in AR and NAR groups with minor adverse events including headache, nasal burning, and bitter mouth taste."	( Efficacy and safety of once daily triamcinolone acetonide aqueous nasal spray in adults with non-allergic and allergic rhinitis. Baccioglu Kavut, A; Kalpaklıoğlu, F, )	0.41
" However, because of its long-acting nature, TA can induce long-term local immunosuppression and subsequent adverse events."	( Cytomegalovirus-associated gastric ulcer: a side effect of steroid injections for pyloric stenosis. Fujihara, S; Kato, K; Kobara, H; Masaki, T; Mori, H; Nishiyama, N; Oryu, M; Rafiq, K, 2013)	0.39
"The consecutive patients using HA attending to our clinic in the past 3 years were divided into 3 categories, according to the time of presentation of the adverse reactions: immediate, early, and late-onset complications."	( Undesirable effects after treatment with dermal fillers. Camacho-Martínez, FM; Rodrigues-Barata, AR, 2013)	0.39
" Physicians need to be aware of these possible adverse events in order to establish proper treatment and prevent scarring or other sequelae."	( Undesirable effects after treatment with dermal fillers. Camacho-Martínez, FM; Rodrigues-Barata, AR, 2013)	0.39
"Intravitreal injection of 4 mg and 8 mg TA are safe for the rabbit retina."	( Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits. Gao, YF; Wang, HJ; Xie, HT; Ye, YF, 2014)	0.64
" Subconjunctival injection of triamcinolone acetonide is a safe and effective treatment of macular edema related to uveitis."	( [Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases]. Bleriot, A; Couret, C; Le Meur, G; Lebranchu, P; Weber, M, 2014)	0.69
"1 ml intravitreal suspension for rabbit eye is found safe in guinea pig eyes."	( [Characteristic of ocular safety profile of triamcinolone made in China]. Cheng, L; Hou, J; Lan, B; Li, J; Sun, S; Zhao, C, 2014)	0.4
" No serious related adverse events occurred."	( One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Lim, JI; Niec, M; Wong, V, 2015)	0.62
" Safety was assessed from adverse events at all study visits."	( Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial. Alleyne, J; Dellaert, F; Emans, PJ; Gill, DP; Maroney, M; Petrella, RJ, 2015)	0.42
" Data, including best-corrected Snellen visual acuity, central macular thickness (CMT), intraocular pressure (IOP), and adverse events (AEs), were collected at baseline, week 1, month 1, month 3, and month 6 after initiation of treatment."	( Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide (Triesence) for Macular Edema. Broadhead, GK; Chang, AA; Li, H; Luo, K; Zhu, M, 2015)	0.67
"Subconjunctival injection of triamcinolone acetonide is an effective and safe method for uveitic macular edema."	( [The efficacy and safety of subconjunctival triamcinolone acetonide injections in treatment of uveitic macular edema]. Gao, F; Liu, X; Wang, M; Zhang, M; Zhao, C, 2015)	0.97
"Steroid injection combined with LMS in the treatment of BVFLs was safe and associated with improved voice quality."	( Efficacy and Safety of Adjunctive Steroid Injection After Microsurgical Removal of Benign Vocal Fold Lesions. Cho, JH; Hwang, WS; Joo, YH; Kim, SY; Park, YH; Sun, DI, 2017)	0.46
" Knee pain (Numeric Rating Scale [NRS]), Oxford Knee Score, overall treatment effect (Global Perceived Effect), analgesic drug use, and adverse events were compared between CRFA and IAS cohorts at 1, 3, and 6 months after intervention."	( Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Buvanendran, A; Choi, D; Davis, T; DePalma, M; Desai, M; Gupta, A; Hunter, C; Kapural, L; Lindley, D; Loudermilk, E; Patel, N; Soloman, M, 2018)	0.48
" There were no procedure-related serious adverse events."	( Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Buvanendran, A; Choi, D; Davis, T; DePalma, M; Desai, M; Gupta, A; Hunter, C; Kapural, L; Lindley, D; Loudermilk, E; Patel, N; Soloman, M, 2018)	0.48
"Intralesional steroid injection appears to be a safe and effective alternative treatment for recurrent AF."	( Safety and efficacy of intralesional steroid injection for aggressive fibromatosis. Arpornchayanon, O; Chaiyawat, P; Klangjorhor, J; Kosachunhanun, N; Lorsomradee, S; Phanphaisarn, A; Pruksakorn, D; Settakorn, J; Teeyakasem, P, 2017)	0.46
" Adverse effects of these drugs include oral candidiasis with associated burning mouth and hypogeusia, hypersensitive reactions to the drug, and inhibition of the hypothalamic-pituitary-adrenal axis and secondary adrenal insufficiency."	( A potential side effect of oral topical steroids: Central serous chorioretinopathy. Balan, A; George, S, )	0.13
"Charts of all patients receiving PF-IVTA (2 mg or 4 mg) in a defined time period (2012-2014) at the Cole Eye Institute were examined for patient demographics, time to treatment failure (TTF), use of systemic immunosuppression, use of intraocular pressure-lowering therapies, date of cataract surgery and glaucoma filtration surgery, and adverse events."	( Treatment Duration and Side Effect Profile of Long-Term Use of Intravitreal Preservative-Free Triamcinolone Acetonide in Uveitis. Arepalli, S; Baynes, K; Bena, J; Ganapathy, PS; Li, M; Lowder, CY; Srivastava, SK, 2018)	0.7
"This retrospective study supports that 2 mg PF-IVTA displayed noninferior treatment duration to 4 mg PF-IVTA, and may carry a significantly lower side-effect profile of cataract development and glaucoma filtering surgery."	( Treatment Duration and Side Effect Profile of Long-Term Use of Intravitreal Preservative-Free Triamcinolone Acetonide in Uveitis. Arepalli, S; Baynes, K; Bena, J; Ganapathy, PS; Li, M; Lowder, CY; Srivastava, SK, 2018)	0.7
"02% TA cream could significantly reduce postlaser downtime including swelling, redness, crusting, and scaling in 5-7 days, with comparable efficacies in decreasing downtime and adverse reactions, as well as wound healing improvement and lower PIH without statistically significant difference between the two treatments."	( Efficacy and safety of moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese versus 0.02% triamcinolone acetonide cream in decreasing adverse reaction and downtime after ablative fractional carbon dioxide laser resurfacing: A split Lueangarun, S; Srituravanit, A; Tempark, T, 2019)	0.72
"The moisturizer with anti-inflammatory ingredients could be a novel treatment modality for reduction of postablative laser downtime by using nonsteroidal anti-inflammatory agents to avoid adverse effects and improve wound healing process with lower PIH."	( Efficacy and safety of moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese versus 0.02% triamcinolone acetonide cream in decreasing adverse reaction and downtime after ablative fractional carbon dioxide laser resurfacing: A split Lueangarun, S; Srituravanit, A; Tempark, T, 2019)	0.72
" Prolonging corticosteroid presence by controlled release from biomaterials may allow for longer pain relief while circumventing adverse effects such as high bolus dosages."	( Safety of intradiscal delivery of triamcinolone acetonide by a poly(esteramide) microsphere platform in a large animal model of intervertebral disc degeneration. Beukers, M; Creemers, L; Meij, B; Mihov, G; Öner, F; Rudnik-Jansen, I; Tellegen, A; Thies, J; Tryfonidou, M; Woike, N, 2019)	0.79
" Sustained release of TAA locally in the IVD appeared safe and reduced NGF expression, suggesting its potential applicability for pain relief, although beneficial effects were absent on tissue degeneration."	( Safety of intradiscal delivery of triamcinolone acetonide by a poly(esteramide) microsphere platform in a large animal model of intervertebral disc degeneration. Beukers, M; Creemers, L; Meij, B; Mihov, G; Öner, F; Rudnik-Jansen, I; Tellegen, A; Thies, J; Tryfonidou, M; Woike, N, 2019)	0.79
" No serious adverse events (AEs) related to treatment were reported."	( Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ciulla, TA; Henry, CR; Khurana, RN; Kissner, JM; Noronha, G; Shah, M; Wang, RC; Yeh, S, 2020)	0.56
" However, verapamil has fewer adverse drug reactions than TAC, which allows for a longer treatment period and the possibility that it might be effective for patients who cannot receive TAC."	( The Safety and Efficacy of Intralesional Verapamil Versus Intralesional Triamcinolone Acetonide for Keloids and Hypertrophic Scars: A Systematic Review and Meta-analysis. Fu, ZH; Guo, GH; Jiang, ZY; Liao, XC; Liu, MZ; Min, DH, 2020)	0.79
" Although triamcinolone acetonide (TAC) is one of the most common and effective treatments for keloids and hypertrophic scars, TAC is not effective in some patients, and some may even experience adverse outcomes."	( Efficacy and safety of verapamil vs triamcinolone acetonide for keloids and hypertrophic scars: A systematic review and meta-analysis. Deng, Z; Liu, L; Liu, R; Yang, B; Zhao, X, 2020)	1.24
" The three treatment modalities were effective, safe with minimal side effects."	( Efficacy and safety of Nd:YAG laser alone compared with combined Nd:YAG laser with intralesional steroid or botulinum toxin A in the treatment of hypertrophic scars. Hamed, AM; Mohamed, MS; Rahman, SHA, 2021)	0.62
" RCTs that evaluated treatment effects with the Vancouver Scar Scale or reported adverse effects were included."	( Comparing the Efficacy and Safety of Intralesional Verapamil With Intralesional Triamcinolone Acetonide in Treatment of Hypertrophic Scars and Keloids: A Meta-Analysis of Randomized Controlled Trials. Bi, H; Gu, L; Qin, Z; Wang, P; Wang, Q, 2021)	0.85
" Although total adverse effects (RR = 0."	( Comparing the Efficacy and Safety of Intralesional Verapamil With Intralesional Triamcinolone Acetonide in Treatment of Hypertrophic Scars and Keloids: A Meta-Analysis of Randomized Controlled Trials. Bi, H; Gu, L; Qin, Z; Wang, P; Wang, Q, 2021)	0.85
" Although total adverse effects did not change, the incidence of telangiectasia and skin atrophy was lower with verapamil than with TAC."	( Comparing the Efficacy and Safety of Intralesional Verapamil With Intralesional Triamcinolone Acetonide in Treatment of Hypertrophic Scars and Keloids: A Meta-Analysis of Randomized Controlled Trials. Bi, H; Gu, L; Qin, Z; Wang, P; Wang, Q, 2021)	0.85
" Although total adverse effects did not change, the incidence of telangiectasia and skin atrophy was lower with verapamil than with TAC."	( Comparing the Efficacy and Safety of Intralesional Verapamil With Intralesional Triamcinolone Acetonide in Treatment of Hypertrophic Scars and Keloids: A Meta-Analysis of Randomized Controlled Trials. Bi, H; Gu, L; Qin, Z; Wang, P; Wang, Q, 2021)	0.85
" Best-corrected visual acuity (BCVA), adverse event (AE) assessment, ophthalmic examinations and optical coherence tomography (OCT) were conducted every 4 weeks for 24 weeks."	( Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Barakat, MR; Ciulla, T; Dayani, P; Hall, C; Henry, CR; Khurana, RN; Rifkin, L; Shah, M; Wang, RC; Yeh, S, 2022)	0.72
"Suprachoroidally administered CLS-TA was safe and well tolerated over the 24-week, open-label study in NIU subjects with and without MO."	( Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Barakat, MR; Ciulla, T; Dayani, P; Hall, C; Henry, CR; Khurana, RN; Rifkin, L; Shah, M; Wang, RC; Yeh, S, 2022)	0.72
" No serious adverse events related to study treatment were observed."	( Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Barakat, MR; Ciulla, T; Henry, CR; Kapik, B; Khurana, RN; Merrill, P; Shah, M; Suhler, E; Uchiyama, E; Wang, RC; Yeh, S, 2022)	0.72
" Our results show that the intravitreal injection of corticosteroids is more effective, but is associated with more adverse events, than periocular injection."	( Efficacy and safety of intravitreal and periocular injection of corticosteroids in noninfectious uveitis: a systematic review. Ferreira, A; Figueira, L; José-Vieira, R; Menéres, P; Sousa-Pinto, B, )	0.13
" Primary outcome for safety was defined as the occurrence of adverse events (AEs) during the follow up period after IAJI."	( The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis. Amarilyo, G; Gendler, Y; Goldberg, O; Habot-Wilner, Z; Harel, L; Levinsky, Y; Ohana, O; Peled, O; Rubin, S; Tal, R, 2022)	0.97
"Suprachoroidal administration of triamcinolone appears to be a safe and effective technique to achieve CD resolution in eyes with RRD."	( Safety and efficacy of suprachoroidal triamcinolone acetonide for the management of serous choroidal detachment prior to rhegmatogenous retinal detachment surgery: A Pilot study. Halim, D; Kohli, GM; Nigam, S; Sen, A; Shenoy, P; Shetty, S; Talwar, D, 2022)	0.99
" The aim of this study was to describe the occurrence of local and systemic adverse effects after peribulbar injection of triamcinolone in patients with thyroid eye disease."	( Adverse effects associated with peribulbar injection of triamcinolone for the treatment of thyroid eye disease: a retrospective case series. Barlatay, JMG; Basso, TO; Benavente, M; Boza, CP; Hernández-Gauna, GV; Premoli, EJ, 2023)	0.91
" Verapamil had fewer adverse events than TAC and can be used as a safer alternative for the treatment of keloids and hypertrophic scars."	( Efficacy and Safety of Verapamil Versus Triamcinolone Acetonide in Treating Keloids and Hypertrophic Scars: A Systematic Review and Meta-Analysis. Li, X; Zhang, W, 2023)	1.18
" Although traditional corticosteroid treatments may demonstrate high levels of efficacy, systemic delivery carries the risk of potentially serious systemic adverse effects (AEs), and standard local modes of delivery may be associated with low bioavailability in posterior ocular tissues and steroid-associated AEs due to anterior ocular tissue exposure."	( Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with noninfectious uveitis: an in-depth look at efficacy and safety. Ciulla, T; Yeh, S, 2023)	1.26
" No serious adverse reactions and good tolerability were reported in the included studies."	( Efficacy and safety of needle-free jet injector-assisted intralesional treatments in dermatology-a systematic review. Bekkers, VZ; Bik, L; Prens, EP; van Doorn, MBA; van Huijstee, JC; Wolkerstorfer, A, 2023)	0.91
" Enalapril could be a safe alternative to steroids in the treatment of keloid and hypertrophic scars."	( Safety and efficacy of intralesional injection of enalapril versus triamcinolone acetonide in the treatment of keloids. Eltahlawy, S; Hamada Mohamed, B; Marzouk, WA; Mohamad, NE, 2023)	1.15

Excerpt	Reference	Relevance
" Plasma levels of the steroids were measured and pharmacokinetic parameters were calculated."	( Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Derendorf, H; Grüner, A; Gyselby, G; Haack, D; Möllmann, H, 1986)	0.27
" Plasma levels of the ester and triamcinolone acetonide were measured and pharmacokinetic parameters were calculated."	( Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Derendorf, H; Möllmann, H; Rohdewald, P; Salomon, V; Schmidt, EW, 1985)	0.88
" Drug concentration-time data monitored in whole blood showed bi-exponential decay and were analysed by a least-squares regression analysis procedure to obtain pertinent pharmacokinetic parameters."	( Effect of liposomal surface charge on the pharmacokinetics of an encapsulated model compound. Abraham, I; Goundalkar, A; Mezei, M, )	0.13
" Pharmacodynamic parameters were determined by monitoring lymphocytes, granulocytes, and cortisol."	( Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. Barth, J; Derendorf, H; Erdmann, M; Galia, E; Hochhaus, G; Mollmann, H; Rohatagi, S; Sourgens, H, 1995)	0.54
" Serum samples were obtained and pharmacokinetic parameters estimated from the dose-normalized serum concentrations of doxepin and desmethyldoxepin."	( Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. Cohen, L; Drake, LA; Flood, JG; Gillies, R; Phillips, SB; Riordan, AT; Stiller, MJ, 1999)	0.3
" Serial plasma samples were collected after the first and last dose of test medication for pharmacokinetic analysis."	( A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. Argenti, D; Heald, D; Shah, B, 2000)	0.53
" The half-life of the rapid elimination phase was 83."	( Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. French, K; Pass, MA; Pollitt, CC, 2000)	0.57
" The terminal half-life was significantly longer (82%) at 20:00."	( Circadian changes in the pharmacokinetics of triamcinolone acetonide in rabbits. Burm, JP; Choi, JS; Shin, SC, 2000)	0.57
" The objectives of this study were to assess the deposition in the lungs and oropharynx of triamcinolone acetonide (TAA; Azmacort, Aventis Pharma, Collegeville, PA) delivered by pMDI formulated with HFA-134a, together with the pharmacokinetic profile of TAA, and to determine the extent to which the Azmacort spacer improves targeting of TAA to the lungs."	( Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. Gillen, MS; Hirst, PH; Newman, SP; Pitcairn, GR; Richards, JC; Rohatagi, S, 2001)	0.78
" Available literature data for a suspension-based aqueous triamcinolone acetonide formulation (Nasacort AQ) were used to describe its pharmacokinetic profile after similar single doses of 110, 220, and 440 microg."	( A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial allergic rhinitis: how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspension-based formulation? Dockhorn, RJ; González, MA; Hochhaus, G; Karafilidis, J; Shilstone, J, 2002)	0.84
" Concentrations were determined using high performance liquid chromatography; pharmacokinetic analysis was carried out using PK Analyst, an iterative, nonlinear, weighted, least-squares regression program."	( Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Bakri, SJ; Beer, PM; Liu, W; Miller, M; Peters, GB; Singh, RJ, 2003)	0.57
"Intraocular concentrations of triamcinolone were measured and population pharmacokinetic parameters were calculated."	( Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Bakri, SJ; Beer, PM; Liu, W; Miller, M; Peters, GB; Singh, RJ, 2003)	0.57
" After a single intravitreal injection of triamcinolone, the mean elimination half-life was 18."	( Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Bakri, SJ; Beer, PM; Liu, W; Miller, M; Peters, GB; Singh, RJ, 2003)	0.57
" This approach was supported by the pharmacokinetic hypothesis that the intravitreal triamcinolone concentration decreases in accordance with an exponential biphasic equation."	( Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Audren, F; Benosman, R; Bergmann, JF; Caulin, C; Erginay, A; Gaudric, A; Haouchine, B; Massin, P; Tod, M, 2004)	0.57
"The pharmacodynamic profile of the effect of triamcinolone on CMT was characterized by a curve in three phases: a fast decrease, a steady state, and a relapse."	( Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Audren, F; Benosman, R; Bergmann, JF; Caulin, C; Erginay, A; Gaudric, A; Haouchine, B; Massin, P; Tod, M, 2004)	0.57
"Pharmacokinetic-pharmacodynamic modeling using CMT constitutes a valid alternative to pharmacokinetic studies."	( Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Audren, F; Benosman, R; Bergmann, JF; Caulin, C; Erginay, A; Gaudric, A; Haouchine, B; Massin, P; Tod, M, 2004)	0.57
"The half-life of TA in the vitreous after a 4-mg injection of either TA-PF or Kenalog was comparable."	( Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Bungay, PM; Csaky, KG; DE Monasterio, F; Gravlin, L; Grimes, G; Kim, H; Lutz, RJ; Potti, GK; Robinson, MR; Tansey, G; Yuan, P, )	0.38
"51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13."	( Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. Abraham, G; Demiraj, F; Ungemach, FR, 2006)	0.54
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The purpose of this study was to compare the pharmacokinetic behavior of this hospital pharmacy preparation of TA (HPP-TA) to that of a commercial preparation of TA (CP-TA) in rats."	( Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. Hashida, N; Kurokawa, N; Maeda, S; Ohguro, N; Oishi, M; Tano, Y, )	0.4
" The rats were killed between days 1 and 21, and the concentration of TA in the vitreous was measured by high-performance liquid chromatography to determine the pharmacokinetic parameters."	( Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. Hashida, N; Kurokawa, N; Maeda, S; Ohguro, N; Oishi, M; Tano, Y, )	0.4
"Traditional ocular pharmacokinetic studies are invasive and cannot be easily applied to humans in vivo."	( Ocular pharmacokinetic study of a corticosteroid by 19F MR. Jeong, EK; Li, SK; Liu, X, 2010)	0.36
"Triamcinolone acetonide concentration in the samples was measured, and pharmacokinetic parameters were calculated."	( Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Chen, Y; Cheng, L; Qu, J; Shen, L; Sun, S; You, Y, 2010)	2.06
" The terminal elimination half-life in aqueous, vitreous, and plasma was 11."	( Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Chen, Y; Cheng, L; Qu, J; Shen, L; Sun, S; You, Y, 2010)	0.62
" The method was applied to a pharmacokinetic study in rodents using microdialysis to determine protein unbound TA concentrations in blood and muscle."	( Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. Derendorf, H; Singh, RP; Vieira, Mde L, 2010)	0.65
" Currently, there is a scant amount of evidence-based literature evaluating the pharmacokinetic profile of TA despite clinical data showing the efficacy of intravitreal TA for multiple forms of macular edema."	( Pharmacokinetics of triamcinolone acetonide for the treatment of macular edema. Cordero-Coma, M; Federici, TJ; Yilmaz, T, 2011)	0.69
"The pharmacokinetic profile of TA is unpredictable and the agent has a time-limited therapeutic action due to its relatively short half-life."	( Pharmacokinetics of triamcinolone acetonide for the treatment of macular edema. Cordero-Coma, M; Federici, TJ; Yilmaz, T, 2011)	0.69
"To compare the intravitreal pharmacokinetic profile of a triamcinolone acetonide formulation containing the preservative benzyl alcohol (TA-BA) versus a preservative-free triamcinolone acetonide formulation (TA-PF), and evaluate potential signs of toxicity to the retina."	( Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes. Bonini-Filho, MA; Crispim, PT; Cunha, AS; Damico, FM; Haddad, A; Jorge, R; Maia-Filho, A; Messias, A; Oliveira, RC; Ribeiro, JA; Saliba, JB; Scott, IU; Siqueira, RC, 2012)	0.84
"To compare a theoretical pharmacokinetic model of triamcinolone acetonide after posterior sub-Tenon's injection with experimental serum and undiluted vitreous triamcinolone acetonide concentrations obtained during pars plana vitrectomy."	( Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection. Arroyo, JG; Ceron, OM; Gukasyan, HJ; Kovacs, K; Quirk, MT; Silva, PA; Singh, RJ; Wagley, S, 2012)	0.87
" Pharmacokinetic experiment: Rabbits were intravitreally injected with one of four 4-mg triamcinolone acetonide formulations."	( Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Burke, J; Feldmann, B; Ghosn, C; Kuppermann, BD; Li, Y; Lin, T; Migon, R; Orilla, W; Ruiz, G; Zacharias, LC, 2013)	0.82
" The plasma terminal elimination half-life was 11."	( Pharmacokinetics of triamcinolone acetonide following intramuscular and intra-articular administration to exercised Thoroughbred horses. Casbeer, HC; Knych, HK; McKemie, DS; Vidal, MA, 2013)	0.71
" The terminal half-life of intravitreal TA was 23."	( Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes. Jung, JH; Kim, SI; Lee, JE; Lee, JS; Oum, BS; Pak, KY; Park, HJ, 2014)	0.65
" Although the terminal half-life of TA was shorter, higher early concentration and similar effective duration were achieved in the vitrectomized eyes."	( Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes. Jung, JH; Kim, SI; Lee, JE; Lee, JS; Oum, BS; Pak, KY; Park, HJ, 2014)	0.65
"A simple and accurate method including liquid-liquid extraction and protein precipitation procedures from silicone oil and aqueous humor samples followed by high-performance liquid chromatography (HPLC-UV) was developed and validated to determine the pharmacokinetic profile of triamcinolone acetonide in silicone oil and aqueous humor of rabbits' eyes submitted to the pars plana vitrectomy surgery."	( Determination of triamcinolone acetonide in silicone oil and aqueous humor of vitrectomized rabbits' eyes: Application for a pharmacokinetic study with intravitreal triamcinolone acetonide injections (Kenalog® 40). Fernandes-Cunha, GM; Jorge, R; Saliba, JB; Silva-Cunha, A; Siqueira, RC, 2014)	0.92
"The half-life of intravitreal injection of 4 mg and 8 mg TA was 24 days and 34 days, respectively."	( Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits. Gao, YF; Wang, HJ; Xie, HT; Ye, YF, 2014)	0.64
" The injection of 8 mg TA produced a longer vitreous half-life and had a prolonged effect on the retina."	( Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits. Gao, YF; Wang, HJ; Xie, HT; Ye, YF, 2014)	0.64
" The method was successfully applied to a long-term pharmacokinetic study of TAP and TA after 28-day repeated intravenous administration of TAP lipid emulsion injection to beagle dogs."	( Simultaneous determination of triamcinolone acetonide palmitate and triamcinolone acetonide in beagle dog plasma by UPLC-MS/MS and its application to a long-term pharmacokinetic study of triamcinolone acetonide palmitate lipid emulsion injection. Guan, J; Lin, H; Liu, H; Men, L; Tang, X; Wu, P; Yang, M; Yu, Z; Zhao, Y, 2015)	0.71
"Available corticosteroids for diabetic macular edema exhibit different pharmacokinetic profiles that impact efficacy and adverse events and should be taken into account when developing individualized treatment plans."	( INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS. Bailey, C; Loewenstein, A; Massin, P; Yang, Y, 2015)	0.42
" The method was successfully applied to a preclinical pharmacokinetic (PK) study of the six GCs on female nude mice after a single oral dose of 1 mg/kg."	( Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. Guo, Y; Hao, C; Kong, D; Li, J; Tian, X; Xue, J; Yao, Q; Zhou, T, 2020)	0.56

Excerpt	Reference	Relevance
" The clinical efficacy of hydrocolloid dressing as a monotherapy and the pronounced clinical efficacy of this occlusive in combination with triamcinolone acetonide were confirmed."	( Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Boezeman, JB; Chang, A; Huigen-Tijdink, R; van de Kerkhof, PC; van der Walle, HB; van Vlijmen-Willems, I, 1994)	0.72
"To investigate the efficacy of posterior sub-Tenon's capsule triamcinolone injection (PSTI) combined with focal laser (FL) photocoagulation in treatment of diffuse clinically significant diabetic macular edema (CSME)."	( Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Kaya, M; Onder, HI; Tunc, M, 2005)	0.33
" A total of 30 eyes received macular focal and grid laser photocoagulation (MP), and the second group of 30 eyes received FL photocoagulation combined with PSTI (FL + PSTI)."	( Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Kaya, M; Onder, HI; Tunc, M, 2005)	0.33
"Posterior sub-Tenon's capsule application of triamcinolone may improve early visual outcome in diffuse diabetic macular edema when combined with FL photocoagulation."	( Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Kaya, M; Onder, HI; Tunc, M, 2005)	0.33
"To evaluate the efficacy and safety of photodynamic therapy with verteporfin combined with intravitreal triamcinolone in choroidal neovascularization secondary to age-related macular degeneration (AMD)."	( Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Augustin, AJ; Schmidt-Erfurth, U, 2006)	0.33
"Verteporfin photodynamic therapy combined with intravitreal triamcinolone may improve the outcome of standard verteporfin photodynamic therapy in the treatment of choroidal neovascularization secondary to AMD."	( Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Augustin, AJ; Schmidt-Erfurth, U, 2006)	0.33
"To detect patients with neovascular age-related macular degeneration (AMD) who experience retinal pigment epithelium tears after initial verteporfin therapy combined with intravitreal triamcinolone during early follow-up."	( Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Aue, A; Geitzenauer, W; Michels, S; Sacu, S; Schmidt-Erfurth, U; Simader, C, 2006)	0.33
"Forty-five consecutive patients with choroidal neovascularization (CNV) in AMD were treated with verteporfin therapy combined with 4 mg of intravitreal triamcinolone."	( Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Aue, A; Geitzenauer, W; Michels, S; Sacu, S; Schmidt-Erfurth, U; Simader, C, 2006)	0.33
" In combination with PRP, IVTA might be more effective than focal or grid laser photocoagulation and PRP for reducing diabetic macular edema and preventing aggravation of macular edema without transient visual disturbance in patients requiring immediate PRP."	( Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema. Choi, KS; Chung, JK; Lim, SH, 2007)	0.59
"To examine transpupillary thermotherapy combined with intravitreal triamcinolone for treatment of subfoveal choroidal neovascularization."	( Low-power transpupillary thermotherapy combined with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization. Jonas, JB; Wang, D; Xu, L; Zhang, X; Zhu, X, 2007)	0.58
"Transpupillary thermotherapy combined with intravitreal triamcinolone may be a therapeutic option for choroidal neovascularization particularly if other treatment modalities are not available."	( Low-power transpupillary thermotherapy combined with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization. Jonas, JB; Wang, D; Xu, L; Zhang, X; Zhu, X, 2007)	0.58
"To report the efficacy of a single intravitreal bevacizumab injection alone or in combination with intravitreal triamcinolone acetonide versus macular laser photocoagulation (MPC) as primary treatment of diabetic macular edema (DME)."	( Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Ahmadieh, H; Azarmina, M; Bijanzadeh, B; Dehghan, MH; Moradian, S; Peyman, GA; Ramezani, A; Soheilian, M; Tabatabaei, H; Yaseri, M, )	0.34
"To evaluate the therapeutic effect of photodynamic therapy (PDT) combined with posterior subtenon injection of triamcinolone acetonide (PSTA) in the treatment of choroidal neovascularization (CNV)."	( Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Chen, MS; Ho, TC; Lee, YA; Yang, CH; Yang, CM, 2009)	0.81
"Compared with PDT alone, PDT combined with PSTA has a better therapeutic effect for both myopic and age-related predominantly classic CNV; the myopic CNV subgroup shows the best response."	( Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Chen, MS; Ho, TC; Lee, YA; Yang, CH; Yang, CM, 2009)	0.6
"To compare the effectiveness of subthreshold grid laser treatment (SGLT) with infrared micropulse diode laser alone or in combination with intravitreal triamcinolone injection (SGLT-IVTJ) for the treatment of macular oedema (MO) secondary to branch retinal vein occlusion (BRVO)."	( Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Iacono, P; Parodi, MB; Ravalico, G, 2008)	0.72
"To compare early treatment effect of reduced fluence versus standard photodynamic therapy (rPDT, sPDT, respectively) in combination with intravitreal triamcinolone (IVTA) in neovascular age-related macular degeneration."	( Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Michels, S; Polak, K; Sacu, S; Schmidt-Erfurth, U; Varga, A; Vécsei-Marlovits, PV; Weigert, G, 2008)	0.35
"To report acute visual loss associated with dynamic vascular changes after photodynamic therapy (PDT) combined with intravitreal triamcinolone (IVTA) for the treatment of occult choroidal neovascularization (CNV)."	( Acute visual loss and chorioretinal infarction after photodynamic therapy combined with intravitreal triamcinolone. De Belvis, V; Galan, A; Lo Giudice, G; Piermarocchi, S; Prosdocimo, G, )	0.13
"To examine the effects of photodynamic therapy (PDT) with verteporfin combined with low-dose intravitreal triamcinolone acetonide (IVTA) for exudative age-related macular degeneration (AMD) that is resistant to PDT alone."	( Photodynamic therapy combined with low-dose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone. Gotoh, N; Iwama, D; Otani, A; Sasahara, M; Tamura, H; Tsujikawa, A; Yodoi, Y; Yoshimura, N, 2008)	0.8
"PDT combined with low-dose IVTA for exudative AMD seems to be as effective and safe as combined therapy with the higher-dose IVTA that was reported previously."	( Photodynamic therapy combined with low-dose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone. Gotoh, N; Iwama, D; Otani, A; Sasahara, M; Tamura, H; Tsujikawa, A; Yodoi, Y; Yoshimura, N, 2008)	0.59
" The purpose of this study was to determine the changes in the focal macular electroretinograms (FMERGs) after PDT combined with TA for age-related macular degeneration."	( Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide. Ishikawa, K; Ito, Y; Kondo, M; Nishihara, H; Ozawa, S; Piao, CH; Terasaki, H, 2009)	0.57
"There are current tendencies in the use of photodynamic therapy (PDT) in combination with intravitreal injection of long-acting corticosteroids."	( [Photodynamic therapy with visudine in combination with intravitreal kenalog in the treatment of choroidal neovascularization]. Chikovani, KR; Neroev, VV; Neroeva, NV; Riabina, MV, )	0.13
"To compare the results of intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal triamcinolone acetonide (IVT) versus macular laser photocoagulation (MPC) as a primary treatment of diabetic macular edema (DME)."	( Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ahmadieh, H; Azarmina, M; Bijanzadeh, B; Dehghan, MH; Moradian, S; Obudi, A; Peyman, GA; Ramezani, A; Salehipour, M; Soheilian, M; Yaseri, M, 2009)	0.57
"To compare the effects of laser photocoagulation combined with subtenon injection of triamcinolone acetonide with photocoagulation alone, for diabetic cystoid macular edema."	( Laser photocoagulation combined with subtenon injection of triamcinolone acetonide for diabetic cystoid macular edema. Chen, YH; Cheng, LS; Kuo, HK; Wu, PC, )	0.6
"This retrospective comparative study analyzed data for 34 eyes with cystoid macular edema treated with photocoagulation alone (n=17) or combined with triamcinolone (n=17)."	( Laser photocoagulation combined with subtenon injection of triamcinolone acetonide for diabetic cystoid macular edema. Chen, YH; Cheng, LS; Kuo, HK; Wu, PC, )	0.37
"This study, with a follow-up of 6 months, suggests that subtenon injection of triamcinolone combined with macular photocoagulation provides a better chance of stabilizing vision loss in patients with diabetic cystoid macular edema than photocoagulation alone."	( Laser photocoagulation combined with subtenon injection of triamcinolone acetonide for diabetic cystoid macular edema. Chen, YH; Cheng, LS; Kuo, HK; Wu, PC, )	0.37
" IA-guided laser photocoagulation combined with STTA might be effective for treating types 1 and 2 idiopathic macular telangiectasia."	( Indocyanine green angiography-guided laser photocoagulation combined with sub-Tenon's capsule injection of triamcinolone acetonide for idiopathic macular telangiectasia. Hirano, Y; Nozaki, M; Ogura, Y; Usui, Y; Yasukawa, T, 2010)	0.57
"This study aimed to evaluate the course of macular sensitivity (MS) following treatment with reduced fluence photodynamic therapy (RPDT) versus standard photodynamic therapy (SPDT) in combination with intravitreal triamcinolone acetonide (IVTA) in patients with neovascular age-related macular degeneration, and to investigate the correlation between MS and angiographic outcomes."	( Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. Dunavoelgyi, R; Pruente, C; Sacu, S; Schmidt-Erfurth, U; Simader, C, 2011)	0.56
"To investigate the effect of intravitreal bevacizumab (IVB) combined with intravitreal high-dose triamcinolone acetonide (IVTA) for therapy of exudative age-related macular degeneration (AMD) after unsuccessful IVB monotherapy."	( Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. Jonas, JB; Tao, Y, 2010)	0.58
" This study aimed to compare the efficacy and safety of a single intravitreal injection of bevacizumab alone versus bevacizumab combined with triamcinolone acetonide in eyes with diabetic macular edema (DME)."	( Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Li, MH; Li, X; Su, XN; Wang, HY; Wang, YS; Zhang, ZF, 2011)	0.83
"05 ml) combined with triamcinolone acetonide (2 mg/0."	( Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Li, MH; Li, X; Su, XN; Wang, HY; Wang, YS; Zhang, ZF, 2011)	0.95
"To observe the clinical treatment effectiveness of Clarithromycin combined with nasal glucocorticoids for chronic rhinosinusitis (CRS)."	( [Clinical observation of Clarithromycin combined with nasal steroid treatment for chronic rhinosinusitis]. Feng, Z; Hong, Y; Li, Q; Li, X; Liu, J; Liu, L; Lu, X; Wan, Y; Zhong, G, 2011)	0.37
"The treatment with Long term use of low dosage oral macrolide Clarithromycin combined with nasal steroid on CRS was efficacy."	( [Clinical observation of Clarithromycin combined with nasal steroid treatment for chronic rhinosinusitis]. Feng, Z; Hong, Y; Li, Q; Li, X; Liu, J; Liu, L; Lu, X; Wan, Y; Zhong, G, 2011)	0.37
"To assess serum level changes of antiretinal antibodies (ARA) in patients with exudative age-related macular degeneration (AMD), treated with transpupillary thermotherapy (TTT) alone and with TTT combined with injection of triamcinolone acetonide (sTTA) under posterior Tenon's capsule and to compare the efficacy of TTT and TTT+sTTA."	( [Serum antiretinal antibodies (ARA) in patients with exudative age-related macular degeneration (AMD) treated with transpupillary thermotherapy (TTT) alone and with transpupillary thermotherapy (TTT) combined with injection of triamcinolone acetonide (sTT Kubicka-Trzaska, A; Wilańska, J, 2011)	0.74
"To compare the effect of an intravitreal injection of bevacizumab alone (IVB) or combined with triamcinolone (IVB/IVT) versus triamcinolone (IVT) in patients with diabetic macular edema (DME)."	( Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Lee, HK; Lim, JW; Shin, MC, 2012)	0.38
"The purpose of this study was to report the 24-month findings of a randomized clinical trial comparing intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal triamcinolone acetonide (IVT) versus macular laser photocoagulation (MPC) as a primary treatment for diabetic macular edema."	( Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Garfami, KH; Peyman, GA; Ramezani, A; Soheilian, M; Yaseri, M, 2012)	0.57
" The aim of this study was to assess the clinical behaviour and long-term therapeutic response in OFG patients treated with intralesional triamcinolone acetonide (TA) injections alone or in combination with topical pimecrolimus 1%, as adjuvant, in those patients partially responders to TA."	( Clinical behaviour and long-term therapeutic response in orofacial granulomatosis patients treated with intralesional triamcinolone acetonide injections alone or in combination with topical pimecrolimus 1%. Fortuna, G; Leuci, S; Mignogna, MD; Pollio, A; Ruoppo, E, 2013)	0.8
"To compare the 2-year results after photodynamic therapy (PDT) alone and PDT combined with intravitreal injections of bevacizumab and triamcinolone acetonide (triple therapy) for polypoidal choroidal vasculopathy (PCV)."	( Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy. Akagi-Kurashige, Y; Iwama, D; Nakata, I; Ooto, S; Otani, A; Tsujikawa, A; Ueda-Arakawa, N; Yamashiro, K; Yoshimura, N, 2013)	0.81
"Local injections of TA therapy combined with traditional interventional techniques for BAS has good curative effect and safety."	( [Intralesional triamcinolone acetonide injection combined with conventional interventional modalities for the management of recalcitrant benign central airway stenosis: preliminary experience]. Chen, Y; Li, SY; Wu, HY, 2012)	0.73
"To report the results of triple therapy with photodynamic therapy (PDT) (PDT combined with intravitreal injection of bevacizumab (IVB) and sub-tenon injection of triamcinolone acetonide (STTA)) for the treatment of age-related macular degeneration (AMD) in Japanese patients."	( Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Hirose, S; Ishida, S; Kitamei, H; Noda, K; Saito, W; Yoshizawa, C, 2013)	0.82
"This retrospective case series included 38 eyes of 38 patients with exudative AMD treated with PDT combined with IVB (1."	( Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Hirose, S; Ishida, S; Kitamei, H; Noda, K; Saito, W; Yoshizawa, C, 2013)	0.62
" TA, SA-B, and TA combined with SA-B were consecutively applied intralesionally weekly for 20 weeks."	( Efficacy of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis. Jiang, XW; Lu, K; Sun, GL; Yang, SK; Zhang, H; Zhang, Y, 2013)	0.65
"To evaluate the efficacy of vitrectomy combined with intravitreal injection of triamcinolone acetonide (IVTA) and macular laser photocoagulation for the treatment of nontractional diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) therapy."	( Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema. Ha, HS; Kang, SW; Kim, JH; Kim, JR, 2013)	0.89
"Vitrectomy combined with IVTA and macular laser photocoagulation had a beneficial effect on both anatomical and functional outcomes in eyes with nontractional DME refractory to anti-VEGF therapy."	( Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema. Ha, HS; Kang, SW; Kim, JH; Kim, JR, 2013)	0.66
"The purposes of this study were to examine the cartilage degradation effects of triamcinolone acetonide (TA) on normal and osteoarthritic (OA) primary canine chondrocytes and cartilage explants and to examine the cartilage degradation effects of TA in combination with low-molecular-weight hyaluronan (LMWHA)."	( In vitro effects of triamcinolone acetonide and in combination with hyaluronan on canine normal and spontaneous osteoarthritis articular cartilage. Buddhachat, K; Chomdej, S; Euppayo, T; Nganvongpanit, K; Ongchai, S; Pradit, W; Siengdee, P, 2016)	0.98
" We aimed to compare the efficacy and safety of TAC alone and in combination with 5-FU for the treatment of hypertrophic scars and keloids."	( Efficacy and safety of triamcinolone acetonide alone and in combination with 5-fluorouracil for treating hypertrophic scars and keloids: a systematic review and meta-analysis. Fan, B; Feng, S; Lin, W; Ren, Y; Wei, Z; Zhou, X, 2017)	0.77
"To compare the results of intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal 1 mg triamcinolone acetonide (IVT) in center-involved diabetic macular edema."	( Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial. Ahmadraji, A; Ghasemi, F; Karkhaneh, R; Mahmoudi, A; Riazi-Esfahani, H; Riazi-Esfahani, M; Roohipoor, R; Yaseri, M, 2018)	0.69
"TA combined with SA-B were consecutively applied intralesionally 1 time weekly for 30 times."	( [Methods and effects of injection of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis]. DU, YX; Jian, XC; Xiao, YC; Zheng, L; Zhou, C, 2017)	0.69
"To evaluate the effect of low-intensity pulsed ultrasound（LIPUS） combined with triamcinolone acetonide on oral mucosal ulcer in syrian hamster in several ways, including healing time, contents of superoxide dismutase（SOD）and malondialdehyde (MDA)."	( [Effect of low-intensity pulsed ultrasound combined with triamcinolone acetonide on oral mucosal ulcer healing in syrian hamster]. Fei, CX; Feng, TM; Pan, LL; Sun, J; Wang, C; Xiang, XR; Yang, MC, 2017)	0.93
"Low-intensity pulsed ultrasound combined with triamcinolone acetonide can effectively improve the activity of SOD and reduce the contents of MDA in ulcerated tissues, and therefore accelerate the process of ulcer healing．."	( [Effect of low-intensity pulsed ultrasound combined with triamcinolone acetonide on oral mucosal ulcer healing in syrian hamster]. Fei, CX; Feng, TM; Pan, LL; Sun, J; Wang, C; Xiang, XR; Yang, MC, 2017)	0.96
"In this paper, we presented a simple yet versatile strategy to generate a high drug payload nanoparticles by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation."	( Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation. Huang, J; Li, X; Song, Q; Wang, Q; Yu, X; Zhang, R; Zhou, Y, 2018)	0.48
" Herein, we conducted a study to compare the efficacy of intralesional triamcinolone used alone, or in combination with BTA, in the treatment of formed keloid scars."	( Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study. Bakhshaeekia, A; Feily, A; Gianfaldoni, S; Hadibarhaghtalab, M; Lange, CS; Lotti, T; Matta, J; Pazyar, N; Ramirez-Fort, MK; Ramirez-Pacheco, LA; Rasaii, S; Seifi, V; Sohrabian, N, 2019)	0.51
"Intralesional 5-fluorouracil (5-FU) in combination with triamcinolone acetonide (TAC) has been recommended as a promising alternative for keloids not responding to silicone-based products, cryotherapy or intralesional corticosteroids alone."	( Treatment of keloids using 5-fluorouracil in combination with crystalline triamcinolone acetonide suspension: evaluating therapeutic effects by using non-invasive objective measures. Gauglitz, GG; Guertler, A; Poetschke, J; Reinholz, M; Schwaiger, H, 2020)	1.04
"Transurethral resection of the scar tissue combined with intra- and post-operative triamcinolone acetonide injections resulted in a success rate of 92."	( Management of highly recurrent bladder neck contractures via transurethral resection combined with intra- and post-operative triamcinolone acetonide injections. Liu, S; Mu, X; Wu, K; Yang, L; Zhang, L, 2021)	1.05
"To compare anti-vascular endothelial growth factor (anti-VEGF) monotherapy with anti-VEGF therapy combined with sub-Tenon's capsule injections of triamcinolone acetonide (STTA) in patients with macular edema (ME) associated with branch retinal vein occlusion (BRVO)."	( One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Koyama, Y; Miyoshi, Y; Muraoka, Y; Nakano, Y; Osaka, R; Suzuma, K; Takasago, Y; Tsujikawa, A, 2020)	0.98
"Retrospective observational study METHODS: This study included 186 eyes: 138 eyes received intravitreal injection of ranibizumab (IVR), and the remaining 48 eyes received IVR combined with STTA therapy."	( One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Koyama, Y; Miyoshi, Y; Muraoka, Y; Nakano, Y; Osaka, R; Suzuma, K; Takasago, Y; Tsujikawa, A, 2020)	0.78
"To investigate the incidence and outcomes of cystoid macular edema (CME) after Descemet membrane endothelial keratoplasty (DMEK) alone and DMEK combined with cataract surgery (DMEK triple)."	( Incidence and Outcomes of Cystoid Macular Edema after Descemet Membrane Endothelial Keratoplasty (DMEK) and DMEK Combined with Cataract Surgery. Bae, SS; Ching, G; Covello, AT; Holland, S; Iovieno, A; McCarthy, M; Ritenour, R; Yeung, SN, 2021)	0.62
" Thereinto, surgery combined with radiotherapy and triamcinolone acetonide injection is considered to be the proper choice for comprehensive treatment of auricular keloids."	( Individualized surgery combined with radiotherapy and triamcinolone acetonide injection for the treatment of auricular keloids. Guo, S; Sun, Q; Tong, S; Yu, ET; Zhou, KJ; Zhou, Y, 2021)	1.12
"Individualized surgery combined with early postoperative radiotherapy and triamcinolone acetonide injection is an ideal treatment method to ensure good auricular appearance, low incidences of complications and recurrence based on effective treatment of auricular keloids."	( Individualized surgery combined with radiotherapy and triamcinolone acetonide injection for the treatment of auricular keloids. Guo, S; Sun, Q; Tong, S; Yu, ET; Zhou, KJ; Zhou, Y, 2021)	1.1
"The aim of the present study is to explore the efficacy and safety of using different concentrations of intralesional corticosteroid combined with NB-UVB phototherapy in the treatment of non-segmental vitiligo (NSV) patients."	( The use of intralesional corticosteroid combined with narrowband ultraviolet B in vitiligo treatment: clinical, histopathologic, and histometric evaluation. Abdel-Aziz, RTA; Anbar, TS; El-Domyati, M; Yehia, M, 2022)	0.72
"Intralesional corticosteroid injections combined with NB-UVB showed a good and well-tolerated therapeutic option for vitiligo."	( The use of intralesional corticosteroid combined with narrowband ultraviolet B in vitiligo treatment: clinical, histopathologic, and histometric evaluation. Abdel-Aziz, RTA; Anbar, TS; El-Domyati, M; Yehia, M, 2022)	0.72
"To investigate the clinical study of intravitreal injection of anti-VEGF drugs combined with intravitreal injection of tretinoin for the treatment of Coats disease."	( Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease. Fang, J; Han, F; Wu, S; Xiao, J; Yu, F, 2022)	0.95
"Intravitreal injection of anti-VEGF drugs combined with tretinoin injection can significantly improve the clinical efficacy of patients with Coats disease and improve visual acuity and central retinal thickness, which has certain reference value for the clinical treatment of Coats disease."	( Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease. Fang, J; Han, F; Wu, S; Xiao, J; Yu, F, 2022)	0.95
"The purpose of this study was to investigate the efficacy of surgery combined with triamcinolone acetonide injection in managing the difficult problem of keloid formation after syndactyly release."	( Surgical excision and skin grafting combined with intralesional injection of triamcinolone for the treatment of keloids after syndactyly release. Du, X; Jiang, Y; Sun, W; Tian, J; Wang, B; Zhou, S, 2023)	1.14
" • Compared with HA treatment, intra-articular injection of biological agents combined with glucocorticoids can not only relieve joint pain but also significantly inhibit joint swelling."	( Efficacy of tumor necrosis factor inhibitor combined with intra-articular injection of triamcinolone acetonide in the treatment of refractory rheumatoid arthritis synovitis: a retrospective study. Cai, Z; Chen, Y; Ma, Y; Yuan, J, 2023)	1.13
" Intra-lesional injection of triamcinolone acetonide (TAC) in combination with 5-fluorouracil (5-FU) is a commonly used pharmacological regimen and long-term repeated injections can achieve sustained inhibition of keloid proliferation."	( Deciphering the single-cell transcriptome network in keloids with intra-lesional injection of triamcinolone acetonide combined with 5-fluorouracil. Hao, Y; Kuang, X; Liang, Z; Liu, H; Shan, M; Wang, Y; Xia, Y, 2023)	1.42
"This study aims to evaluate the effectiveness and economic efficiency of Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray in the treatment of chronic rhinosinusitis(CRS)."	( [Cost-effectiveness analysis of Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray in treatment of chronic rhinosinusitis]. Gong, WQ; Huang, ZY; Liu, J; Lu, LJ; Zhang, XS, 2023)	1.35

Excerpt	Reference	Relevance
" The results suggested that both corticosteroids were poorly absorbed through normal skin in rats, pigs and humans."	( Percutaneous absorption of 14C-9alpha-fluoro-11beta,21-dihydroxy-3,20-dioxopregna-1,4-dieno (17alpha,16alpha-d)-2'-methyloxazolidine-21-acetate (L 6400) in rats, pigs and humans. Comparison with 3H-triamcinolone acetonide. Cameron, BD; Chasseaud, LF; Franklin, ER; Hawkins, DR; Lewis, JD, 1975)	0.44
" This indicates that in vitro data can be useful in predicting oral bioavailability of GCS."	( Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver. Andersson, P; Lihné, M; Ryrfeldt, A; Thalén, A, 1987)	0.27
"In order to quantify the intensity of skin blanching and thus predict the bioavailability of topical corticoids, a physical device allowing the measurement of light reflected from skin without any contact between the probe and the skin was used (Leveque et al."	( Objective determination of the bioavailability of dermocorticoids--influence of the formulation. Le Gall, F; Leveque, JL; Poelman, MC, 1984)	0.27
" An increase in the bioavailability of corticosteroids in the skin after local application cannot be achieved by addition of salicylic acid or sulfur under the conditions chosen."	( [Effect of salicylic acid and finely divided sulfur on the bioavailability of corticosteroids in the skin in external therapy]. Gloor, M; Lindemann, L, 1980)	0.26
" The volume of distribution was 103 L, and oral bioavailability averaged 23%."	( Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. Barth, J; Derendorf, H; Erdmann, M; Hochhaus, G; Möllmann, H; Rohatagi, S; Sourgens, H, 1995)	0.61
" The objectives of this study were to determine the absolute bioavailability of triamcinolone acetonide following inhalation administration and to delineate the airway contribution of triamcinolone acetonide absorption relative to the absolute bioavailability."	( A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. Argenti, D; Heald, D; Shah, B, 1999)	0.77
" Systemic bioavailability of INSs, by way of nasal and intestinal absorption, can be substantial; but current INSs vary significantly in their degree of first-pass hepatic inactivation and clearance from the body of the swallowed drug."	( Systemic effects of intranasal steroids: an endocrinologist's perspective. Allen, DB, 2000)	0.31
"The pharmacokinetics and bioavailability of triamcinolone acetonide were determined to investigate buccal absorption from the mucoadhesive gels in rabbits."	( Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. Bum, JP; Choi, JS; Shin, SC, 2000)	0.82
" Data support the use of dermatopharmacokinetic methods for bioequivalence and bioavailability assessment of topical drug products."	( Comparison of skin stripping, in vitro release, and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. Bakhtian, S; Corlett, JL; Pershing, LK; Poncelet, CE; Shah, VP, 2002)	0.52
" Hence, the lung bioavailability will determine the overall systemic absorption and the systemic bioactivity."	( A novel method for assessing dissolution of aerosol inhaler products. Davies, NM; Feddah, MR, 2003)	0.32
"Pre-occlusion showed no effect on the topical bioavailability of TACA in the stratum corneum."	( Topical bioavailability of triamcinolone acetonide: effect of occlusion. Figueiredo, V; Imanidis, G; Pellanda, C; Rufli, T; Strub, C; Surber, C, 2007)	0.64
" To increase the drug's bioavailability by ocular instillation, TA was encapsulated in nanostructured lipid carriers (NLC), previously optimized by our group using a factorial design approach."	( Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Araújo, J; Egea, MA; Garcia, ML; Nikolic, S; Souto, EB, 2011)	0.65
"The aim of this study was to evaluate the intraocular pressure (IOP) increasing effect and bioavailability of triamcinolone acetonide (TA) microspheres, as a novel drug delivery system, after intravitreal administration."	( Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration. Malaekeh-Nikouei, B; Pourmazar, R; Seyedi, S; Zarei-Ghanavati, S, 2012)	0.84
"Results of previous studies on the benefits of ocular drug delivery using polymeric mucoadhesive nanoparticles suggested longer presence and better penetration of nanoparticles, and, thus, increased effect and bioavailability of drugs entrapped in nanoparticles."	( Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide. Adibkia, K; Atyabi, F; De Geest, BG; Dinarvand, R; Ghahremani, MH; Hashemi, H; Khoshayand, MR; Mohsenzadeh, N; Sabzevari, A, 2013)	0.6
" Compared to a traditional subtenon injection, this drug film demonstrated superior therapeutic duration, better drug bioavailability in the choroid and retina, and better-targeted drug delivery ability."	( Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL). Cheng, L; Lan, B; Li, J; Li, X; Meng, Y; Sun, S; Zhou, S, 2016)	0.43
" Triamcinolone acetonide (TA) was selected as the model drug since it undergoes extensive first-pass metabolism, leading to poor oral bioavailability of 23%."	( Microemulsion-based delivery of triamcinolone acetonide to posterior segment of eye using chitosan and butter oil as permeation enhancer: an in vitro and in vivo investigation. Khunt, D; Misra, M; Raval, N, 2018)	1.67
"Despite eye drops generally represent the most convenient, simple and patient-friendly formulations to treat ocular diseases, they suffer from poor retention on the ocular surface and low drug bioavailability leading to the necessity of prolonged and continuous treatment over time."	( Microfibrillar polymeric ocular inserts for triamcinolone acetonide delivery. Carfì Pavia, F; Cavallaro, G; Di Prima, G; Giammona, G; Licciardi, M; Lo Monte, AI, 2019)	0.78
"Development of topically administered drug delivery systems for the treatment of ocular diseases have majorly focused on enhancing bioavailability of drugs in the ocular tissues."	( Spatio-temporal control on the delivery of triamcinolone acetonide using polymeric nanoparticles reduces steroid induced cataract. Katti, DS; Reddy, GB; Reddy, SS; Srinivasarao, DA, 2019)	0.78
" Therefore, as a continuation of our previous study using TA-chitosan coated liposomes (TA-CHLs) as a topical drug delivery system, the present study aimed to determine the drug safety, stability, permeability, and bioavailability of TA-CHLs."	( Triamcinolone acetonide-chitosan coated liposomes efficiently treated retinal edema as eye drops. Cheng, T; Cheng, Y; Li, J; Qu, Y; Zhang, X, 2019)	1.96
" Invasive drug administration via intracameral, subconjunctival, and intravitreal injection can enhance ocular bioavailability and minimize dose and dosing frequency of administration, yet may exacerbate ocular side effects of corticosteroids."	( Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Abdelkader, H; Alany, RG; Alqahtani, AM; Elgarhy, O; Gaballa, SA; Kompella, UB; Pierscionek, B, 2021)	0.62
" Application of these chitosan-coated nanoparticles as eye drops to C57BL/6 mice showed higher bioavailability in choroid and retina when compared to the uncoated nanoparticles."	( A non-invasive nanoparticle-based sustained dual-drug delivery system as an eyedrop for endophthalmitis. Ahamad, N; Baruah, N; Katti, DS; Lavik, E; Mahaling, B; Maisha, N, 2021)	0.62
"Customized cationic oil-in-water nanoemulsions (NEs) have been produced to improve the bioavailability of poorly water-soluble drugs, such as triamcinolone acetonide (TA)."	( Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes. Dos Santos, T; Fernandes, AR; Garcia, ML; Granja, PL; Sánchez-López, E; Silva, AM; Souto, EB; Vidal, LB, 2022)	1.19
" Although traditional corticosteroid treatments may demonstrate high levels of efficacy, systemic delivery carries the risk of potentially serious systemic adverse effects (AEs), and standard local modes of delivery may be associated with low bioavailability in posterior ocular tissues and steroid-associated AEs due to anterior ocular tissue exposure."	( Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with noninfectious uveitis: an in-depth look at efficacy and safety. Ciulla, T; Yeh, S, 2023)	1.26

Excerpt	Relevance	Reference
" Whether similar improvement could have been achieved by a different dosage regimen of corticosteroid tablets or whether it might have ocurred spontaneously was not tested."	( Triamcinolone in corticosteroid-resistant asthma. Cayton, RM; Howard, P; Peake, MD, 1979)	0.26
"In an attempt to determine whether chronic glucocorticoid treatment affects speed- and strength-related properties of fast-twitch muscle and slow-twitch muscle, in-situ contractile properties of soleus and gastrocnemius muscles were measured in rats after 14 days on a regiment of triamcinolone acetonide injected at a dosage of 2 mg/kg/day."	( Contractile responses of rat fast-twitch and slow-twitch muscles to glucocorticoid treatment. Edgerton, VR; Gardiner, PF, )	0.31
" Our belief is that this large dosage of corticosteroid was responsible for the late erosion of the medium-sized artery, which caused the hemorrhage."	( Late development of hematoma around a breast implant, necessitating removal. Barwick, W; Georgiade, NG; Serafin, D, 1979)	0.26
"The parenteral use of triamcinolone acetonide (Kenacort A) is said to have the following advantages: to keep the effect for two weeks by one injection, to be able to reduce the total treatment dosage and to secure the dosage regardless of patients cooperation."	( Parenteral treatment of sarcoidosis with triamcinolone. Hiraga, Y; Mikami, R; Osada, H; Yotsumoto, H, 1977)	0.57
"Twenty-three steroid-dependent severely asthmatic patients, ranging in age from 20 to 67 years, tolerated reduction in their oral dosage of steroids during a one-year trial of triamcinolone acetonide aerosol."	( A one-year trial of triamcinolone acetonide aerosol in severe steroid-dependent asthma. Chmelik, F; doPico, G; Kriz, RJ; Reed, CE, 1977)	0.77
" For most patients the monthly injection of 8 ml or less of a solution containing 5 mg/ml of triamcinolone proved to be the most effective dosage schedule."	( Intralesional triamcinolone therapy for pretibial myxedema. Lang, PG; Lynch, PJ; Sisson, JC, 1975)	0.25
" Conventional doses may not be sufficient to provide control in many patients, and dosing should be tailored to the individual."	( Inhaled steroids in asthma. Dworski, R; Sheller, J, 1992)	0.28
" The results of this study indicate that 6 weeks of treatment with 220 micrograms/day or 440 micrograms/day of ITAA has no effect on adrenocortical function, but prednisone, at a dosage of 10 mg/day for 6 weeks, produces partial adrenocortical suppression."	( A comparative study of the effects of intranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function. Dockhorn, R; Ellis, E; Feiss, G; Mansfield, L; Morris, R; Rom, D; Smith, JA; Tobey, RE, 1992)	0.54
" THA must be injected with a rigorous technique and with a dosage adapted to the articular volume."	( Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Job-Deslandre, C; Menkes, CJ, )	0.13
" Large doses of the corticosteroid had no additional effect on the reduction of retinal detachments, indicating an optimal dosage of 2 mg."	( The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Chandler, DB; de Juan, E; Machemer, R; Rozakis, G, 1985)	0.63
" Pretreatment of ROS cells for 2 days with the glucocorticoid triamcinolone acetonide (TRM), shifted the dose-response curve for PKA activation by PTH upward compared to the control value."	( Glucocorticoids and 1,25-dihydroxyvitamin D3 regulate parathyroid hormone stimulation of adenosine 3',5'-monophosphate-dependent protein kinase in rat osteosarcoma cells. Catherwood, BD; Lorang, MT; Rubin, JE; Titus, L, 1988)	0.52
" radiata [7]) during gestational days (GD) 23 to 41 using various dosing schedules."	( Central nervous system malformations induced by triamcinolone acetonide in nonhuman primates: pathology. Cordy, DR; Hendrickx, AG; Tarara, RP, 1989)	0.53
" Doses that cause receptor down-regulation are also effective at inducing tyrosine aminotransferase, suggesting that dexamethasone down-regulates its own receptors over a physiologically meaningful dosage range."	( The biopotency of dexamethasone at causing hepatic glucocorticoid receptor down-regulation in the intact mouse. Svec, F, 1988)	0.27
" Further studies are indicated to determine appropriate dosage necessary to maximize the beneficial local effects."	( The beneficial effect of triamcinolone acetonide on nerve repair with autogenous grafts. Ellis, J; Lipton, R; McCaffrey, TV, 1986)	0.57
" These effects were mitigated at a lower dosage especially by the addition of cefoxitin and deoxycortone."	( An attempt to develop a model to study the effects of intrathecal steroids. Rosen, M; Swai, EA, 1986)	0.27
" Pyrophosphate (PPi) is as effective as ATP in promoting receptor activation, since it elicits similar increases in DNA-cellulose binding, shifts in elution patterns from DEAE-cellulose, and dose-response relationships."	( ATP-induced activation of purified rat hepatic glucocorticoid receptors. Diehl, EE; Schmidt, TJ, 1987)	0.27
" Female rats were divided into five groups: 1) a sedentary group that received cortisol acetate (CA, 100 mg/kg body wt); 2) a sedentary group that received the dosing vehicle (1% aqueous carboxymethyl cellulose); 3) an exercise group that received CA immediately after each exercise session; 4) an exercise group that received CA 90 min after each exercise session; and 5) an exercise group that received the vehicle."	( Initiating regular exercise protects against muscle atrophy from glucocorticoids. Czerwinski, SM; Hickson, RC; Kurowski, TG; O'Neill, TM, 1987)	0.27
" These dose-response relationships are consistent with mediation of this effect by the glucocorticoid receptor."	( Glucocorticoid receptors and regulation of phenylethanolamine-N-methyltransferase activity in cultured chromaffin cells. Kelner, KL; Pollard, HB, 1985)	0.27
"Triamcinolone acetonide was administered in excessive dosage to dogs to study the renal mechanism responsible for polyuria which is a clinically undesirable side effect of long term glucocorticoid therapy."	( Renal effects of long term administration of triamcinolone acetonide in normal dogs. Osbaldiston, GW, 1971)	1.95
" Five glucocorticoids, when administered daily to rats for 5-7 days at a dosage of 5mg/kg, were in the following order of effectiveness with respect to their ability to decrease the weight gain of whole animals and the vastus lateralis, vastus medialis and gluteus medius muscles: corticosterone	( Relative changes in the function of muscle ribosomes and mitochondria during the early phase of steroid-induced catabolism. Bullock, GR; Carter, EE; Elliott, P; Peters, RF; Simpson, P; White, AM, 1972)	0.42
"Systemic vitamin A palmitate at three dosage levels was evaluated for its effect on experimental herpes simplex virus (HSV) keratitis in corticosteroid-treated rabbits."	( Vitamin A in experimental herpetic keratitis. Briones, O; Dawson, CR; Oh, J; Starr, MB, 1981)	0.26
" Calcium transport rates could be partially restored by in vivo administration of 1,25-dihydroxyvitamin D-3 at a dosage which did not affect vesicular calcium uptake in control animals."	( Calcium and glucose uptake in rat small intestinal brush-border membrane vesicles. Modulation by exogenous hypercortisolism and 1,25-dihydroxyvitamin D-3. Birkenhäger, JC; Braun, HJ; De Jonge, HR, 1984)	0.27
" Dose-response relations were analyzed by the log-probit transformation method."	( Dose-response relations of palatal slit, cleft palate, and fetal mortality in mice treated with a glucocorticoid. Kusanagi, T, 1983)	0.27
" Significant differences were observed between the liposome-encapsulated dosage form and the solution of the steroid in beta and Vd beta."	( Pharmacokinetic profile of intravenous liposomal triamcinolone acetonide in the rabbit. Abraham, I; Hilchie, JC; Mezei, M, 1983)	0.52
" The sensitive stages of palatal slit and cleft palate induction were studied and dose-response relations on days 9 and 12 of pregnancy were analyzed by the log-probit transformation method and compared."	( Sensitive stages and dose-response analyses of palatal slit and cleft palate in C57BL/6 mice treated with a glucocorticoid. Kusanagi, T, 1984)	0.27
"Eighty percent of 26 steroid-dependent, chronically asthmatic adults eliminated oral steroid dosage after 12 weeks of treatment with triamcinolone acetonide aerosol (800 micrograms/day)."	( Long-term triamcinolone acetonide aerosol treatment in adult patients with chronic bronchial asthma. Golub, JR, 1980)	0.87
" Dose-response curves and kinetic studies show that ADP is as effective as ATP in stabilizing the unoccupied glucocorticoid receptor against heat inactivation."	( In vitro stabilization of the unoccupied glucocorticoid receptor by adenosine 5'-diphosphate. Barnett, CA; Litwack, G; Palmour, RM; Seegmiller, JE, 1983)	0.27
" It is concluded that the combination of the aromatic retinoid (Ro 10-9359) given in low dosage orally with corticosteroids topically is as effective as therapy with the retinoid in high dosage alone, but with markedly less side-effects."	( Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: a double-blind trial. Herrmann, WA; Polano, MK; Tijssen, JG; van der Rhee, HJ; Waterman, AH, 1980)	0.48
" Twenty-four hours after the administration of triamcinolone hexacetonide condyles incorporated significantly less 35SO4, a feature that followed a dose-response relationship."	( Studies on hormonal regulation of the growth of the craniofacial skeleton: II. Effects of a glucocorticoid hormone on sulfate incorporation by neonatal condylar cartilage. Raz, E; Silbermann, M; Weiss, A, 1982)	0.26
" For children we recommend the short-acting triamcinolone diacetate at 4-week intervals with dosage adjusted to age."	( Cushing's syndrome: complication of triamcinolone injection for urethral strictures in children. Augspurger, RR; Wettlaufer, JN, 1980)	0.26
"Because some patients may prefer aqueous nasal sprays and once-daily dosing for relief of seasonal allergic rhinitis symptoms, a new aqueous formulation of triamcinolone acetonide (TAA Aqueous) was developed."	( Triamcinolone acetonide Aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Alderfer, VB; Korenblat, PE; Lumry, W; Murphree, J; Settipane, G; Simpson, B; Smith, JA; Winder, J, )	1.77
" When using local corticosteroid injections to treat interdigital neuromas, the physician should be familiar with the properties and recommended dosage of the given steroid."	( Interdigital neuroma. Local cutaneous changes after corticosteroid injection. Holder, J; Reddy, PD; Ruotolo, C; Zelicof, SB, 1995)	0.29
"With use of partial suppression of immediate response to inhaled allergen and 24-hour urinary free cortisol output, three-point dose-response curves were constructed for beclomethasone dipropionate (50 micrograms/puff), triamcinolone acetonide (100 micrograms/puff), and flunisolide (250 micrograms/puff)."	( A bioassay for topical and systemic effect of three inhaled corticosteroids. Ahrens, R; Grandgeorge, S; McCubbin, MM; Milavetz, G; Sargent, C; Vaughan, LM; Weinberger, M, 1995)	0.48
" Dose-response relationships were shown for each inhaled corticosteroid for both topical and systemic effect."	( A bioassay for topical and systemic effect of three inhaled corticosteroids. Ahrens, R; Grandgeorge, S; McCubbin, MM; Milavetz, G; Sargent, C; Vaughan, LM; Weinberger, M, 1995)	0.29
" Dose-response analyses also revealed a coordinate down-regulation of GR and c-jun (but not POMC or c-fos) mRNA levels."	( Coordinate regulation of glucocorticoid receptor and c-jun mRNA levels: evidence for cross-talk between two signaling pathways' at the transcriptional level. Barrett, TJ; Vedeckis, WV; Vig, E, 1994)	0.29
" The varying dosages of TA produced insignificant differences; however, the proportional distribution of the types of filtering blebs differed significantly among the various dosage groups, and complications occurred mostly in the high dosage group of 12 mg."	( [A randomized controlled study of the anti-cicatricial effect of preoperative subconjunctival triamcinolone on the filtering bleb]. Wang, NL; Ye, TC; Zhou, WB, 1994)	0.29
" Transmission electron microscopy showed that FD at a dosage of over 5 micrograms or DL over 20 micrograms was toxic to the retina and that up to 4 mg TA was nontoxic."	( Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Cai, YS; Heimann, K; Hui, YN; Kirchhof, B; Liang, HC, 1993)	0.29
" Dose-response analyses reveal the expected coordinate regulation of both GR and c-jun mRNA and protein in L929 cells (decreasing) and in CEM-C7 cells (increasing)."	( Coordinate regulation of glucocorticoid receptor and c-jun gene expression is cell type-specific and exhibits differential hormonal sensitivity for down- and up-regulation. Barrett, TJ; Vedeckis, WV; Vig, E, 1996)	0.29
" Once symptoms are under control, the dosage of aqueous triamcinolone acetonide may be reduced from 220 to 110 micrograms/day without loss of effect."	( Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Faulds, D; Jeal, W, 1997)	1.99
" Further dose-ranging studies are required at steady-state in asthmatic subjects in order to see whether differences occur at lower doses on the steep part of the dose-response curve for both plasma and urinary cortisol suppression."	( Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Clark, DJ; Lipworth, BJ; McFarlane, L; Wilson, AM, 1997)	0.53
"This study evaluated whether more convenient once-daily dosage times (8 AM and 5:30 PM) produce improvement in asthma equivalent to QID."	( Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. Humeston, TR; Martin, RJ; Pincus, DJ, 1997)	0.3
" Dosing at 8 AM did not produce results consistently comparable to QID dosing."	( Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. Humeston, TR; Martin, RJ; Pincus, DJ, 1997)	0.3
" Twice daily dosing may increase compliance with therapy."	( A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. Bernstein, DI; Cohen, R; Ginchansky, E; Pedinoff, AJ; Tinkelman, DG; Winder, JA, 1998)	0.55
"At this time, no placebo-controlled studies in the clinical literature compare the efficacy and safety of the most widely prescribed oral inhaled corticosteroids when dosed at their recommended daily doses."	( Comparative clinical study of inhaled beclomethasone dipropionate and triamcinolone acetonide in persistent asthma. Bronsky, E; Chen, R; Harris, AG; Korenblat, P, 1998)	0.53
" Both treatments were dosed at their most commonly used daily doses (within labeling)."	( A comparison of triamcinolone acetonide MDI with a built-in tube extender and beclomethasone dipropionate MDI in adult asthmatics. Berkowitz, R; Chen, R; Harris, AG; Rachelefsky, G, 1998)	0.65
"We sought to evaluate the dose-response effect of inhaled BUD and TAA in terms of adrenal, bone, and blood markers."	( Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. Brewster, HJ; Lipworth, BJ; Wilson, AM, 1998)	0.53
" There was no evidence of a significant overall dose-response effect for any parameter of hypothalamo-pituitary-adrenocortical axis activity, with neither drug being significantly different from placebo at any dose."	( Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. Brewster, HJ; Lipworth, BJ; Wilson, AM, 1998)	0.53
" Chronic dosing did result in a statistically significant 20% reduction in basal 24-hour serum cortisol AUC(0-24) for both compounds."	( A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. Argenti, D; Heald, D; Shah, B, 2000)	0.53
" A review of available information indicates that (1) sensitive tests can measure the effects of INSs on biologic feedback systems, but they do not accurately predict clinically relevant adverse effects; (2) the primary factors that influence the relationship between therapeutic and adverse systemic effects of INSs are dosing frequency and efficiency of hepatic inactivation of swallowed drug; (3) INS treatment in recommended doses does not cause clinically significant hypothalamic-pituitary-adrenal axis suppression; (4) growth suppression can occur with twice-daily administration of certain INSs but does not appear to occur with once-daily dosing or with agents with more complete first-pass hepatic inactivation; (5) harmful effects of INSs on bone metabolism have not yet been adequately studied but would not be expected with the use of an INS dose and dosing frequency that do not suppress basal hypothalamic-pituitary-adrenal axis function or growth; and (6) these conclusions apply to INS treatment alone and in recommended doses-the risk of adverse effects in individual patients who are treated with INSs is increased by excessive dosing or concomitant inhaled corticosteroid or other topical corticosteroid therapy."	( Systemic effects of intranasal steroids: an endocrinologist's perspective. Allen, DB, 2000)	0.31
" A dosage of 1 mg/0."	( Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Cheema, R; El-Dessouky, ES; Hegazy, H; Kazi, AA; Kivilcim, M; Peyman, GA, )	0.45
") dosing was best described by a three-compartment open model."	( Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. French, K; Pass, MA; Pollitt, CC, 2000)	0.57
" In addition, the spacer devices investigated will allow a higher dose of drug to reach the deep lung, which may permit the use of lower dosage regimens with increased therapeutic efficacy."	( Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. Barron, MK; Patel, AM; Rogers, TL; Williams, RO, 2001)	0.31
" The algorithm was designed to calculate CCS based on 5 input parameters: name of drug, dose, dosing interval, time(s) of dosing, and type of inhaler device."	( An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. Derendorf, H; Hochhaus, G; Krishnaswami, S, 2000)	0.31
" In summary, based on the results of this PK/PD simulation, the plasma levels observed afternasal administration of the solution or the aqueous suspension are unlikely to induce a clinically relevant cortisol suppression, especially for the recommended dosing regimens of 200 and 220 microg/day."	( A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial allergic rhinitis: how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspension-based formulation? Dockhorn, RJ; González, MA; Hochhaus, G; Karafilidis, J; Shilstone, J, 2002)	0.6
" It is likely that once-daily dosing and patient preference for the sensory attributes of TAA AQ may enhance treatment compliance."	( A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis. el-Akkad, T; Hampel, F; Kiechel, F; LaForce, C; Lumry, W; Murray, JJ, )	0.43
" The highest dosage of MPA (10 mg/ml) reduced GAG synthesis less than lower dosages of MPA and all dosages of TA."	( Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. Baxter, GM; Dechant, JE; Frisbie, DD; McIlwraith, CW; Trotter, GW, 2003)	0.56
" In contrast, a conventional formulation of triamcinolone-acetonide requires a 10-fold higher drug dosage to achieve a similar effect."	( Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. Blume, G; Cevc, G, 2003)	0.32
" The duration of the effect of a single intravitreal injection of triamcinolone ranges between 2 and 9 months, probably depending on the dosage used."	( [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases]. Degenring, RF; Jonas, JB; Kamppeter, B; Kreissig, I, 2004)	0.68
"The aim of this study was to compare the effectiveness of triamcinolone hexacetonide (THA) and methylprednisolone acetate (MPA), given via the intra-articular route at equipotent dosage to patients with symptomatic knee OA with effusion, in a double-blind randomized comparative trial."	( Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Bhanji, A; Ioannou, Y; Mootoo, R; Pyne, D, 2004)	0.32
" This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema."	( Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Akkoyun, I; Degenring, RF; Jonas, JB; Kamppeter, BA; Kreissig, I, 2004)	0.82
" During the follow-up period, recurrent macular edema was retreated with the same dosage and followed for another 6 months."	( Intravitreal triamcinolone injection for macular edema secondary to increased retinal vascular permeability. Lee, WF; Yang, CM, 2004)	0.32
" Moreover, the transient effect on CMT may warrant further studies to determine optimal timing and dosage of further ivTA injections."	( Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Chan, CK; Chan, WM; Fan, DS; Lai, TY; Lai, WW; Lam, DS; Lee, VY; Mohamed, S, 2005)	0.33
" Due to the transient nature of IVTA, re-treatment seems necessary but the optimal timing and dosage will require further investigations."	( Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Chan, CK; Chan, WM; Fan, DS; Lam, DS; Li, KK; Tang, EW, 2004)	0.32
" It did not have a significantly different therapeutic efficacy from the commercial paste dosage form in the treatment of oral lichen planus."	( Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. Kietthubthew, S; Maneenuan, D; Nittayananta, W; Phadoongsombat, N; Ungphaiboon, S; Vuddhakul, V; Wongpoowarak, W, 2005)	0.62
" For the second pharmacy, mean triamcinolone acetonide dosage was 23."	( Triamcinolone acetonide concentration after filtration of the solvent agent. Derse, M; Jonas, JB; Papoulis, C; Sagstetter, BU; Schmitz-Valckenberg, P; Spandau, UH; Stiefvater, K, 2005)	2.06
" The duration of the effect of a single intravitreal injection of triamcinolone depended on the dosage given."	( Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Degenring, R; Jonas, JB; Kreissig, I, 2005)	0.7
" Dosage measurement was performed before filtration."	( Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Derse, M; Jonas, JB; Papoulis, C; Schmitz-Valckenberg, P; Spandau, UH, 2005)	0.61
"38) correlated with the dosage of intravitreal triamcinolone acetonide."	( Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Derse, M; Jonas, JB; Papoulis, C; Schmitz-Valckenberg, P; Spandau, UH, 2005)	0.86
"In patients with diffuse diabetic macular oedema receiving intravitreal triamcinolone acetonide, treatment response may last longer and be more pronounced with a dosage of 13 mg than in lower doses of 5 mg or 2 mg."	( Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Derse, M; Jonas, JB; Papoulis, C; Schmitz-Valckenberg, P; Spandau, UH, 2005)	0.84
" The dosage of oral corticosteroids and/or second-line immunosuppressive medication was reduced or stopped altogether in 18 of 33 eyes (54."	( Outcome of intravitreal triamcinolone in uveitis. Kok, H; Lau, C; Lightman, S; Maycock, N; McCluskey, P, 2005)	0.33
" The objective of the current study was to compare the relative patient satisfaction with budesonide inhalation powder administered via Turbuhaler (AstraZeneca LP, Wilmington, DE) (200 to 1600 microg/d using one of 3 dosing strengths: 100, 200, or 400 microg per inhalation) and triamcinolone acetonide administered via pressurized metered-dose inhaler (200 to 1600 microg/d) among persons treated in managed care settings."	( Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting. Liljas, B; Luce, BR; Paramore, LC; Revicki, DA; Weiss, KB, 2005)	0.75
" In non-vitrectomized eyes, the duration of the effect and side-effects of a single intravitreal injection of triamcinolone is about 6-9 months for a dosage of about 20 mg, and about 2-4 months for a dosage of 4 mg."	( Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Jonas, JB, 2005)	0.7
"Intravitreal triamcinolone acetonide (TA) has been widely used as a therapeutic method for many ocular diseases, but a consensus on an appropriate safe therapeutic window of dosage for intravitreal injection, and whether vehicle of TA should be reduced or eliminated, has not yet been reached."	( Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Kai, W; Xiaoxin, L; Yanrong, J, 2006)	1.09
" In nonvitrectomized eyes, the duration of the effect and side effects of a single intravitreal injection of triamcinolone is about 6-9 months for a dosage of about 20 mg, and about 2-4 months for a dosage of 4 mg."	( Intravitreal triamcinolone acetonide: a change in a paradigm. Jonas, JB, 2006)	0.7
"Using a dosage of approximately 20 mg of intravitreal TA, visual acuity temporarily increases for 6 months after injection."	( Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. Harder, B; Jonas, JB; Kamppeter, BA; Sauder, G; Spandau, UH; Vossmerbaeumer, U, 2006)	0.7
" The AR subjects were administered TAA in a daily dosage of a 220-microg intranasal route."	( The effect of triamcinolone acetonide aqueous nasal spray on the nasal carriage of Staphylococcus aureus. Karabay, O; Kocoglu, E; Koybasi, S; Talay, F; Yilmaz, F, )	0.49
" During each flare-up, the patient was housebound and required therapeutic dosing of nonsteroidal anti-inflammatory drugs and codeine to control joint pain."	( Carbonated apatite-induced arthropathy: a consideration in cases of polyarthritis. Blair-Levy, JM, 2006)	0.33
" The duration of the effect of a single IVTA is dosage dependent (about 6-9 months with 20 mg, and about 2-4 months with 4 mg)."	( Intravitreal triamcinolone acetonide for diabetic retinopathy. Jonas, JB, 2007)	0.71
" This makes it possible to decrease the dosage and duration of topical prednisolone acetate."	( Intracameral triamcinolone acetonide to control postoperative inflammation following cataract surgery with phacoemulsification. Akova, YA; Borazan, M; Karalezli, A, 2008)	0.72
"Younger age, higher baseline IOP, IVI, and increased TA dosage were associated with TA-induced IOP elevation."	( Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Hirano, Y; Hirooka, K; Inatani, M; Iwao, K; Kawaji, T; Matsumura, M; Nakanishi, Y; Negi, A; Ogura, Y; Sakamoto, T; Shima, C; Shimonagano, Y; Shiraga, F; Tanihara, H; Yamamoto, H, 2008)	0.6
"Differential gene expression profiles of human TM cells treated by TA and DEX, and a dosage effect by TA, were revealed by microarray technology."	( Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Fan, BJ; Lam, DS; Pang, CP; Tham, CC; Wang, DY, 2008)	0.35
"Although the sample in this study was small, there was a dose-response trend toward better visual outcomes and fewer treatments in the group treated with IVT injection and reduced-fluence PDT."	( Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Saperstein, DA; Singh, CN, 2008)	0.35
"To evaluate the efficacy of the self-adjustable dosing regimen and explore potential dose-response relationships of intranasal corticosteroids in persistent allergic rhinitis."	( Dose-related effect of intranasal corticosteroids on treatment outcome of persistent allergic rhinitis. Chansaksung, P; Kirtsreesakul, V; Ruttanaphol, S, 2008)	0.35
"A self-adjustable dosing approach proved to be an efficacious approach to controlling allergic rhinitis."	( Dose-related effect of intranasal corticosteroids on treatment outcome of persistent allergic rhinitis. Chansaksung, P; Kirtsreesakul, V; Ruttanaphol, S, 2008)	0.35
"75) times and the mean oral dosage of NSAID was (1267 +/- 325) mg."	( Continuous epidural block of the cervical vertebrae for cervicogenic headache. Guo, YN; He, MW; Liu, JJ; Ni, JX; Wang, Q; Yang, LQ, 2009)	0.35
"In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 mg, than after lower doses of 8 mg or 4 mg."	( Dose dependent effects of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. Bae, JS; Ham, IR; Lee, TG; Park, SJ, 2009)	0.62
" More studies are required to determine the optimal dosage and treatment frequency in different posterior segment disease."	( Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide. Gillies, M; Kuo, CH; McCluskey, P, 2010)	0.6
" Other factors, including past medical history and renal function, also need to be taken into account when choosing the proper dosing regimen."	( Intrapericardial triamcinolone for acute pericarditis after electrophysiologic procedures. Crouch, MA; Maxwell, CB, 2010)	0.36
"A worse treatment outcome despite more clinical improvements during the treatment period in a higher severity score suggests the therapeutic predictive value of pretreatment nasal symptom scoring and the need for more dosing and continuing medication in higher scores, especially in blocked nose."	( Impact of pretreatment nasal symptoms on treatment outcome in allergic rhinitis. Chansaksung, P; Kirtsreesakul, V; Ruttanaphol, S, 2010)	0.36
" This strategy results in prolonged dosage intervals and reduced tablet intake due to a reduced overall dose that is needed."	( [Cushing syndrome after steroid-infiltration in two HIV-patients with antiretroviral therapy]. Günthard, HF; Herold, MA, 2010)	0.36
" The dosage of immunosuppressive systemic therapy was reduced or able to be stopped in three patients (50%)."	( Periocular corticosteroid injection in the management of uveitis in children. Grigg, JR; Habot-Wilner, Z; Kabasele, PM; Lightman, S; McCluskey, P; Roufas, A; Sallam, A, 2010)	0.36
" The patient's PM achieved complete remission in both lower extremities after an approximately 6-month period that included seven courses of treatment with a total dosage of 280 mg triamcinolone acetonide."	( Multipoint subcutaneous injection of long-acting glucocorticid as a cure for pretibial myxedema. Deng, A; Song, D, 2011)	0.56
"The treatment with Long term use of low dosage oral macrolide Clarithromycin combined with nasal steroid on CRS was efficacy."	( [Clinical observation of Clarithromycin combined with nasal steroid treatment for chronic rhinosinusitis]. Feng, Z; Hong, Y; Li, Q; Li, X; Liu, J; Liu, L; Lu, X; Wan, Y; Zhong, G, 2011)	0.37
"Intra-articular and intralesional glucocorticoid injections are commonly used by dermatologists, orthopedic surgeons, and rheumatologists because they offer many advantages over oral or parenteral dosage forms."	( Linear rays of hypopigmentation following intra-articular corticosteroid injection for post-traumatic degenerative joint disease. Feinberg, JS; Javvaji, S; Schwartz, C, 2012)	0.38
"9% were prepared to investigate the dosage effect on transdermal delivery and anti-inflammatory activity."	( A novel transdermal fomulation of 18β-glycyrrhetic acid with lysine for improving bioavailability and efficacy. Gao, YH; Li, S; Qiu, YQ; Zhang, SH, 2012)	0.38
"The lack of anatomic and functional efficacy observed in our study does not appear to be related to the method, dosage or timing of injection, nor to the presence of subretinal macroaneurysms."	( [Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide]. Duncombe, A; Genevois, O; Le Moigne, O; Muraine, M; Portmann, A, 2012)	0.58
"A low dosage of TA(4 mg) administered via intravitreal injection might be useful as an initial treatment for macular edema secondary to CRVO."	( Different dosages of intravitreal triamcinolone acetonide injections for macular edema secondary to central retinal vein occlusion. Bi, C; Chen, F; Wang, H; Wei, Y; Yang, X; Zu, Z, 2012)	0.66
"To evaluate the effect of intravitreal triamcinolone acetonide (TA) on healing of retinal photocoagulation lesions using drug and laser dosing typically employed in clinical practice."	( Effect of intravitreal triamcinolone acetonide on healing of retinal photocoagulation lesions. Blumenkranz, MS; Dalal, R; Lavinsky, D; Leung, LS; Nomoto, H; Palanker, D; Paulus, YM, 2013)	0.97
" The present text provides a systematic review of all previously reported cases of Cushing's syndrome resulting from intralesional TAC in an effort to discover whether an association exists between dosage or frequency of injection and the subsequent development of Cushing's syndrome."	( Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Fredman, R; Tenenhaus, M, 2013)	0.66
" Survey data reveals that at least 30% (25/84) of plastic surgeons exceed the recommended dosage of TAC and 47% (46/97) are not aware of Cushing's syndrome as a possible complication of intralesional TAC."	( Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Fredman, R; Tenenhaus, M, 2013)	0.66
" Intralesional dosage should not exceed 30 mg per month in children while noting that at least one reported case of Cushing's syndrome resulted from a smaller dose."	( Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Fredman, R; Tenenhaus, M, 2013)	0.66
" The dosage of oral corticosteroids and/or second-line immunosuppressive agents was able to be reduced or stopped in 22 patients, 29 of 35 eyes (82."	( Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Do, HH; Habot-Wilner, Z; Lightman, S; McCluskey, P; Pacheco, PA; Sallam, A, 2011)	0.74
"The lack of recommendations regarding dosing and administration, an undetermined risk of hypothalamic-pituitary-adrenal axis alteration, and the unknown effectiveness of intramuscular (IM) corticosteroid injection to treat dermatologic disease may be deterrents to use."	( A prospective observational study evaluating hypothalamic-pituitary-adrenal axis alteration and efficacy of intramuscular triamcinolone acetonide for steroid-responsive dermatologic disease. Ananthakrishnan, S; Garg, A; Reddy, S, 2013)	0.6
" Patients received pro re nata dosing of ranibizumab."	( One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Lim, JI; Niec, M; Wong, V, 2015)	0.62
" The model can estimate drug release from implants or the dissolution of suspensions as a first step in their clearance mechanism, which will be the rate-limiting step for the overall resident time of a candidate dosage form in the vitreous."	( The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development. Awwad, S; Brocchini, S; Khaw, PT; Lockwood, A, 2015)	0.42
" Results in the BET group suggest that investigation into types, dose, and dosage schedule of glucocorticoids may facilitate placental maturation."	( Localization of TGF-β and TGF-β receptor in bovine term placentome and expression differences between spontaneous and induced parturition. Fujii, T; Fukuda, S; Hirayama, H; Kageyama, S; Koyama, K; Naito, A; Sawai, K, 2015)	0.42
"There is insufficient data in the literature concerning optimal intralesional kenalog (ILK) dosing for the treatment of alopecia areata (AA)."	( ILK Index and Regrowth in Alopecia Areata. Bergfeld, WF; Fiessinger, LA; Kyei, A; Mesinkovska, NA; Piliang, MP; Stallings, AM; Velez, MW, 2015)	0.42
" The validated method was applied for the determination of uniformity of dosage units and the reasons for variability (inhomogeneity and the analytical method error) were analyzed based on the overall uncertainty."	( Development of an ultra high performance liquid chromatography method for determining triamcinolone acetonide in hydrogels using the design of experiments/design space strategy in combination with process capability index. Fariña, JB; Llabrés, M; Monzón, C; Oliva, A; Santoveña, A, 2016)	0.66
"The HPLC-MS analytical method is an alternative to HPLC-MS/MS methods, sensitive enough for identifying and quantifying steroids in vitreous humor at a therapeutic dosage scale."	( Determination of Three Corticosteroids in the Biologic Matrix of Vitreous Humor by HPLC-tandem Mass Spectrometry: Method Development and Validation. Fraile, JM; Garcia-Martin, E; Mayoral, JA; Otín-Mallada, S; Pablo, LE; Polo-Llorens, V; Prieto, E; Vispe, E, 2017)	0.46
" The combination of the modified VM and EyeMoS seems a valuable tool for characterizing intravitreal dosage forms in a reproducible simulation of diversified eye movements and a partially liquefied or vitrectomized vitreous body."	( Distribution of fluorescein sodium and triamcinolone acetonide in the simulated liquefied and vitrectomized Vitreous Model with simulated eye movements. Bogdahn, M; Rosenbaum, C; Seidlitz, A; Stein, S; Weitschies, W, 2017)	0.72
"Despite the higher dosage of triamcinolone, both therapies were safe and effective for treating diabetic macular edema."	( Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Karst, SG; Kriechbaum, K; Kundi, M; Lammer, J; Mehta, J; Mitsch, C; Schmidt-Erfurth, U; Schober, M; Scholda, C, 2018)	0.48
" A dose-response effect in duration of maximal analgesic effect was evident (13 weeks with 32 mg versus 9 weeks with 16 mg), with FX006 32 mg providing increased therapeutic benefit relative to FX006 16 mg."	( Brief Report: A Phase IIb Trial of a Novel Extended-Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis. Berenbaum, F; Bodick, N; Cohen, SB; Conaghan, PG; Johnson, JR; Lufkin, J, 2018)	0.7
" Following a single intravitreal injection, the proposed TA-SA-Glu hydrogel hardly caused apparent retinal toxicity at a dosage of 69 nmol per eye."	( Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation. Lei, L; Li, X; Song, Q; Xiong, T; Zhang, R; Zhou, Y, 2018)	0.48
"A dose-response characteristic was demonstrated in the treatment of trigger finger with triamcinolone acetonide."	( Different Dosages of Triamcinolone Acetonide Injection for the Treatment of Trigger Finger and Thumb: A Randomized Controlled Trial. Kosiyatrakul, A; Loketkrawee, W; Luenam, S, 2018)	1.02
" Triesence, a preservative-free sterile formulation of triamcinolone acetonide, has been used in a wide spectrum of ocular pathologies, but there have been few large studies validating its dosing or detailing long-term side effects in uveitic disease."	( Treatment Duration and Side Effect Profile of Long-Term Use of Intravitreal Preservative-Free Triamcinolone Acetonide in Uveitis. Arepalli, S; Baynes, K; Bena, J; Ganapathy, PS; Li, M; Lowder, CY; Srivastava, SK, 2018)	0.95
" However, the clinically used dosage has poor tissue permeability and injection safety."	( Transdermal permeability of triamcinolone acetonide lipid nanoparticles. Ban, J; Chen, D; Chen, F; Qin, Z; Tan, Y; Wang, Y, 2019)	0.81
"Sixty-three adult patients with ethmoidal involvement in cone beam computerised tomography (CBCT) whose first-line medical treatment with topical corticosteroids had failed and who were candidates for ESS were randomised either to a DES group, which received triamcinolone acetonide stents (n = 34), or to a topical intranasal corticosteroid group (n = 29) that used optimally dosed triamcinolone acetonide nasal spray."	( Ethmoidal drug-eluting stent therapy is not superior to nasal corticosteroid spray in the prevention of endoscopic sinus surgery: Results from a randomised, clinical trial. Numminen, J; Rautiainen, M; Sillanpää, N; Taulu, R, 2020)	0.74
" The dosage regimens vary from 10 to 40 mg triamcinolone acetonide."	( Injection of Steroid in Nasal Polyps: A Systematic Review. Alanin, MC; Hansen, MB, 2020)	0.82
" Invasive drug administration via intracameral, subconjunctival, and intravitreal injection can enhance ocular bioavailability and minimize dose and dosing frequency of administration, yet may exacerbate ocular side effects of corticosteroids."	( Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Abdelkader, H; Alany, RG; Alqahtani, AM; Elgarhy, O; Gaballa, SA; Kompella, UB; Pierscionek, B, 2021)	0.62
" The combination of additives and dosage are various and controversial."	( Efficacy of Periarticular Multimodal Analgesic Injection Containing High-Dose Ketorolac versus Triamcinolone in Early Postoperative Total Knee Arthroplasty: A Randomized Controlled Trial. Apinyankul, R; Goodman, SB; Lilakhunakon, K; Vechvitvarakul, M; Witayakom, W, 2022)	0.72
" Increasing the dosage and duration of keloid scar treatment is required in future studies to determine whether it would result in a significant therapeutic outcome."	( Efficacy of a triamcinolone acetonide-loaded dissolving microneedle patch for the treatment of hypertrophic scars and keloids: a randomized, double-blinded, placebo-controlled split-scar study. Disphanurat, W; Leelawattanachai, J; Sivapornpan, N; Srisantithum, B, 2023)	1.27
" Reported corticosteroid dosing that one would inject in one specific keloid differed by a factor of 40."	( Intralesional corticosteroid administration in the treatment of keloids: a survey among Dutch dermatologists and plastic surgeons. Gibbs, S; Lapid, O; Louter, JMI; Niessen, FB; van Zuijlen, PPM; Wolkerstorfer, A; Yin, Q, 2023)	0.91
" Dosing per cm2 could only be compared among ten (26%) studies and varied from 1 to 20 mg."	( Intralesional Corticosteroid Administration in the Treatment of Keloids: A Scoping Review on Injection Methods. Gibbs, S; Lapid, O; Louter, JMI; Niessen, FB; Tasdemir-Kilic, G; van Zuijlen, PPM; Wolkerstorfer, A; Yin, Q, 2023)	0.91
" However, it is crucial to closely monitor patients for any adverse effects resulting from the treatment, which may arise from high dosage or increased frequency."	( Iatrogenic cushing's syndrome post intralesional triamcinolone acetonide in oral submucous fibrosis: 2 case reports. Choden, K; Gyeltshen, T, 2023)	1.16

Role	Description
anti-inflammatory drug	A substance that reduces or suppresses inflammation.
anti-allergic agent	A drug used to treat allergic reactions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
11beta-hydroxy steroid	Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
20-oxo steroid	An oxo steroid carrying an oxo group at position 20.
21-hydroxy steroid
3-oxo-Delta(4) steroid	A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
glucocorticoid	Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
cyclic ketal	A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
fluorinated steroid	A steroid which is substituted with one or more fluorine atoms in any position.
primary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	89.1251	0.0447	17.8581	100.0000	AID485294
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	0.0239	3.1890	29.8841	59.4836	AID1224846
SMAD family member 2	Homo sapiens (human)	Potency	24.6884	0.1737	34.3047	61.8120	AID1346859
ATAD5 protein, partial	Homo sapiens (human)	Potency	0.1158	0.0041	10.8903	31.5287	AID504467
SMAD family member 3	Homo sapiens (human)	Potency	24.6884	0.1737	34.3047	61.8120	AID1346859
GLI family zinc finger 3	Homo sapiens (human)	Potency	29.0648	0.0007	14.5928	83.7951	AID1259368; AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	5.5787	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID1259381; AID743035; AID743040; AID743042; AID743054; AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.0100	0.0013	7.7625	44.6684	AID914; AID915
progesterone receptor	Homo sapiens (human)	Potency	0.0040	0.0004	17.9460	75.1148	AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	17.2245	0.0123	7.9835	43.2770	AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0430	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	70.8364	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	49.2599	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	20.4362	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptor	Homo sapiens (human)	Potency	31.7457	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	12.1422	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743077; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	15.4871	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	61.6524	0.0010	24.5048	61.6448	AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	6.8812	0.0237	23.2282	63.5986	AID743222
IDH1	Homo sapiens (human)	Potency	0.4611	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	89.1251	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	0.2731	0.0007	23.0674	1,258.9301	AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	14.4277	0.0017	23.8393	78.1014	AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	9.7712	19.7391	45.9784	64.9432	AID1159509
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	12.5893	0.1000	9.1916	31.6228	AID1346983
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.0041	0.0041	9.9848	25.9290	AID504444
heat shock protein beta-1	Homo sapiens (human)	Potency	21.5350	0.0420	27.3789	61.6448	AID743210
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	12.5893	0.0079	8.2332	1,122.0200	AID2551
geminin	Homo sapiens (human)	Potency	0.0046	0.0046	11.3741	33.4983	AID624296
lamin isoform A-delta10	Homo sapiens (human)	Potency	10.0000	0.8913	12.0676	28.1838	AID1487
Cellular tumor antigen p53	Homo sapiens (human)	Potency	68.5896	0.0023	19.5956	74.0614	AID651631
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	0.3162	1.7783	16.2081	35.4813	AID652104
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	0.0723	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	0.0033	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.0044	0.0000	0.4953	10.0000	AID625263
Glucocorticoid receptor	Homo sapiens (human)	Ki	0.0020	0.0001	0.3863	7.0010	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0044	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Ki	0.0020	0.0007	0.7653	7.0010	AID625263
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0044	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	Ki	0.0020	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0044	0.0015	0.8044	5.0740	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Ki	0.0020	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0044	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Ki	0.0020	0.0007	0.7846	7.0010	AID625263
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glycine receptor subunit beta	Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID346025	Binding affinity to beta cyclodextrin	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID74378	Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150117	Alkylating activity of the compound assessed as alkylation of 4-(p-nitrobenzyl)pyridine after 20 mins by colorimetric analysis	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and biological action of two glucocorticoid alkylating agents.
AID144114	Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay	2002	Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5	Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate.
AID74376	Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID213396	Glucocorticoid induced Tyrosine Aminotransferase activity relative to Dexamethasone	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID91225	Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay; Potent	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID1443047	Inhibition of retinal leukostasis in STZ-induced Wistar rat diabetic retinopathy model assessed as adherent leukocyte count per retina at 50 ug/eye administered intravitreally measured after 3 days by FITC-ConA staining based fluorescence microscopic meth	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.
AID1219277	Activity at recombinant CYP3A4 (unknown origin) assessed as half life at 1 uM by LC-MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
AID162613	Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1443048	Downregulation of TNFalpha level in STZ-induced Wistar rat diabetic retinopathy model at 50 ug/eye administered intravitreally measured after 3 days by Western blot method	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID74377	Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443040	Inhibition of retinal vascular leakage in STZ-induced Wistar rat diabetic retinopathy model assessed as reduction in FITC-dextran leakage at 50 ug/eye administered intravitreally measured after 3 days by fluorescence microscopic method	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.
AID39320	Relative binding affinity for androgen receptor of prostate of rat at 2 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID188016	Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID74374	Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150110	Growth inhibition of mouse L929 cells at 3 x 10'-7 M preincubated for 48 hrs followed by compound washout	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and biological action of two glucocorticoid alkylating agents.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID144115	Maximal percent of fibroblast cell growth inhibition using antiproliferative assay	2002	Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5	Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID311367	Permeability coefficient in human skin	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID74375	Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1219279	Activity at recombinant CYP3A7 (unknown origin) assessed as half life at 1 uM by LC-MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
AID74373	Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID126435	Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443049	Downregulation of ICAM-1 level in STZ-induced Wistar rat diabetic retinopathy model at 50 ug/eye administered intravitreally measured after 3 days by Western blot method	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.
AID90104	Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID1443041	Inhibition of retinal vascular leakage in STZ-induced Wistar rat diabetic retinopathy model assessed as Evans blue albumin level in retina at 50 ug/eye administered intravitreally measured after 3 days (Rvb = 82.94 +/- 11.2 ug/g)	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling.
AID1219278	Activity at recombinant CYP3A5 (unknown origin) assessed as half life at 1 uM by LC-MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1150112	Growth inhibition of mouse L929 cells after 6 days	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and biological action of two glucocorticoid alkylating agents.
AID1778704	Inhibition of DNP-HAS-stimulated mast cell degranulation in rat RBL-2H3 cells assessed as reduction in beta-hexosaminidase release at 300 uM incubated for 5 mins followed by DNP-HAS stimulation for 1 hr by multiplate reader analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Hybrids between H
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346849	Human Glucocorticoid receptor (3C. 3-Ketosteroid receptors)	1995	Brain research, Jul-10, Volume: 685, Issue:1-2	Distinction between binding of [3H]triamcinolone acetonide to a ligand binding domain on the glucocorticoid receptor complex in cytosol fractions of brain and liver from the rat with intact adrenals.
AID1346849	Human Glucocorticoid receptor (3C. 3-Ketosteroid receptors)	1981	Endocrinology, Apr, Volume: 108, Issue:4	Species-related differences in steroid-binding specificity of glucocorticoid receptors in lung.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1838 (32.68)	18.7374
1990's	554 (9.85)	18.2507
2000's	1441 (25.62)	29.6817
2010's	1374 (24.43)	24.3611
2020's	417 (7.41)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,017 (16.44%)	5.53%
Reviews	284 (4.59%)	6.00%
Case Studies	992 (16.03%)	4.05%
Observational	28 (0.45%)	0.25%
Other	3,867 (62.49%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (357)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema [NCT00367133]	Phase 3	840 participants (Actual)	Interventional	2004-07-31	Completed
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis: a Non-inferiority Randomized Controlled Double-blind Study [NCT05806021]	Phase 4	327 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Active Control,Randomized,Double- Blinded Clinical Trial of BD [NCT03771768]		38 participants (Anticipated)	Interventional	2019-05-25	Not yet recruiting
Physiotherapy Alone, in Combination With Corticosteroid Injection or Wait-and-see for Acute Lateral Epicondylitis in General Practice: a Randomised, Placebo-controlled Study With 12 Months Follow-up [NCT00826462]	Phase 4	177 participants (Actual)	Interventional	2009-03-31	Completed
Analysis of Antalgic Efficacy of an Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis by Perfusion MRI:a Superiority, Randomized, Controlled, Double Blind Study [NCT03726788]	Phase 2	105 participants (Anticipated)	Interventional	2019-09-30	Not yet recruiting
A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of t [NCT03382262]	Phase 2	55 participants (Actual)	Interventional	2017-12-18	Completed
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion [NCT01178697]	Phase 2	0 participants	Interventional	2010-01-31	Recruiting
A Randomized Phase II Double-Blinded Study of The Efficacy of Oleogel-S10 (AP101) Gel for the Treatment of Grade 2/3 Radiation Dermatitis in Breast Cancer Patients [NCT05190770]	Phase 2	50 participants (Anticipated)	Interventional	2021-12-15	Recruiting
Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery in Treating Refractory Granulomatous Lobular Mastitis: A Randomized Controlled Trial [NCT05281419]		100 participants (Anticipated)	Interventional	2022-05-01	Recruiting
The NOR-CACTUS Trial - A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome [NCT05306548]	Phase 4	258 participants (Anticipated)	Interventional	2022-04-08	Recruiting
Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema [NCT03126786]	Phase 2	71 participants (Actual)	Interventional	2017-07-11	Completed
MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis [NCT02952001]		33 participants (Actual)	Observational	2017-12-13	Completed
Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis [NCT02399800]		1 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Low enrollment)
Comparing the Efficacy of Rotator Interval Steroid Injection Versus Steroid Intraarticular Hydrodilatation in the Treatment of Frozen Shoulder [NCT03678038]		64 participants (Actual)	Interventional	2018-09-28	Completed
Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial [NCT04115644]	Phase 4	82 participants (Actual)	Interventional	2017-05-01	Terminated(stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018)
SAPPHIRE: A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal CLS-TA In Conjunction With Intravitreal Aflibercept In Subjects With Retinal Vein Occlusion [NCT02980874]	Phase 3	460 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent.)
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy [NCT02329288]	Phase 3	60 participants (Anticipated)	Interventional	2015-05-31	Not yet recruiting
25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients [NCT02328118]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Randomized, Double-Blind Study of the Efficacy of Platelet-Rich Growth Factor (PRGF) Supplementation Compared to Steroid Supplementation After Temporomandibular Joint (TMJ) Arthrocentesis in Female Patients With TMJ Osteoarthritis (OA) [NCT04731233]	Phase 4	36 participants (Anticipated)	Interventional	2021-03-30	Recruiting
A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal CLS-TA In Combination With An Intravitreal Anti-VEGF Agent In Subjects With Retinal Vein Occlusion [NCT03203447]	Phase 3	325 participants (Actual)	Interventional	2018-03-05	Terminated(stopped due to The early termination is due to the results obtained from the sister study, SAPPHIRE (CLS1003-301), which did not meet the 8-week primary efficacy endpoint.)
Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial [NCT04895280]	Phase 4	400 participants (Anticipated)	Interventional	2024-04-30	Not yet recruiting
Outcome Comparison of Ultrasound-guided Hydrodissection Between Normal Saline and Combination of Triamcinolone Acetonide, Normal Saline, and Lidocaine in Mild to Moderate Carpal Tunnel Syndrome: A Single Blinded Randomized Clinical Trial [NCT05577676]		62 participants (Anticipated)	Interventional	2022-09-13	Recruiting
A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients [NCT01356602]	Phase 3	397 participants (Actual)	Interventional	2011-05-31	Completed
Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study. [NCT03640650]	Phase 4	80 participants (Actual)	Interventional	2018-08-15	Terminated(stopped due to COVID-19 pandemic leading to uncertainty in the recruitement)
A Comparative Study of Betamethasone (Diprospan) and Triamcinolone Acetonide as Single Intra-Articular Injection in Knee Osteoarthritis, A Double-Blinded, Randomized Controlled Trial [NCT05139875]	Phase 4	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Formulated Posterior Subtenon Triamcinolone (PSTA) Injection Versus Posterior Subtenon Triamcinolone Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions [NCT05385562]		78 participants (Actual)	Interventional	2020-01-02	Completed
Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis [NCT03097315]	Phase 3	38 participants (Actual)	Interventional	2017-04-04	Completed
A Randomized, Controlled, Double-blind Study to Evaluate the Efficacy of Intralesional Triamcinolone in the Treatment of Hidradenitis Suppurativa. [NCT02781818]		32 participants (Actual)	Interventional	2016-06-30	Completed
Intralesional Steroid Injection Versus Accent Method of Voice Therapy in Management of Vocal Nodules: A Randomized Controlled Trial [NCT03914092]	Phase 4	40 participants (Anticipated)	Interventional	2019-09-29	Recruiting
Evaluation of Salivary Levels of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid [NCT03871114]		30 participants (Actual)	Observational	2019-03-10	Completed
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion [NCT01044329]	Phase 2	90 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Randomized Single Blinded Prospective Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients [NCT03319784]	Phase 4	0 participants (Actual)	Interventional	2018-09-05	Withdrawn(stopped due to never initiated)
Eco-guided Treatment With Triamcinolone-Acetonide in the Treatment of Medial Plica Syndrome - A Pilot Study [NCT04943341]		30 participants (Anticipated)	Interventional	2021-10-28	Recruiting
Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial [NCT03535233]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
A Prospective Randomized Comparative Trial of Targeted Injection Via a Transforaminal Approach With Dexamethasone Versus an Epidural Catheter Via an Interlaminar Approach With Particulate Steroid for the Treatment of Cervical Radicular Pain [NCT03382821]	Phase 4	120 participants (Actual)	Interventional	2017-09-15	Completed
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in Patients With Neovascular Age-Related Macular Degeneration [NCT02457026]		0 participants (Actual)	Interventional	2016-01-31	Withdrawn
Ketorolac Versus Triamcinolone Intra-articular Knee Injections for the Treatment of Osteoarthritis. A Prospective, Double-Blinded Randomized Trial [NCT02295189]		36 participants (Actual)	Interventional	2013-01-31	Completed
Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter [NCT03165344]		66 participants (Actual)	Interventional	2017-02-10	Completed
Sonographic Evaluation of Patients With Carpal Tunnel Syndrome Following Steroid Injection [NCT03132051]		54 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement [NCT02920177]	Phase 4	4 participants (Actual)	Interventional	2016-08-01	Terminated(stopped due to low enrollment)
Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment [NCT03431961]		20 participants (Anticipated)	Interventional	2018-03-07	Recruiting
Efficacy of Oral Zinc Supplement as an Adjunctive Therapy for Erosive Oral Lichen Planus (a Randomized, Controlled Clinical Trial) [NCT06042010]		22 participants (Actual)	Interventional	2023-01-05	Completed
Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids [NCT02996097]		30 participants (Actual)	Interventional	2016-04-30	Completed
Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis [NCT05005000]	Phase 2	1 participants (Actual)	Interventional	2022-05-12	Terminated(stopped due to Difficulties getting subjects recruited and enrolled.)
Suprachoroidal Triamcinolone Acetonide for the Treatment of Macular Edema Associated With Retinal Vein Occlusion: A Pilot Study [NCT05038072]		16 participants (Actual)	Interventional	2019-07-25	Completed
A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus [NCT02762370]	Phase 2	33 participants (Actual)	Interventional	2016-04-30	Completed
Safety and Efficacy of Of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein In Acute Gout [NCT05925166]		100 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Comparing the Efficacy of Ultrasound Guided Hyaluronic Injection With Ultrasound Guided Corticosteroid Injection in Treatment of Trigger Finger [NCT03131882]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2016-10-01	Recruiting
Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation [NCT03473600]	Phase 4	40 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
Comparison Between Blind and Ultrasound Guided Injection in Morton Neuroma [NCT03046108]	Phase 4	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough [NCT04468542]	Phase 3	65 participants (Anticipated)	Interventional	2021-01-12	Recruiting
Evaluation of the Use of Intraoperative Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy During Bare Scleral Pterygium Excision [NCT03377348]		30 participants (Actual)	Interventional	2017-12-01	Completed
Efficacy of Neural Prolotherapy Versus Local Corticosteroid Soft Tissue Injection for Treatment of Anserine Bursitis [NCT04509440]		43 participants (Actual)	Interventional	2018-05-01	Completed
Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema [NCT01095809]	Phase 3	5 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to New intraocular steroid in the market. Recruitment no longer ethical.)
A Multi-Center Randomized, Double-Blind, Placebo Controlled, Parallel Group Comparison Study of Once Daily Triamcinolone Acetonide 0.5% DuraPeel™ Versus Placebo DuraPeel in the Treatment of Hand Dermatitis [NCT00890968]	Phase 2	56 participants (Actual)	Interventional	2009-04-30	Completed
Triamcinolone Acetonide Injections Compared With Micro Injections (MMP Technique) of Triamcinolone Acetonide for the Treatment of Female Genital Lichen Sclerosus and Atrophic [NCT06079645]	Phase 4	20 participants (Anticipated)	Interventional	2023-10-20	Recruiting
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa [NCT04582669]	Phase 4	11 participants (Actual)	Interventional	2022-01-24	Terminated(stopped due to This study was administratively closed.)
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide [NCT02294656]	Phase 1	4 participants (Actual)	Interventional	2014-11-30	Completed
A Randomized, Double-blind, Dose-ranging Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Low Dose Triamcinolone and Low Dose Lidocaine for Reduction of Submental Fat With Reduction of Pain and Swelling [NCT03361176]	Phase 4	30 participants (Actual)	Interventional	2018-03-26	Completed
Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema [NCT02949024]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2016-11-10	Completed
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab [NCT01249937]	Phase 2	30 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Granulation Tissue at G Tube Site: Treatment With Kenalog vs Chemical Cauterization With Silver Nitrate vs Soap Washcloth Abrasion [NCT02519738]	Phase 3	52 participants (Actual)	Interventional	2015-01-15	Terminated(stopped due to enrollment difficulties)
Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis [NCT01318590]	Phase 3	2 participants (Actual)	Interventional	2011-11-18	Terminated(stopped due to Closed by CHUM REB for incomplete documentation of research activities.)
Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study [NCT04326959]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week D [NCT01029652]	Phase 3	230 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized Controlled Pilot Study Evaluating the Efficacy of Early Glenohumeral Cortisone Injection in Patients With Shoulder Stiffness Following Proximal Humerus Fractures [NCT04216017]	Phase 2	9 participants (Actual)	Interventional	2020-01-01	Completed
A Phase 3 Multi-centre Double-masked Randomised Controlled Trial of Adjunctive Intraocular and Periocular Steroid (Triamcinolone Acetonide) Versus Standard Treatment in Eyes Undergoing Vitreoretinal Surgery for Open Globe Trauma. [NCT02873026]	Phase 3	300 participants (Actual)	Interventional	2014-10-31	Completed
Arteriovenous Crossing Sheathotomy Versus Intravitreal Triamcinolone Acetonide Injection for Treatment of Macular Edema Associated With Branch Retinal Vein Occlusion [NCT00612261]		40 participants (Actual)	Interventional	2006-10-31	Completed
Subacromial Ultrasound-guided or Systemic Steroid Injection for Rotator Cuff Disease, a Randomized Double Blinded Study [NCT00640575]		106 participants (Actual)	Interventional	2005-03-31	Completed
A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema [NCT00737971]	Phase 4	142 participants (Actual)	Interventional	2008-08-31	Completed
Prospective, Controlled Study of the Efficacy of NdYag for Acne Keloidalis Nuchae [NCT00757315]		20 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results [NCT05337332]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2022-04-14	Recruiting
Rotator Interval and Intra-articular Corticosteroid Injection for Adhesive Capsulitis (Frozen Shoulder): a Randomised, Double Blind, Placebo Controlled Trial [NCT00840229]		122 participants (Actual)	Interventional	2009-02-28	Completed
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial [NCT02858297]	Phase 4	30 participants (Actual)	Interventional	2015-05-31	Completed
Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy [NCT02806752]	Phase 4	120 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
The Evaluation of Effect of the Cervical İnterlaminar Epidural Steroid İnjection on Quality of Life, Neuropathic Pain and Disability in Patients With Cervical Radiculopathy [NCT04235478]		78 participants (Actual)	Interventional	2017-12-27	Active, not recruiting
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study [NCT02221453]	Phase 2	3 participants (Actual)	Interventional	2015-09-30	Completed
One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases [NCT05496530]		100 participants (Anticipated)	Interventional	2022-07-10	Recruiting
Comparative Study on the Efficacy of Periocular Methotrexate Versus Periocular Triamcinolone Injections in Management of Thyroid Associated Orbitopathy [NCT05429450]	Phase 2	18 participants (Actual)	Interventional	2020-07-01	Completed
Symptom Clusters in Children With Exacerbation-prone Asthma [NCT04002362]	Phase 2	173 participants (Anticipated)	Interventional	2019-11-13	Recruiting
The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children [NCT04524897]	Phase 4	20 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study [NCT03572959]	Phase 4	24 participants (Actual)	Interventional	2016-12-27	Completed
Alazher University Dean [NCT05464953]		75 participants (Actual)	Interventional	2020-01-20	Completed
Comparison of Triamcinolone Acetonide Mucoadhesive Film With Liquorice Mucoadhesive Film On Radiotherapy-Induced Oral Mucositis: A Randomized Double-Blinded Clinical Trial [NCT02075749]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2013-05-31	Completed
Methotrexate With Microneedling Versus Triamcinilone Acetonide With Microneedling in Treatment of Recalcitrant Alopecia Areata [NCT06088147]		34 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis [NCT04976816]	Phase 2/Phase 3	92 participants (Actual)	Interventional	2021-12-01	Completed
Comparison of Different Dose of Steroid Injection in Carpal Tunnel Syndrome [NCT03072290]		56 participants (Actual)	Interventional	2017-02-18	Completed
Evaluation of the Effectiveness of Photodynamic Therapy in the Treatment of Lesions of the Lichen Planus Type in the Oral Mucosa and Its Diagnostics With the Use of Autofluorescence, in Various Wavelength Ranges, in Combination With the Use of Texture Ana [NCT04991012]	Phase 2	30 participants (Actual)	Interventional	2020-02-08	Completed
Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis [NCT02437461]	Phase 4	159 participants (Actual)	Interventional	2015-04-30	Active, not recruiting
A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis [NCT02595398]	Phase 3	160 participants (Actual)	Interventional	2015-11-17	Completed
OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy [NCT04075136]	Phase 4	150 participants (Anticipated)	Interventional	2023-03-30	Suspended(stopped due to Deviations)
Safety and Effectiveness of Triamcinolone Acetonide in Patients With Serous Pigment Detachment Associated With Age-Related Macular Degeneration [NCT04292756]		63 participants (Actual)	Interventional	2018-03-27	Completed
Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery [NCT02917564]	Phase 4	20 participants (Anticipated)	Interventional	2020-10-14	Recruiting
Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata [NCT04003376]	Phase 4	40 participants (Anticipated)	Interventional	2019-07-26	Recruiting
A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial [NCT00398866]	Phase 3	200 participants (Actual)	Interventional	2006-08-31	Completed
A Comparison of a Single Orbital Floor Injection of Triamcinolone Versus Conventional Steroid and Antibiotic Drops Used Post Operatively in Uneventful Phacoemulsification Surgery [NCT00789971]		150 participants (Actual)	Interventional	2007-03-31	Completed
An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colch [NCT00798369]	Phase 2	200 participants (Actual)	Interventional	2008-11-30	Completed
Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial [NCT02823236]	Phase 3	102 participants (Anticipated)	Interventional	2016-10-24	Recruiting
Office-Based Superior Laryngeal Nerve (SLN) Block for Treatment of Neurogenic Cough [NCT04642352]		50 participants (Anticipated)	Observational	2022-01-03	Recruiting
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis. [NCT05906433]	Phase 1	75 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Effect of Epidural Steroid Injection on Bone Mineral Density In Postmenopausal Women [NCT00941473]	Phase 4	28 participants (Actual)	Interventional	2007-07-31	Completed
Influence of Perception of Patients Suffering of Osteoarthritis of Knee Over the Effectiveness and Tolerance in Intra-articular Injection of Corticoids: a Prospective, Controlled and Randomized Study [NCT02835521]	Phase 4	100 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees [NCT02829281]	Phase 4	105 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Ultrasonographic Evaluation of the Effectiveness of Stellate Ganglion Block in Patients With Breast Cancer Related Lymphedema [NCT04165512]		22 participants (Anticipated)	Interventional	2020-01-07	Enrolling by invitation
Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus: A Randomized Controlled Clinical Trial With Immunohistochemical Analysis [NCT05882864]	Phase 4	28 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
Trial Extension Protocol to Add a 39 Week Follow Up to Cingal 16-02, a Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection of Cingal to Provide Symptomatic Relief of Knee Osteoarthritis [NCT03390036]	Phase 3	526 participants (Actual)	Interventional	2017-12-07	Completed
Comparison Between Anterior and Posterior Approaches for Ultrasound-guided Glenohumeral Steroid Injection: A Randomized Controlled Trial [NCT02461368]		50 participants (Actual)	Interventional	2012-12-31	Completed
Triamcinolone Assisted Anterior Vitrectomy in Complicated Cataract Surgery and Anterior Segment Reconstruction [NCT01051648]	Phase 2	10 participants (Actual)	Interventional	2007-12-31	Completed
[NCT00987233]	Phase 3	0 participants	Interventional		Completed
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study [NCT00279916]	Phase 3	91 participants (Actual)	Interventional	2005-09-01	Completed
Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema [NCT00444600]	Phase 3	691 participants (Actual)	Interventional	2007-03-31	Completed
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields [NCT04469075]	Phase 2	58 participants (Anticipated)	Interventional	2020-07-09	Recruiting
Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis [NCT00742846]		0 participants (Actual)	Interventional	2008-08-31	Withdrawn(stopped due to No enrollment)
Incidence of Flare Reaction Following Shoulder Steroid Injections: Comparison of Depo-medrol (Methylprednisolone) and Kenalog (Triamcinolone) [NCT05438277]	Phase 4	421 participants (Actual)	Interventional	2020-01-01	Completed
The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. [NCT02618603]	Phase 4	50 participants (Anticipated)	Interventional	2016-02-29	Not yet recruiting
Prospective Randomize Trial Comparing Corticosteroid Injection to High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis [NCT02613455]	Phase 4	80 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Pilot Study of Transforaminal Epidural Injection of Clonidine for the Treatment of Acute Lumbosacral Radiculopathy [NCT00588354]		26 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Targeted enrollment was not reached.)
Efficacy and Safety of Intra-Articular Injections of Durolane® in the Treatment of Osteoarthritis in the Knee [NCT00731289]	Phase 4	60 participants (Actual)	Interventional	2003-07-31	Completed
Pilot Study of Chinese Medicine Medicated Bath as Complementary Medicine for Mild to Moderate Plaque -Type Psoriasis Patient. [NCT04117919]	Phase 2	30 participants (Anticipated)	Interventional	2019-10-05	Recruiting
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy [NCT00445003]	Phase 3	333 participants (Actual)	Interventional	2007-03-31	Completed
A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema [NCT00924508]		23 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Loss of Funding)
Resistant Diabetic Macular Edema and Suprachoroidal Injection [NCT04690608]	Early Phase 1	100 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure [NCT00665977]	Phase 3	44 participants (Anticipated)	Interventional	2007-09-30	Completed
Phase 2 Study of Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema. [NCT00874744]	Phase 2	13 participants (Actual)	Interventional	2008-03-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adr [NCT01154153]	Phase 4	140 participants (Actual)	Interventional	2010-06-30	Completed
Efficacy of Dextrose Injections, Corticosteroids Injections and Surgical Release for Treatment of the Carpal Tunnel Syndrome: a Prospective, Randomized, Double-blind Controlled Trial [NCT04014244]		100 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Efficacy of Post-Surgical Intralesional Injection With Triamcinolone Versus Triamcinolone Plus Fluorouracil in the Treatment of Keloids [NCT04710719]		7 participants (Actual)	Interventional	2021-02-01	Completed
Efficacy and Safety of Intravitreal Triamcinolone as Treatment of the Diffuse Diabetic Macular Edema [NCT00309192]	Phase 3	292 participants (Anticipated)	Interventional	2006-04-30	Completed
Investigator-Initiated, Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout [NCT03636373]	Phase 4	5 participants (Actual)	Interventional	2019-10-25	Terminated(stopped due to The Sponsor has decided to stop funding this study due to lack of enrollment during COVID-19 pandemic and decreased interest in funding investigator initiated studies pertaining to the study drug)
VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema [NCT00764244]	Phase 3	72 participants (Actual)	Interventional	2005-01-31	Completed
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination Treatment of Crisaborole Ointment, 2% and a Concomitant Topical Corticosteroid Over a 8 Week Period [NCT04008784]		16 participants (Actual)	Observational	2019-09-16	Completed
A Multi-Center, Open-label, 24-week Clinical Investigation to Evaluate Safety and Tolerability of Treatment With the Oxulumis®, Suprachoroidal Drug Administration Device Delivering 2.4mg Triesence® With Diabetic Macular Edema [NCT05172401]		0 participants (Actual)	Interventional	2022-09-15	Withdrawn(stopped due to unforeseen, continued (>12month) global shortage of study medication. Study Drug Triesence, manufacturer Novartis, not supplied throughout 2022)
The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery in Patients With Lumbar Disc Herniations [NCT01073995]	Phase 3	54 participants (Actual)	Interventional	2010-03-31	Completed
Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat [NCT00908817]		150 participants (Actual)	Interventional	2008-05-31	Completed
A Phase IIb, Randomized, Masked, Sham-Controlled, Clinical Trial to Study the Efficacy and Safety of the Helical Triamcinolone Acetonide Implant (MK0140) in Diabetic Patients With Clinically Significant Macular Edema [NCT00692614]	Phase 2	2 participants (Actual)	Interventional	2008-06-30	Terminated
A Randomized Parallel, Masked to Evaluate the Efficacy of Triamcinolone Associated With Nepafenac (Nevanac) Compared With Intravitreal Injection of Triamcinolone for Treatment of Clinically Significant Diabetic Macular Edema [NCT00780780]	Phase 3	40 participants (Actual)	Interventional	2007-07-31	Completed
Injection Treatment of Slow-Release Corticosteroid to the Sacrospinous Ligament Insertions on Women With Long-Lasting Low Back Pain Starting in Pregnancy. [NCT00757016]		38 participants (Actual)	Interventional	2004-10-31	Completed
[NCT00801450]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2007-09-30	Active, not recruiting
Comparison Between Steroid and Two Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia: A Randomized Double-blind Active Drug-controlled Pilot Study [NCT02767635]	Phase 3	90 participants (Anticipated)	Interventional	2012-01-31	Recruiting
The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Osteoarthritis Research Society International (OARSI) Recommended Physical Performance Measures in Adults With Knee Osteoarthritis [NCT03895840]	Phase 4	70 participants (Actual)	Interventional	2018-03-19	Completed
Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. [NCT00811200]	Phase 2/Phase 3	220 participants (Anticipated)	Interventional	2009-09-30	Not yet recruiting
Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation [NCT00779792]	Phase 4	36 participants (Actual)	Interventional	2008-09-30	Active, not recruiting
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) [NCT02598869]	Phase 4	0 participants (Actual)	Interventional	2015-11-30	Withdrawn
Role of Conditioning in the Pharmacotherapy of Psoriasis [NCT00005922]		138 participants (Actual)	Interventional	2000-08-31	Completed
A Prospective Study Comparison of Clinical Outcome After Different Rate Infusion in Caudal Epidural Steroid Injection [NCT02939482]		112 participants (Actual)	Interventional	2016-10-01	Completed
Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy [NCT05292339]	Phase 4	160 participants (Anticipated)	Interventional	2023-01-31	Recruiting
The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata [NCT00999869]		20 participants (Anticipated)	Interventional	2009-11-30	Recruiting
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [NCT00369486]	Phase 2	113 participants (Actual)	Interventional	2004-12-31	Completed
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata [NCT00484679]	Phase 2	18 participants (Actual)	Interventional	2007-05-31	Completed
Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee: A Prospective, Double-blind Randomized Controlled Trial [NCT01874574]	Phase 4	100 participants (Actual)	Interventional	2011-01-31	Completed
Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial [NCT01906944]	Phase 2	62 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer [NCT00473083]	Phase 2	150 participants (Actual)	Interventional	2009-01-31	Completed
Steroid Versus Hyaluronic Acid Ultrasound-guided Injection for Trigger Finger: A Comparative Study of Outcomes [NCT01950793]		36 participants (Actual)	Interventional	2012-11-30	Completed
Intralesional Vitamin D3 Injection in Treatment of Alopecia Areata: A Novel Approach [NCT04660786]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
Ultrasound-Guided Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger: Randomized Controlled Study [NCT04645303]	Early Phase 1	100 participants (Anticipated)	Interventional	2020-11-06	Recruiting
[NCT01961752]		111 participants (Actual)	Interventional	2012-07-31	Completed
A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials [NCT01978301]	Phase 1	9 participants (Actual)	Interventional	2014-04-15	Terminated(stopped due to Temporary hold on recruitment during staff changes at the site)
Open-Label, Parallel-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Corticosteroid Intra Articular Injection Given 7 Days Before or 7 Days After Lorecivivint Intra-articular Injection Into the Knee of Healthy Volunteers [NCT04598542]	Phase 1	40 participants (Actual)	Interventional	2020-10-13	Completed
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) [NCT04593706]		40 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Randomized Clinical Control Trial Comparing the Effects of a Steroid Eluting Implant Versus Triamcinolone-impregnated Carboxymethylcellulose Foam on the Postoperative Clinic Experience in Patients That Underwent Functional Endoscopic Surgery for Nasal Pol [NCT03607175]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2023-07-24	Not yet recruiting
Assessment Of Pain Subsidence And Sexual Function Amelioration Using Either Pelvic Rehabilitation Or Trigger Point Injections [NCT02022722]	Phase 4	36 participants (Anticipated)	Interventional	2013-08-31	Recruiting
A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee [NCT02022930]	Phase 3	510 participants (Anticipated)	Interventional	2014-01-31	Completed
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study [NCT02025023]	Phase 3	120 participants (Anticipated)	Interventional	2013-12-31	Recruiting
A Randomized Single-blinded Clinical Trial of the Efficacy of Intra-articular Infiltration of Cingal (Sodium Hyaluronate/Triamcinolone) Versus Cortisone (Triamcinolone) in Patients With Osteoarthritis of the Shoulder. [NCT05408065]		84 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater [NCT02031367]	Early Phase 1	50 participants (Anticipated)	Interventional	2014-03-31	Not yet recruiting
The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial [NCT05939817]	Phase 4	24 participants (Actual)	Interventional	2021-10-01	Completed
The Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Patients With Dupuytren's Contracture: a Randomized Controlled Study [NCT00565019]	Phase 3	51 participants (Actual)	Interventional	2007-11-30	Completed
A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective Including a 12 Weeks Extension Study [NCT01080131]	Phase 3	226 participants (Actual)	Interventional	2010-03-31	Completed
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus: A Randomized Controlled Clinical Trial [NCT06135259]	Phase 3	18 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery [NCT00853905]	Phase 2/Phase 3	77 participants (Actual)	Interventional	2009-02-28	Completed
Efficacy of Combined Ultrasound Guided Steroid Injection and Splinting in Patients With Carpal Tunnel Syndrome [NCT02708693]		52 participants (Actual)	Interventional	2013-04-30	Completed
The Effect of Ethosomal Gel Bearing Losartan 5% on The Patient and Observer Scar Assessment Scale Score, Degree of Erythema and Pigmentation, Surface Area, Thickness and Pliability of Human Keloids [NCT05893108]	Phase 1/Phase 2	46 participants (Anticipated)	Interventional	2024-03-30	Not yet recruiting
Assessment of the Effectiveness of Ultrasound-guided Acupuncture in the Management of Carpal Tunnel Syndrome [NCT02870673]	Phase 2/Phase 3	72 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Triamcinolone Ketorolac (TriKe) Knee Trial Evaluating the Effectiveness and Possible Superiority of Ketorolac vs. Cortisone When Injected Intra-Articular in Subjects With Osteoarthrosis [NCT05336968]	Phase 4	150 participants (Anticipated)	Interventional	2022-09-15	Enrolling by invitation
Clinical Trials in Stroke Rehabilitation [NCT00597766]	Phase 2	28 participants (Actual)	Interventional	2007-12-31	Completed
Effect of Intracameral Steroids Injection During Phacoemulsification on Postoperative Corneal Edema and Corneal Endothelium [NCT05271058]	Phase 3	69 participants (Actual)	Interventional	2019-06-16	Completed
Medicated Punctured-Glove-Finger Spacer Study [NCT01420471]	Phase 4	50 participants (Actual)	Interventional	2011-09-30	Completed
Phase I/II Study of Intravitreal Triamcinolone Acetonide Microspheres for Treatment of Diffuse Diabetic Macular Edema Unresponsive to Conventional Laser Photocoagulation Treatment. [NCT00407849]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2006-10-31	Active, not recruiting
Comparative Study Between Intralesional Autologous Platelet Rich Plasma and Intralesional Triamcinolone Acetonide in the Oral Erosions of Pemphigus Vulgaris Patients [NCT02828163]	Phase 3	11 participants (Actual)	Interventional	2016-01-31	Completed
Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis: A Randomized Clinical Trial [NCT00554476]	Phase 4	50 participants	Interventional	2003-01-31	Terminated(stopped due to Because the sample volume was completed during three years.)
The Role of Triamcinolone Injection During Cataract Extraction for Diabetic Patients With Pre-Operative Macular Edema [NCT00229931]		11 participants (Actual)	Interventional	2005-11-30	Completed
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose [NCT01851278]		60 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Additive Effects of Hyaluronidase in Intra-articular Steroid Injection Treating the Initial Stage of Adhesive Capsulitis for Shoulder [NCT04347733]	Phase 3	30 participants (Actual)	Interventional	2017-05-02	Completed
A Randomised, Double-blind, French Multi-centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults [NCT00344942]	Phase 3	77 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to patient's recruitment too difficult)
Efficacy and Safety of Different Concentrations of Intralesional Triamcinolone Acetonide in Alopecia Areata: A Prospective, Randomized, Double-blind, Placebo-controlled Study [NCT01246284]		5 participants (Actual)	Interventional	2010-12-31	Completed
Dosage Dependency of Intravitreal Triamcinolone Acetonide for Treatment of Diabetic Macular Edema [NCT00476918]	Phase 1	60 participants (Anticipated)	Interventional	2006-07-31	Recruiting
Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery [NCT00532415]	Phase 3	60 participants (Actual)	Interventional	2007-09-30	Completed
Dropless Pars Plana Vitrectomy Study [NCT05331664]	Phase 4	168 participants (Anticipated)	Interventional	2022-07-25	Recruiting
An Open-Label Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Persistent, Moderate to Severe Atopic Dermatitis [NCT02465606]	Phase 2	55 participants (Actual)	Interventional	2015-07-30	Completed
Biological Response to Platelet-rich Plasma and Corticosteroid Injections [NCT05657496]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2022-12-28	Recruiting
The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation: A Randomized Trial [NCT03995641]	Phase 4	19 participants (Actual)	Interventional	2019-02-02	Terminated(stopped due to Never received appropriate formulation.)
A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus [NCT00242580]	Phase 3	111 participants (Actual)	Interventional	2005-09-30	Completed
Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal [NCT01720056]	Phase 4	14 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to Objective of study achieved after interim analysis.)
Intra-articular Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain: a Multicentric, Double Blind Randomised, Versus Steroid Study [NCT01473277]	Phase 2	52 participants (Anticipated)	Interventional	2012-01-31	Not yet recruiting
Combined Posterior Sub-Tenon Injection of Triamcinolone Acetonide and Laser Photocoagulation for the Treatment of Clinically Significant Macular Edema [NCT00229918]	Phase 2	60 participants	Interventional	2005-09-30	Recruiting
Efficacy of Ultrasound-Guided Deep Perineural Platelet Rich Plasma Versus Corticosteroid Injection in Patients With Ulnar Neuropathy at Elbow, a Comparative Study [NCT05567081]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2021-06-01	Completed
Evaluation of the Effect of Triamcinolone at Different Doses on Local Infiltration Anesthesia During Total Knee Arthroplasty [NCT05997238]		90 participants (Anticipated)	Observational	2023-04-25	Recruiting
Combined Phacoemulsification Surgery and Intravitreal Triamcinolone Injection Versus Stand-alone Surgery in Patients With Type 2 Diabetes: A Randomized Controlled Trial [NCT05413330]	Phase 2/Phase 3	73 participants (Actual)	Interventional	2020-09-12	Completed
Evaluation of Diode Laser and Topical Steroid Therapy in the Treatment of Erosive Oral Lichen Planus (A Randomized Controlled Clinical Trial) [NCT05951361]		44 participants (Actual)	Interventional	2022-02-01	Completed
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema [NCT00105404]	Phase 3	5 participants	Interventional	2005-03-09	Completed
Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy [NCT00443521]	Phase 2/Phase 3	30 participants	Interventional	2005-03-31	Completed
Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone Acetonide Injection Versus Intravitreal Bevacizumab for Age Related Macular Degeneration [NCT00447031]		0 participants (Actual)	Interventional	2007-03-31	Withdrawn(stopped due to Insufficient patients who met inclusion criteria)
Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration [NCT00464347]	Phase 2	100 participants (Anticipated)	Interventional	2007-01-31	Terminated(stopped due to Study was terminated because of poor enrollment.)
Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial. [NCT00148551]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2004-01-31	Active, not recruiting
Effectiveness of Matrix Metalloproteinase Neutralizing Agent in Treatment of Oral Lichen Planus: A Pilot Study [NCT04336488]	Early Phase 1	40 participants (Anticipated)	Interventional	2020-01-01	Active, not recruiting
Comparison of the Short-term Clinical Effects of Anterior Extra-articular and Posterior Intra-articular Administration of Ultrasound-guided Steroid Injection in the Treatment of Adhesive Capsulitis. A Prospective, Randomized and Single-blind Study [NCT05668286]		50 participants (Anticipated)	Interventional	2023-05-24	Recruiting
Can Dexmedetomidine With Hyalase Augment Quality and Duration of Analgesia When Added to Lumbar Epidural Steroid in Failed Back Surgery. Randomized Double Blind Study [NCT05349448]	Early Phase 1	100 participants (Anticipated)	Interventional	2022-03-28	Recruiting
Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy [NCT00411333]	Early Phase 1	100 participants (Anticipated)	Interventional	2006-07-31	Completed
Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema [NCT00468351]	Phase 1	0 participants	Interventional	2006-04-30	Active, not recruiting
[NCT00600301]	Phase 3	0 participants	Interventional		Recruiting
Ultrasound-guided Glenohumeral Versus Subacromial Steroid Injections for Impingement Syndrome With Mild Stiffness: A Randomized Controlled Trial [NCT06051370]		51 participants (Actual)	Interventional	2013-01-12	Completed
Heated Lidocaine Patch Compared to Subacromial Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome, A Pilot [NCT01544283]	Phase 2	60 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Comparison of Topical Tacrolimus, Triamcinolone and Placebo in the Treatment of Symptomatic Oral Lichen Planus [NCT01544842]		28 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to Lack of resources)
Multi-Center, Randomized, Phase II/III Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants With Neovascular Age-Related Macular Degeneration [NCT00100009]	Phase 3	30 participants	Interventional	2004-12-09	Completed
Phase I Study of Intravitreal Injections Versus Anterior Sub-Tenon Injections of Triamcinolone Acetonide Formulation for Macular Edema in Retinal Disorders [NCT00101764]	Phase 1	120 participants	Interventional	2005-01-05	Completed
The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study [NCT00106132]	Phase 3	1,260 participants	Interventional	2005-03-31	Completed
Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders [NCT00071227]	Phase 1	16 participants	Interventional	2003-10-15	Completed
A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD [NCT00140803]	Phase 2	106 participants (Actual)	Interventional	2003-10-31	Completed
Injection After Arthroscopic Partial Meniscectomy [NCT04641351]	Phase 4	150 participants (Anticipated)	Interventional	2021-05-27	Enrolling by invitation
Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis: A Double-Blind Prospective Randomized Clinical Trial [NCT04002037]	Phase 4	120 participants (Actual)	Interventional	2019-06-25	Terminated(stopped due to Preliminary analysis revealed no difference)
Using Saline for Myofascial Pain Syndromes (USAMPS) [NCT02120261]	Phase 4	51 participants (Actual)	Interventional	2014-05-31	Terminated(stopped due to lack of activity, Primary researcher moved to another institution)
Identifying Variables Associated With Steroid-Induced Hyperglycemia Following Intra-articular Knee Injections Among Diabetic Patients [NCT04317404]		11 participants (Actual)	Observational	2020-11-01	Completed
The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery [NCT01995045]	Phase 4	58 participants (Actual)	Interventional	2012-07-31	Completed
The Safety and the Efficacy of Combined Vitrectomy, Intravitreal Triamcinolone Acetonide and Macular Focal Laser Photocoagulation for the Treatment of Intractable Diffuse Diabetic Macular Edema [NCT00371410]	Phase 1	0 participants	Interventional	2005-04-30	Completed
A Double-blind, Randomized Study Comparing Steroid Injection and BioDRestore for Patients With Knee Osteoarthritis [NCT02767492]		90 participants (Actual)	Interventional	2017-01-31	Completed
Early Anti-inflammatory Treatment in Patients With Acute ACL Tear [NCT01692756]	Phase 2	49 participants (Actual)	Interventional	2013-03-31	Completed
Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema [NCT00231023]	Phase 2	10 participants	Interventional	2005-09-30	Completed
Phase 1 Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema [NCT00915837]	Phase 1	31 participants (Actual)	Interventional	2005-06-30	Completed
Neovascular Age Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy [NCT00305630]	Phase 2/Phase 3	100 participants	Interventional	2002-07-31	Completed
Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial [NCT01045694]	Phase 4	8 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to Unable to acquire additional funding needed to continue this study.)
A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee [NCT01487161]	Phase 2	229 participants (Actual)	Interventional	2012-06-30	Completed
A Study to Evaluate the Safety, and Efficacy of Minimally Manipulated Autologous Bone Marrow Aspirate to Treat Knee Osteoarthritis in Patients [NCT05288725]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
Changes Noted After Suprachoroidal Triamcinolone Acetonide Injection. [NCT05288192]		30 participants (Anticipated)	Interventional	2022-02-15	Recruiting
Bayesian Non-inferiority Trial of Injection Therapies for Acromioclavicular Joint Pain: a Randomized Clinical Trial [NCT05161468]	Phase 4	150 participants (Anticipated)	Interventional	2022-07-01	Recruiting
An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide to Provide Symptomatic Relief of Osteoarthritis of the Knee [NCT02381652]	Phase 3	242 participants (Actual)	Interventional	2015-02-28	Completed
Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL) [NCT00815360]	Phase 2	22 participants (Actual)	Interventional	2008-02-29	Completed
25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China: a Randomized, Single Blind Trial [NCT02447185]	Phase 3	200 participants (Anticipated)	Interventional	2015-06-30	Recruiting
An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses [NCT01736670]		30 participants (Actual)	Interventional	2012-04-30	Completed
Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy [NCT01652495]	Phase 4	44 participants (Actual)	Interventional	2012-03-31	Completed
Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis: a Randomized Controlled Superiority Trial [NCT06176248]		62 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. [NCT05106192]		22 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial [NCT01766609]	Phase 2	18 participants (Anticipated)	Interventional	2013-01-31	Recruiting
PRevention of Macular EDema After Cataract Surgery [NCT01774474]	Phase 3	1,127 participants (Actual)	Interventional	2013-07-10	Completed
The Use of Intraocular Triamcinolone in the Perioperative Period of Congenital Cataract Surgery [NCT01800708]		60 participants (Actual)	Interventional	2010-01-31	Completed
Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification [NCT01801774]	Phase 4	140 participants (Anticipated)	Interventional	2012-05-31	Recruiting
A Randomized, Intraindividual, Phase 4 Study to Evaluate the Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects With Atopic Dermatitis [NCT05844618]	Phase 4	20 participants (Anticipated)	Interventional	2023-05-09	Recruiting
Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone [NCT02242630]		61 participants (Actual)	Interventional	2014-09-30	Completed
[NCT00370539]	Phase 3	0 participants	Interventional	2006-09-30	Recruiting
Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata [NCT01797432]	Phase 2	14 participants (Actual)	Interventional	2009-03-31	Completed
Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis [NCT01789320]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2013-02-28	Completed
Efficacy and Safety of Intralesional Triamcinolone Acetonide Alone and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars [NCT04812626]		66 participants (Actual)	Interventional	2021-01-28	Completed
A Randomized, Double-Blind Study of the Efficacy of Steroid Supplementation After Temporomandibular Joint Arthrocentesis [NCT01770912]	Phase 2	24 participants (Actual)	Interventional	2013-03-31	Completed
A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee [NCT02468583]	Phase 2	6 participants (Actual)	Interventional	2015-02-28	Terminated
Randomized Prospective Study of Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Steroid Injection [NCT03166761]	Phase 4	41 participants (Actual)	Interventional	2017-09-14	Terminated(stopped due to recruitment and staffing)
The Effect of Epidural Steroid Injections on Glycemic Control in Diabetic Patients According to the Doses of Steroids [NCT01435707]		125 participants (Actual)	Interventional	2011-09-30	Completed
Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury [NCT04331002]	Phase 2	1 participants (Actual)	Interventional	2020-08-21	Terminated(stopped due to Funding Termination)
Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized Controlled Trial [NCT03127137]	Phase 4	123 participants (Actual)	Interventional	2018-08-01	Completed
A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (T [NCT03378076]	Phase 2	24 participants (Actual)	Interventional	2017-12-06	Completed
Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) [NCT03380026]	Phase 2	28 participants (Actual)	Interventional	2017-12-13	Completed
Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone [NCT04744623]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2020-09-30	Active, not recruiting
Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study [NCT03797872]	Phase 4	1 participants (Actual)	Interventional	2019-04-17	Completed
An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD [NCT01175395]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2010-09-30	Completed
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases: A Pilot Study [NCT05488860]		20 participants (Anticipated)	Interventional	2022-07-30	Recruiting
A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal [NCT02317276]	Phase 4	11 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Unable to meet the study's recruitment goals)
Prospective, Randomized, Double-blinded Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection [NCT02126878]		120 participants (Actual)	Interventional	2014-04-30	Completed
Intra-Articular Use of Platelet Rich Plasma Versus Corticosteroid: A Clinical Trials in Osteoarthritis of Knee. [NCT03086759]	Phase 4	99 participants (Actual)	Interventional	2017-01-02	Completed
Comparison of the Effects of Ultrasonography-guided Suprascapular Nerve Block and Intra-articular Shoulder Injection on Pain, Functional Status and Range of Motion in Patients With Adhesive Capsulitis; Randomized, Controlled Trial [NCT05909462]		60 participants (Actual)	Interventional	2023-01-21	Completed
Steroid and Sodium Hyaluronate Hydrodilatation [NCT05861570]		84 participants (Anticipated)	Interventional	2023-05-18	Recruiting
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12) [NCT05436535]	Phase 4	600 participants (Anticipated)	Interventional	2022-11-21	Recruiting
A Prospective Triple-Blinded Single-Center Study of Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid Treatment for Keloids [NCT04786210]	Phase 4	20 participants (Actual)	Interventional	2021-01-30	Completed
Modified SALT Score for Assessment of Alopecia Areata [NCT04412148]	Phase 4	20 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Efficacy of Autologous Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids [NCT04391621]	Phase 2	30 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Subakromiyal sıkışma Sendromunda Hyaluronik Asit, Kortikosteroid ve Elektroterapi [NCT04833738]		90 participants (Actual)	Interventional	2013-09-11	Completed
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema [NCT00105027]	Phase 3	682 participants (Actual)	Interventional	2004-10-31	Completed
The Effectiveness of Intra-articular Corticosteroid Injection in Patients With Whiplash-related Neck Pain [NCT04959721]		32 participants (Anticipated)	Interventional	2021-07-15	Not yet recruiting
Effects of Ultrasound-guide Hypertonic Dextrose Injection for Chronic Subacromial Bursitis [NCT04916353]		60 participants (Anticipated)	Interventional	2021-06-10	Recruiting
[NCT00373282]	Phase 3	0 participants	Interventional	2001-06-30	Completed
Comparing Low Dose and High Dose Steroid Injection for Adhesive Capsulitis [NCT04364425]		80 participants (Anticipated)	Interventional	2020-05-04	Recruiting
Effect of Combined Ultrasound-guided Subdeltoid Corticosteroid Injections and Physiotherapy in Treatment of Patients With Chronic Subacromial Bursitis [NCT03871465]		111 participants (Actual)	Interventional	2018-08-01	Completed
A Randomized, Double-blind, Active-control, Multicenter, Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra Compared to Intramuscular Triamcinolone in the Treatment of Acute Gouty Arthritis, Followed by an Extension Period of up to 2 Year [NCT03002974]	Phase 2	165 participants (Actual)	Interventional	2016-12-31	Completed
A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial [NCT03634852]	Phase 4	1,000 participants (Actual)	Interventional	2016-10-01	Completed
A Clinical and Immunological Study of Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata: A Randomized Controlled Clinical Trial [NCT01559584]		40 participants (Actual)	Interventional	2012-03-31	Completed
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis [NCT04182672]	Phase 2	22 participants (Actual)	Interventional	2020-08-12	Active, not recruiting
Outcome in Shoulder Capsulitis (Frozen Shoulder) Between Corticosteroid and Corticosteroid With Distension Compared to Wait and See Policy, a Randomised Controlled Trial [NCT01570985]	Phase 3	120 participants (Anticipated)	Interventional	2010-02-28	Active, not recruiting
Randomized Multicenter Clinical Trial of Three Parallel Groups to Estimate the Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macu [NCT01572350]	Phase 3	105 participants (Anticipated)	Interventional	2010-10-31	Completed
Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions [NCT05345808]		46 participants (Actual)	Interventional	2021-03-01	Completed
Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection [NCT02084706]		60 participants (Actual)	Interventional	2014-03-31	Completed
Effect of Intra-articular Steroids on Structural Progression of Knee OA: A Randomized Controlled Trial [NCT01230424]	Phase 4	140 participants (Actual)	Interventional	2011-03-31	Completed
A Randomized, Evaluator Blinded, Within Subject, Single-Centre Evaluation of the Vasoconstriction Properties of MC2-01 Cream, Compared to 5 Other Corticosteroids in Healthy Subjects [NCT03758365]	Phase 1	36 participants (Actual)	Interventional	2018-11-05	Completed
Safety and Effectiveness of Single-dose Subconjunctival Triamcinolone Compared to Topical Prednisolone Eye Drops in Manual Small Incision Cataract Surgery [NCT05248139]		100 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Treatment Efficacy of Local Anesthetic/Steroid Mixture Injection for Patients With Odynophonia [NCT05178485]	Phase 4	0 participants (Actual)	Interventional	2023-07-01	Withdrawn(stopped due to Halted prematurely prior to enrollment of first participant)
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee [NCT02357459]	Phase 3	486 participants (Actual)	Interventional	2015-01-31	Completed
The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections [NCT02592629]	Phase 4	19 participants (Actual)	Interventional	2016-02-01	Terminated(stopped due to Lack of time to enroll due to additional responsibilities of the PI and research coordinator.)
Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis [NCT02680301]	Phase 4	40 participants (Actual)	Interventional	2016-03-31	Completed
[NCT00369863]	Phase 2	76 participants	Interventional	2002-06-30	Completed
The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation [NCT02877485]	Phase 4	42 participants (Actual)	Interventional	2016-08-31	Completed
Peripheral Nerve Injections for the Treatment of Upper Extremity Complex Regional Pain Syndrome: A Feasibility Study for a Proposed Randomized Design [NCT04744675]	Phase 4	50 participants (Anticipated)	Interventional	2021-03-31	Not yet recruiting
[NCT00370370]	Phase 3	0 participants	Interventional	2005-11-30	Active, not recruiting
[NCT00370669]	Phase 3	150 participants	Interventional	2005-11-30	Recruiting
Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome [NCT03463915]	Phase 3	90 participants (Actual)	Interventional	2019-01-25	Completed
SporTRIA Study: A Multicentre Trial for Excretion Kinetics of Triamcinolone Acetonide Following Sport Related Intra-articular Injections in Knees; Definitions of the Washout Periods [NCT04574232]		20 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy [NCT02379000]	Phase 4	50 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
A Stratified Investigation of a Single Injection of ZILRETTA™ (Triamcinolone Acetonide Extended-release Injectable Suspension) for Symptomatic Relief in Patients With Idiopathic Adhesive Capsulitis of the Shoulder [NCT04831255]	Phase 1	50 participants (Anticipated)	Interventional	2019-06-21	Recruiting
An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective [NCT01470989]	Phase 3	136 participants (Actual)	Interventional	2011-11-30	Completed
Ultrasound-guided PRP Versus Steroid Injections in Management of Carpal Tunnel Syndrome; a Comparative Study [NCT04434105]	Phase 2/Phase 3	90 participants (Actual)	Interventional	2020-02-01	Active, not recruiting
Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee (EEFFEK Study) [NCT03062787]		60 participants (Actual)	Interventional	2017-04-05	Completed
A Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus- Split-Mouth Randomised [NCT04976673]	Phase 2	30 participants (Actual)	Interventional	2020-12-10	Completed
Cell Therapy for Patients With Symptomatic Knee Osteoarthritis: Phase I / II, Controlled, Randomized and Double-blind Clinical Trial [NCT04863183]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee [NCT03191903]	Phase 3	576 participants (Actual)	Interventional	2017-05-25	Completed
Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas [NCT04658836]	Phase 1	21 participants (Actual)	Interventional	2020-02-01	Completed
Using Intraoperative Triamcinolone Acetonide Irrigation to Reduce Post-Operative Pain From Scleral Buckle Surgery [NCT04701593]	Phase 4	24 participants (Anticipated)	Interventional	2020-01-03	Recruiting
Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance [NCT05058209]	Phase 4	20 participants (Actual)	Interventional	2020-11-30	Completed
Suprachoroidal Triamcinolone Acetonide Injection A Novel Therapy for Serous Retinal Detachment in Vogt-Koyanagi Harada's Disease [NCT05031143]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2020-04-01	Completed
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee [NCT02637323]	Phase 2	81 participants (Actual)	Interventional	2015-11-30	Completed
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. [NCT04994951]	Phase 2	200 participants (Anticipated)	Interventional	2021-09-30	Recruiting
Randomized Trial Evaluating Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema [NCT02985619]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2016-07-21	Completed
Efficacy of Corticosteroid Injection Into Coracohumeral Ligament in Patients With Adhesive Capsulitis of the Shoulder [NCT03013205]		60 participants (Anticipated)	Interventional	2017-02-28	Not yet recruiting
Comparison of Ultrasound-guided Corticosteroid Injection Versus Corticosteroid Injection and Hydrodissection for Carpal Tunnel Syndrome [NCT04346030]		60 participants (Anticipated)	Interventional	2020-04-17	Recruiting
[NCT01614509]		45 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective [NCT01362608]	Phase 3	136 participants (Actual)	Interventional	2011-06-20	Terminated
A Phase 2, Randomized, Active and Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis [NCT04885972]	Phase 2	124 participants (Actual)	Interventional	2021-11-15	Active, not recruiting
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis [NCT03991936]	Phase 4	10 participants (Actual)	Interventional	2020-03-11	Completed
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata [NCT04147845]		60 participants (Actual)	Interventional	2019-10-30	Completed
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors [NCT03627741]	Phase 1	10 participants (Actual)	Interventional	2018-06-07	Completed
Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial. [NCT04614311]	Phase 4	202 participants (Anticipated)	Interventional	2020-12-01	Recruiting
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee [NCT02003365]	Phase 2	50 participants (Actual)	Interventional	2013-11-30	Completed
Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial [NCT05887804]	Phase 4	24 participants (Actual)	Interventional	2021-10-01	Completed
Prospective, Randomized Trial of Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture After Endoscopic Submucosal Dissection [NCT04498260]	Phase 4	30 participants (Anticipated)	Interventional	2019-01-21	Recruiting
Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus [NCT02329600]	Phase 3	40 participants (Actual)	Interventional	2013-06-30	Completed
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma [NCT01748175]		715 participants (Actual)	Observational	2013-01-31	Completed
Effect of the Combination of Photobiomodulation Therapy and the Intralesional Administration of Corticoid in the Preoperative and Postoperative Periods of Keloid Surgery: a Randomized, Controlled, Double-blind Trial [NCT04824612]		58 participants (Anticipated)	Interventional	2021-08-30	Enrolling by invitation
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study [NCT04207931]	Phase 4	250 participants (Anticipated)	Interventional	2018-04-30	Recruiting
Bevacizumabe e Acetato de Triancinolona Intra-vítreo Associados à Laserterapia em Pacientes Com Edema Macular diabético (IBeTA) [NCT02310295]		45 participants (Actual)	Interventional	2009-01-31	Completed
Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized [NCT03382925]	Phase 4	16 participants (Actual)	Interventional	2017-12-20	Terminated(stopped due to Not enough cervical interlaminar patients who meet criteria in order to meet recruitment goals.)
The Clinical Application of PLT Combined With Steroid in Lateral Epicondylopathy and Supraspinatus Calcific Tendinopathy [NCT05648032]	Phase 3	180 participants (Anticipated)	Interventional	2022-10-06	Recruiting
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee [NCT04231318]	Phase 3	231 participants (Actual)	Interventional	2020-09-11	Completed
Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance [NCT04261049]	Phase 1	35 participants (Actual)	Interventional	2020-08-01	Completed
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery [NCT05158699]	Phase 3	808 participants (Anticipated)	Interventional	2021-10-13	Recruiting
Comparison of Corticosteroid and Repeated Dextrose Hydro-dissection for Carpal Tunnel Syndrome Patients [NCT04579783]		60 participants (Anticipated)	Interventional	2020-11-27	Recruiting
Thoracic Epidural Morphine Versus Triamcinolone Acetonide Analgesia in Flail Chest [NCT03413059]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2018-02-01	Not yet recruiting
Evaluation of Triamcinolone's Efficacy on the Ultrasound- Guided Infiltration in the Quadratus Lumborum Syndrome: a Double Blind, Randomized, Controlled Study [NCT03407027]	Phase 4	66 participants (Anticipated)	Interventional	2017-11-01	Enrolling by invitation
Painful Inflammatory Carpometacarpal-1 Osteoarthritis Treated With Intraarticular Steroids, Saline or an Occupational Therapy Intervention: the PICASSO Trial. [NCT06084364]	Phase 4	354 participants (Anticipated)	Interventional	2023-11-03	Recruiting
Pilot Study of Early Postoperative Fractional Ablative Laser Treatment of Skin Grafts for Burns [NCT04176705]		9 participants (Actual)	Interventional	2020-12-14	Completed
Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis: A Randomized Placebo-Controlled Clinical Trial [NCT00746889]		79 participants (Actual)	Interventional	2004-03-31	Completed
A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee [NCT01487200]	Phase 2	24 participants (Actual)	Interventional	2012-07-31	Completed
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering [NCT05535738]	Phase 2/Phase 3	45 participants (Anticipated)	Interventional	2022-11-15	Recruiting
Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo [NCT03365141]		12 participants (Anticipated)	Interventional	2017-11-14	Recruiting
Particulate vs. Nonparticulate Epidural Steroid Injections for the Treatment of Symptomatic Unilateral Lumbar Foraminal Stenosis: a Prospective Double-blinded Randomized Study [NCT03245671]	Phase 4	0 participants (Actual)	Interventional	2017-12-31	Withdrawn(stopped due to Unable to address regulatory concerns.)
Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus [NCT02453503]	Phase 2	60 participants (Actual)	Interventional	2014-01-31	Completed
A Short Term Outcomes of Subacromial Injection of Combined Corticosteroid With Low Volume Compared to High Volume of Local Anesthetic for Rotator Cuff Impingement Syndrome: A Randomized Controlled Trials [NCT03120923]	Phase 4	52 participants (Actual)	Interventional	2015-01-01	Completed
A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered With the Oxulumis® Ophthalmic Administration Device i [NCT05512962]	Phase 2	20 participants (Actual)	Interventional	2022-08-31	Active, not recruiting
Triamcinolone Levels in Cochlear Perilymph [NCT03248856]	Phase 1	40 participants (Actual)	Interventional	2017-10-02	Completed
A Double-Blind, Randomized Study to Compare Onabotulinumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain [NCT02369068]		21 participants (Actual)	Interventional	2015-08-31	Completed
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial [NCT02374060]	Phase 3	192 participants (Actual)	Interventional	2015-06-16	Completed
Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With Rizoarthrosis [NCT03200886]		100 participants (Actual)	Observational	2017-05-24	Active, not recruiting
Efficacy of Intralesional Injection of Autologous Platelet Rich Plasma Versus Intralesional Injection of Corticosteroids on Pain Relief and Ulcers Healing in Patients With Erosive Oral Lichen Planus; Randomized Clinical Trial [NCT03293368]	Phase 2	20 participants (Actual)	Interventional	2018-01-01	Completed
A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata [NCT01898806]	Phase 4	11 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to The PI left the Columbia University Medical Center. Study was not Completed.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00105027 (4) [back to overview]	Adverse Ocular Outcomes
NCT00105027 (4) [back to overview]	Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography
NCT00105027 (4) [back to overview]	The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit
NCT00105027 (4) [back to overview]	Changes From Baseline in Best-corrected ETDRS Visual Acuity Score
NCT00242580 (6) [back to overview]	Number of Participants Requiring Verteporfin Treatment Throughout the Study
NCT00242580 (6) [back to overview]	Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.
NCT00242580 (6) [back to overview]	Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12
NCT00242580 (6) [back to overview]	Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months
NCT00242580 (6) [back to overview]	Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12
NCT00242580 (6) [back to overview]	Mean Change From Baseline in Total Area of Lesion at 12 Months
NCT00279916 (8) [back to overview]	Complete Normalization of Abnormal Tympanometry Considering the Subjects Who Took Additional Treatment as Having Incomplete Resolution
NCT00279916 (8) [back to overview]	Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Plugged Sensation in Ears
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Dampened Hearing/Loss Worse Than Usual
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Pain in Ears
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Popping Sensation in Ears
NCT00279916 (8) [back to overview]	Per-Ear Treatment Outcome
NCT00279916 (8) [back to overview]	Number of Subjects With Change in Symptom Frequency and Severity - Fullness or Pressure in Ears
NCT00367133 (14) [back to overview]	Central Subfield Thickness < 250 Microns at 2 Years
NCT00367133 (14) [back to overview]	Central Subfield Thickness at 2 Years
NCT00367133 (14) [back to overview]	Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years
NCT00367133 (14) [back to overview]	Change in Central Subfield Thickness on OCT Baseline to 3 Years
NCT00367133 (14) [back to overview]	Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.
NCT00367133 (14) [back to overview]	Change in Visual Acuity From Baseline to 3 Years
NCT00367133 (14) [back to overview]	Change in Visual Acuity From Baseline to 3 Years
NCT00367133 (14) [back to overview]	Mean Change in Central Subfield Thickness Baseline to 2 Years
NCT00367133 (14) [back to overview]	Median Change in Central Subfield Thickness Baseline to 2 Years
NCT00367133 (14) [back to overview]	Median Change in Visual Acuity Baseline to 2 Years
NCT00367133 (14) [back to overview]	Overall Central Subfield Thickening Decreased by >=50% Baseline to 2 Years
NCT00367133 (14) [back to overview]	Percentage of Eyes With a Change in Central Subfield Thickness on OCT <250 Microns From Baseline to 3 Years
NCT00367133 (14) [back to overview]	Distribution of Visual Acuity Change Baseline to 3 Years
NCT00367133 (14) [back to overview]	Distribution of Change in Visual Acuity Baseline to 2 Years
NCT00369486 (6) [back to overview]	Change in Central Subfield Thickening From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Central Subfield Thickness <250 Microns From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks
NCT00369486 (6) [back to overview]	Change in Visual Acuity Letter Score From Baseline Through 34 Weeks
NCT00369486 (6) [back to overview]	Mean Visual Acuity Letter Score at Each Follow-up Visit
NCT00398866 (2) [back to overview]	Pain Visual Analogue Scale (VAS)
NCT00398866 (2) [back to overview]	Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire
NCT00444600 (21) [back to overview]	Central Subfield Thickness < 250 With at Least a 25 Micron Decrease From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Change in Retinal Thickening of Central Subfield on Optical Coherence Tomography From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity
NCT00444600 (21) [back to overview]	Mean Optical Coherence Tomography Retinal Volume at 1 Year
NCT00444600 (21) [back to overview]	Number of Injections in First Year
NCT00444600 (21) [back to overview]	Percentage of Eyes Receiving Laser at the 48 Week Visit (%)
NCT00444600 (21) [back to overview]	Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year
NCT00444600 (21) [back to overview]	Change From Moderately Severe Non-proliferative Diabetic Retinopathy or Better From Baseline to 1-year
NCT00444600 (21) [back to overview]	Change From Severe Non-proliferative Diabetic Retinopathy or Worse From Baseline to 1-year
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator
NCT00444600 (21) [back to overview]	Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness
NCT00444600 (21) [back to overview]	Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
NCT00444600 (21) [back to overview]	Eyes With Alternative Treatments Prior to the 1-year Visit
NCT00444600 (21) [back to overview]	Number of Laser Treatments Received Prior to the 1 Year Visit
NCT00444600 (21) [back to overview]	Major Ocular Adverse Events During First Year of Follow-Up
NCT00444600 (21) [back to overview]	Distribution of Logarithmic Transformation of Optical Coherence Tomography (LogOCT) Improvement and Worsening
NCT00445003 (8) [back to overview]	Change in Optical Coherence Tomography Retinal Volume
NCT00445003 (8) [back to overview]	Change in Visual Acuity From Baseline
NCT00445003 (8) [back to overview]	Eyes With Anti-vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema
NCT00445003 (8) [back to overview]	Total Optical Coherence Tomography Retinal Volume
NCT00445003 (8) [back to overview]	Additional Treatments for Diabetic Macular Edema
NCT00445003 (8) [back to overview]	Number of Eyes With Additional Number of Treatments for Diabetic Macular Edema
NCT00445003 (8) [back to overview]	Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks
NCT00445003 (8) [back to overview]	Change in Optical Coherence Tomography Central Subfield Thickness
NCT00473083 (7) [back to overview]	Duration of Treatment
NCT00473083 (7) [back to overview]	Overall Incidence of Grade 3 Rash
NCT00473083 (7) [back to overview]	Overall Incidence of Rash
NCT00473083 (7) [back to overview]	Overall Survival
NCT00473083 (7) [back to overview]	Time to First Presentation of Rash
NCT00473083 (7) [back to overview]	Severity of Rash Caused by Erlotinib
NCT00473083 (7) [back to overview]	Time Duration From Onset of Rash Until Resolution
NCT00484679 (1) [back to overview]	Mean Change in Cortisol Levels From Baseline to Week 24
NCT00588354 (8) [back to overview]	Pain Disability Score at 2 Weeks as Measured by the Roland-Morris Disability Questionnaire
NCT00588354 (8) [back to overview]	Pain Disability Score at 4 Weeks as Measured by Oswestry Low Back Pain Disability Questionnaire
NCT00588354 (8) [back to overview]	Pain Disability Score at 2 Weeks as Measured by Oswestry Low Back Pain Disability Questionnaire (ODI)
NCT00588354 (8) [back to overview]	Pain Disability Score at 4 Weeks as Measured by the Roland-Morris Disability Questionnaire
NCT00588354 (8) [back to overview]	Pain Intensity Score at 2 Weeks as Measured by Pain Intensity Numerical Rating Scale (PI-NRS)
NCT00588354 (8) [back to overview]	Pain Intensity Score at 4 Weeks as Measured by Pain Intensity Numerical Rating Scale (PI-NRS)
NCT00588354 (8) [back to overview]	Pain Score at 2 Weeks as Measured by the Multidimensional Pain Inventory (MPI)
NCT00588354 (8) [back to overview]	Pain Score at 4 Weeks as Measured by the Multidimensional Pain Inventory (MPI)
NCT00597766 (4) [back to overview]	Pain Free Abduction Range of Motion (ROM)
NCT00597766 (4) [back to overview]	Fugl-Meyer Motor Assessment, Upper Limb Domain
NCT00597766 (4) [back to overview]	BPI 12 (Brief Pain Inventory, Question 12) Pain Questionnaire
NCT00597766 (4) [back to overview]	Pain Free External Rotation Range of Motion (ROM)
NCT00746889 (2) [back to overview]	Change in WOMAC Pain Subscale
NCT00746889 (2) [back to overview]	Change in Western Ontario and McMasters Universities Arthritis Index (WOMAC) Pain Subscale
NCT00798369 (7) [back to overview]	The Time to 50% Reduction of Baseline Pain Intensity in the Target Joint
NCT00798369 (7) [back to overview]	Amount of Rescue Medication Taken for Each Treatment Group
NCT00798369 (7) [back to overview]	High Sensitivity C-reactive Protein (hsCRP) at 72 Hours, 7days, 4 Weeks and 8 Weeks Post Dose for Each Treatment Group
NCT00798369 (7) [back to overview]	Serum Amyloid Protein (SAA) Levels at 72 Hours, 7days, 4 Weeks and 8 Weeks Post Dose for Each Treatment Group
NCT00798369 (7) [back to overview]	The Change in Pain Intensity in the Target Joint Following Canakinumab Administration Compared to Triamcinolone Acetonide
NCT00798369 (7) [back to overview]	The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a 0-100 mm Visual Analog Scale (VAS)
NCT00798369 (7) [back to overview]	Percentage of Participants With an Excellent or Good Response With Regards to the Patient's Global Assessment of Response to Treatment
NCT00815360 (2) [back to overview]	Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months
NCT00815360 (2) [back to overview]	Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6.
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Overall Complaint on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a 100 mm VAS-scale
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a 100 mm VAS-scale (Visual Analog Scale).
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a 100 mm VAS-scale (Visual Analog Scale).
NCT00826462 (33) [back to overview]	Pain as Recorded by the Study Doctors on a Visual Analog Scale (VAS Scale)
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain Free Function Index of Everyday Activities
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Pain-free Grip Strength Ratio
NCT00826462 (33) [back to overview]	Treatment Success - Event Rates in Each Group
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	Affected Function on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Affected Function on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Affected Function on 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Affected Function on a 100 mm VAS-scale as Recorded by the Study Doctors
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	Maximum Grip Strength Ratio
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Dorsiflexion of Wrist
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00826462 (33) [back to overview]	No Pain on Three Point Likert Scale on Isometric Extension of Third Finger
NCT00853905 (5) [back to overview]	Anterior Chamber Inflammation (Flare)
NCT00853905 (5) [back to overview]	Patient Comfort
NCT00853905 (5) [back to overview]	Ocular Hypotensive Medications
NCT00853905 (5) [back to overview]	Intraocular Pressure (IOP)
NCT00853905 (5) [back to overview]	Bleb Appearance
NCT00924508 (2) [back to overview]	Number of Adverse Events Associated With Treatment
NCT00924508 (2) [back to overview]	Change in Disease Severity: Percent Change in Mean EASI Score
NCT01029652 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale)
NCT01029652 (33) [back to overview]	Patient's Global Assessment of Response to Treatment
NCT01029652 (33) [back to overview]	Patient's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Percentage of Participants Who Took Rescue Medication
NCT01029652 (33) [back to overview]	Percentage of Participants With Maximum Severity of Last Post-baseline Flare (5-point Likert Scale)
NCT01029652 (33) [back to overview]	Physician's Assessment of Erythema for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Physician's Assessment of Joint Swelling for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Physician's Assessment of Joint Tenderness for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Physician's Assessment of Range of Motion of the Most Affected Joint
NCT01029652 (33) [back to overview]	Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint
NCT01029652 (33) [back to overview]	Physician's Global Assessment of Response to Treatment
NCT01029652 (33) [back to overview]	Physician's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Time to First New Flare
NCT01029652 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels for Core and 24 Weeks Overall
NCT01029652 (33) [back to overview]	Amount of Rescue Medication Taken
NCT01029652 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) Levels for Patients Re-treated With or Switched to Canakinumab
NCT01029652 (33) [back to overview]	Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (24 Weeks Overall)
NCT01029652 (33) [back to overview]	Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (72 Weeks Overall)
NCT01029652 (33) [back to overview]	Flare Rate Per Year
NCT01029652 (33) [back to overview]	Mean Number of New Gout Flares Per Patient
NCT01029652 (33) [back to overview]	Mean Number of New Gout Flares Per Patient During the 24 Weeks of the Study
NCT01029652 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint on a Visual Analog Scale (VAS) in Extension
NCT01029652 (33) [back to overview]	Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks
NCT01029652 (33) [back to overview]	Percentage of Participants With Complete Resolution of Pain
NCT01029652 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)
NCT01029652 (33) [back to overview]	SF36 Physical Function Score at Week 12
NCT01029652 (33) [back to overview]	Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)
NCT01029652 (33) [back to overview]	Time to Complete Resolution of Pain
NCT01029652 (33) [back to overview]	Time to First Intake of Rescue Medication After the Last Post Baseline Flare.
NCT01029652 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Currently Most-affected Joint (Likert Scale)
NCT01029652 (33) [back to overview]	Time to First New Flare
NCT01029652 (33) [back to overview]	Time to First New Flare: Survival Analysis by Treatment (72 Weeks Overall)
NCT01029652 (33) [back to overview]	Serum Amyloid A Protein (SAA) Levels for Patients Re-treated With or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Percentage of Participants Who Took Rescue Medication
NCT01080131 (33) [back to overview]	Percentage of Patients With Maximum Severity of New Gout Flares as Severe or Extreme
NCT01080131 (33) [back to overview]	Physician's Assessment of Erythema for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Physician's Assessment of Joint Swelling for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Physician's Assessment of Joint Tenderness for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Physician's Assessment of Range of Motion of the Most Affected Joint
NCT01080131 (33) [back to overview]	Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint
NCT01080131 (33) [back to overview]	Physician's Global Assessment of Response to Treatment
NCT01080131 (33) [back to overview]	Physician's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100 mm VAS)
NCT01080131 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Last Post-Baseline Measured on a Visual Analog Scale (VAS)
NCT01080131 (33) [back to overview]	Serum Amyloid A Protein (SAA) Levels for Participants Re-treated With or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Time to First Intake of Rescue Medication
NCT01080131 (33) [back to overview]	Flare Rate Per Year
NCT01080131 (33) [back to overview]	Mean Number of New Gout Flares Per Patient During 24 Weeks
NCT01080131 (33) [back to overview]	Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks of the Study
NCT01080131 (33) [back to overview]	Pharmacokinetic Concentrations
NCT01080131 (33) [back to overview]	Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS) at 72 Hours Post-dose
NCT01080131 (33) [back to overview]	SF 36 Physical Function Score at Week 12
NCT01080131 (33) [back to overview]	Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS)
NCT01080131 (33) [back to overview]	Time to Complete Resolution of Pain; Survival Analysis
NCT01080131 (33) [back to overview]	Time to First New Flare: Survival Analysis by Treatment Over 72 Weeks
NCT01080131 (33) [back to overview]	Time to First New Flare: Survival Analysis During the 12 Weeks of Study
NCT01080131 (33) [back to overview]	Time to the First New Gout Flare During 24 Weeks
NCT01080131 (33) [back to overview]	Amount of Rescue Medication Taken
NCT01080131 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels
NCT01080131 (33) [back to overview]	High-sensitivity C-reactive Protein (hsCRP) Levels for Participants Re-treated With or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Number of Participants With Adverse Events, Death and Serious Adverse Events (72 Weeks Overall)
NCT01080131 (33) [back to overview]	Number of Participants With Adverse Events, Death and Serious Adverse Events During 24 Weeks
NCT01080131 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity for Participants Re-treated or Switched to Canakinumab
NCT01080131 (33) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint
NCT01080131 (33) [back to overview]	Patient's Global Assessment of Response to Treatment
NCT01080131 (33) [back to overview]	Patient's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab
NCT01154153 (6) [back to overview]	Ratio of Serum Cortisol Area Under Curve [AUC(0-24 hr)] at the End of Treatment to Baseline
NCT01154153 (6) [back to overview]	The Percent of Days of Rescue Medication Use During the Double-blind Treatment Phase
NCT01154153 (6) [back to overview]	Change From Baseline in the Reflective Total Nasal Symptom Score (rTNSS)
NCT01154153 (6) [back to overview]	Number of Participants Using Rescue Medication
NCT01154153 (6) [back to overview]	Number of Participants by Relief Level as Evaluated by the Physician
NCT01154153 (6) [back to overview]	Number of Participants by Relief Level as Evaluated by the Participant
NCT01175395 (2) [back to overview]	To Assess the Safety & Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD
NCT01175395 (2) [back to overview]	To Determine the Number of Retreatments With Lucentis in Eyes Initially Treated With 20089 TA and Lucentis
NCT01230424 (11) [back to overview]	Change in Knee Stiffness During the Past 48 Hours From the WOMAC LK3.1 Stiffness Score Questionnaire.
NCT01230424 (11) [back to overview]	Change in Time to Complete 5 Chair Stands.
NCT01230424 (11) [back to overview]	Change in Time to Complete a Twenty-meter Walk.
NCT01230424 (11) [back to overview]	Change in Function Severity During the Past 48 Hours From the WOMAC LK3.1 Function Score Questionnaire.
NCT01230424 (11) [back to overview]	Change in Volume of Peri-articular Bone Marrow Lesions Measured on Knee MRI.
NCT01230424 (11) [back to overview]	Change in Patient's Global Assessment (Visual Analogue Scale).
NCT01230424 (11) [back to overview]	Change in Mean Cartilage Thickness in the Index Compartment (Compartment With the Most Damage)
NCT01230424 (11) [back to overview]	Change in Volumetric Cartilage Damage Index (CDI) Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
NCT01230424 (11) [back to overview]	Change in Knee Pain Severity During the Past 48 Hours From the WOMAC LK3.1 Pain Score Questionnaire.
NCT01230424 (11) [back to overview]	Change in Effusion Volume Measured on Knee MRI.
NCT01230424 (11) [back to overview]	Change in Area of Denudation Measured on Knee MRI in the Index Compartment (Compartment With the Most Damage).
NCT01356602 (18) [back to overview]	Physician's Assessment of Erythema
NCT01356602 (18) [back to overview]	Physician's Assessment of Range of Motion of the Most Affected Joint
NCT01356602 (18) [back to overview]	Physician's Assessment of Swelling
NCT01356602 (18) [back to overview]	Physician's Assessment of Tenderness
NCT01356602 (18) [back to overview]	Amount of Rescue Medication Taken (mg)
NCT01356602 (18) [back to overview]	Time to the First New Gouty Arthritis Flare
NCT01356602 (18) [back to overview]	Physician's Global Assessment of Response to Treatment on a 5 Point Likert Scale
NCT01356602 (18) [back to overview]	C-reactive Protein Level
NCT01356602 (18) [back to overview]	Number of Patients With at Least One New Gouty Arthritis Flare After Baseline
NCT01356602 (18) [back to overview]	Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups
NCT01356602 (18) [back to overview]	Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups
NCT01356602 (18) [back to overview]	Patient's Assessment of Pain Intensity on a 0-100mm VAS
NCT01356602 (18) [back to overview]	Proportion of Patients With Rescue Medication Intake
NCT01356602 (18) [back to overview]	Time to 50% Reduction in Baseline Pain on a 0 - 100 VAS
NCT01356602 (18) [back to overview]	Time to First Rescue Medication Intake
NCT01356602 (18) [back to overview]	Time to Resolution of Gouty Arthritis Flare as Reported by Patient
NCT01356602 (18) [back to overview]	Patient's Assessment of Pain Intensity on a 5-point Likert Scale
NCT01356602 (18) [back to overview]	Patient's Global Assessment of Response to Treatment on a 5-point Likert Scale
NCT01362608 (16) [back to overview]	High Sensitivity C-reactive Protein [hsCRP] Measured in the Serum at 72 Hours Post Dose
NCT01362608 (16) [back to overview]	The Number of Patients With at Least 1 New Gout Flare
NCT01362608 (16) [back to overview]	Patients Assessment of Gout Pain Intensity in the Most Effected Joint (0-100mm VAS): Summary Statistics by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Time to First New Flare: Survival Analysis by Treatment: Kaplan Meier Analysis
NCT01362608 (16) [back to overview]	Time to Complete Resolution of Pain: Survival Analysis by Treatment
NCT01362608 (16) [back to overview]	Time to at Least a 50% Reduction in Baseline Pain Intensity: Survival Analysis by Treatment
NCT01362608 (16) [back to overview]	The Change in the Gout Pain Intensity in the Target Joint Following ACZ885 Administration Measured by Visual Analog Scale (VAS)
NCT01362608 (16) [back to overview]	Physician's Assessment of Swelling: Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale): Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Physician's Assessment of Erythema: Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Time to First Rescue Medication Intake
NCT01362608 (16) [back to overview]	Amount of Rescue Medication Taken at Baseline Flare and Post Baseline Flare.
NCT01362608 (16) [back to overview]	Patient's Global Assessment of Response to Treatment: Frequency Table by Timepoint and Treatment Using a Likert Scale.
NCT01362608 (16) [back to overview]	Percent Patients Who Took Rescue Medication
NCT01362608 (16) [back to overview]	Physician's Assessment of Range of Motion: Frequency Table by Timepoint and Treatment
NCT01362608 (16) [back to overview]	Physician's Assessment of Tenderness: Frequency Table by Timepoint and Treatment
NCT01470989 (3) [back to overview]	Patient's Assessment of Gout Pain Intensity in the Most Affected Joint
NCT01470989 (3) [back to overview]	Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants
NCT01470989 (3) [back to overview]	Number of New Flares Per Participant
NCT01487161 (16) [back to overview]	Percent of Responders According to OMERACT-OARSI Criteria at Week 8
NCT01487161 (16) [back to overview]	Responder Status as Defined by the Proportion of Patients Achieving >20% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8
NCT01487161 (16) [back to overview]	Responder Status as Defined by the Proportion of Patients Achieving >30% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8
NCT01487161 (16) [back to overview]	Patient Global Impression of Change Scores at Week 8
NCT01487161 (16) [back to overview]	Change From Baseline to Each of Weeks 1, 2, 3, 4, 5, 6, 7, 9, and 11 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score.
NCT01487161 (16) [back to overview]	Change From Baseline to Week 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Change From Baseline to Week 10 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Responder Status as Defined by the Proportion of Patients Achieving >50% Improvement From Baseline in the Mean Daily Pain Intensity Scores at Week 8
NCT01487161 (16) [back to overview]	WOMAC A (Pain Subscale) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	WOMAC A1 (Pain on Walking Question) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	WOMAC B (Stiffness Subscale) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	WOMAC C (Function Subscale) Change From Baseline at Week 8
NCT01487161 (16) [back to overview]	Change From Baseline to Each of Weeks 8, 10, and 12 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 10mg and 40 mg vs TCA IR 40 mg
NCT01487161 (16) [back to overview]	Average Weekly and Total Consumption of Rescue Medications Over 8 Weeks.
NCT01487161 (16) [back to overview]	Clinical Global Impression of Change Scores at Week 8
NCT01487200 (5) [back to overview]	Total 24-hour Urinary Free Cortisol Excretion
NCT01487200 (5) [back to overview]	Change From Baseline in 24-hour Urinary Free Cortisol Excretion
NCT01487200 (5) [back to overview]	Change From Baseline in 24-hour Weighted Mean Serum Cortisol
NCT01487200 (5) [back to overview]	Change From Baseline to Each Measured Time Point Post-dose in Morning Serum Cortisol
NCT01487200 (5) [back to overview]	Characterize the Pharmacokinetic Profile of FX006 and TCA IR
NCT01614509 (2) [back to overview]	Additional Intravitreal Bevacizumab Injection
NCT01614509 (2) [back to overview]	Changes of Central Retinal Thickness
NCT01652495 (3) [back to overview]	Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis
NCT01652495 (3) [back to overview]	Functional Improvement Measured According to Percentage Change in Constant Score
NCT01652495 (3) [back to overview]	Reduction of Pain Severity Expressed as Percentage Change in VAS Score
NCT01692756 (13) [back to overview]	Synovial Glycosaminoglycans (GAG) Concentration
NCT01692756 (13) [back to overview]	Synovial Interleukin-1 Receptor Antagonist (IL-1ra) Concentration
NCT01692756 (13) [back to overview]	Synovial Interleukin-1α (IL-1α) Concentration
NCT01692756 (13) [back to overview]	Synovial Interleukin-1β (IL-1β) Concentration
NCT01692756 (13) [back to overview]	Synovial Matrix Metalloproteinase 1 (MMP-1) Concentration
NCT01692756 (13) [back to overview]	Synovial Matrix Metalloproteinase 9 (MMP-9) Concentration
NCT01692756 (13) [back to overview]	Synovial TNF-stimulated Gene 6 Protein (TSG-6) Concentration
NCT01692756 (13) [back to overview]	Synovial Type I Collagen Cross-Linked N-Telopeptide (NTX-I) Concentration
NCT01692756 (13) [back to overview]	Synovial Matrix Metalloproteinase 3 (MMP-3) Concentration
NCT01692756 (13) [back to overview]	Efficacy of Kenalog to Alleviate Knee Pain
NCT01692756 (13) [back to overview]	Participant Pain Assessment
NCT01692756 (13) [back to overview]	Synovial C-terminal Peptide II (CTXII) Concentration
NCT01692756 (13) [back to overview]	Synovial Cartilage Oligomeric Matrix Protein (COMP) Concentration
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Palpable Muscle Tenderness at 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Functional Pain (Chewing) at 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in TMJ Loading Pain Rating at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in TMJ Loading Pain Rating at 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in Mandibular Range of Pain-Free Motion at 12 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in Mandibular Range of Motion Without Pain at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in TMJ Loading Pain Rating at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment in Mandibular Range of Motion at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Palpable Muscle Tenderness at 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Palpable Muscle Tenderness at 6 Weeks
NCT01770912 (15) [back to overview]	Number of Participants With Change From Pre-Treatment Joint Sounds in 12 Weeks
NCT01770912 (15) [back to overview]	Number of Participants With Change From Pre-Treatment Joint Sounds in 2 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Functional Pain (Chewing) at 6 Weeks
NCT01770912 (15) [back to overview]	Change From Pre-Treatment Functional Pain (Chewing) at 2 Weeks
NCT01770912 (15) [back to overview]	Number of Participants With Change From Pre-Treatment Joint Sounds in 6 Weeks
NCT01789320 (4) [back to overview]	Vitreous Haze Grade
NCT01789320 (4) [back to overview]	Change in Intraocular Pressure (IOP)
NCT01789320 (4) [back to overview]	Best Corrected Visual Acuity
NCT01789320 (4) [back to overview]	Central Subfield Thickness Using Optical Coherence Tomography (OCT)
NCT01797432 (2) [back to overview]	Number of Adverse Events Reported by Subjects
NCT01797432 (2) [back to overview]	Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline
NCT01898806 (1) [back to overview]	Number of Adverse Events
NCT01995045 (4) [back to overview]	Mean Pain Score
NCT01995045 (4) [back to overview]	Mean Oxycodone Intake
NCT01995045 (4) [back to overview]	Mean Hydrocodone Intake
NCT01995045 (4) [back to overview]	Mean Acetaminophen Intake
NCT02003365 (2) [back to overview]	Concentration of Triamcinolone Acetonide in Synovial Fluid
NCT02003365 (2) [back to overview]	Plasma Drug Concentrations by Time
NCT02084706 (1) [back to overview]	Difference in Visual-analog Score (VAS) for Anticipated Pain Prior to Injection and Actual Pain After Injection
NCT02120261 (4) [back to overview]	Pain Intensity
NCT02120261 (4) [back to overview]	Pain Intensity
NCT02120261 (4) [back to overview]	Pain Intensity
NCT02120261 (4) [back to overview]	Duration of Pain Relief
NCT02242630 (2) [back to overview]	Change in Subject Reported Shoulder Pain as Measured by the Visual Analogue Scale
NCT02242630 (2) [back to overview]	Change in Shoulder Function, as Measured by the QuickDASH ®
NCT02329600 (2) [back to overview]	Pain
NCT02329600 (2) [back to overview]	Salivary Total Oxidative Capacity
NCT02357459 (14) [back to overview]	Responder Status as Defined by Proportion of Patients Experiencing >30% Decrease in Pain From Baseline in Weekly Mean of the ADP Scores at Each Week (Weeks 1-24)
NCT02357459 (14) [back to overview]	Responder Status as Defined by Proportion of Patients Experiencing >50% Decrease in Pain From Baseline in Weekly Mean of the ADP Scores at Each Week (Weeks 1-24)
NCT02357459 (14) [back to overview]	Area Under the Effect Curve (AUE) of Change From Baseline in the Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to Placebo
NCT02357459 (14) [back to overview]	AUE of Change From Baseline in Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to TCA IR
NCT02357459 (14) [back to overview]	AUE of Change From Baseline in Weekly Mean of the ADP Scores From Baseline to Week 24 for FX006 Relative to Placebo
NCT02357459 (14) [back to overview]	Change From Baseline to Week 12 in the Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to TCA IR
NCT02357459 (14) [back to overview]	Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores for 32 mg FX006 Versus Placebo
NCT02357459 (14) [back to overview]	Time to Onset of Pain Relief
NCT02357459 (14) [back to overview]	Average Weekly and Total Consumption of Rescue Medications at Each Week (Weeks 1-24)
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for Knee Injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) Subscale at Weeks 4, 8, 12 and 24
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for WOMAC A (Pain Subscale) at Weeks 4, 8, 12, 16, 20 and 24.
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for WOMAC C (Function Subscale) at Weeks 4, 8, 12, 16, 20 and 24
NCT02357459 (14) [back to overview]	Change From Baseline Over Time for WOMAC B (Stiffness Subscale) at Weeks 4, 8, 12, 16, 20 and 24
NCT02357459 (14) [back to overview]	Change From Baseline to Each Week in Weekly Mean of the ADP Scores
NCT02369068 (9) [back to overview]	Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Assessed by Change in Overall Pain Score Using the Visual Analog Scale (VAS).
NCT02369068 (9) [back to overview]	Pain Interference Assessed by Change in Overall Pain and Other Related Scores Using Questions 9A Through 9G in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Interference Assessed by Change in Overall Pain and Other Related Scores Using Questions 9A Through 9G in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Interference Assessed by Change in Overall Pain and Other Related Scores Using Questions 9A Through 9G in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Severity Assessed by Change in Overall Pain and Other Related Scores Using Questions 3, 4, 5, and 6 in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Severity Assessed by Change in Overall Pain and Other Related Scores Using Questions 3, 4, 5, and 6 in the Brief Pain Inventory (BPI) Questionnaire.
NCT02369068 (9) [back to overview]	Pain Severity Assessed by Change in Overall Pain and Other Related Scores Using Questions 3, 4, 5, and 6 in the Brief Pain Inventory (BPI) Questionnaire.
NCT02374060 (15) [back to overview]	Proportion of Eyes With Resolution of Macular Edema at 8 Weeks
NCT02374060 (15) [back to overview]	Change in Best-corrected Visual Acuity at 24 Weeks
NCT02374060 (15) [back to overview]	Change in Best-corrected Visual Acuity at 8 Weeks
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With an IOP Elevation >=24 mm Hg
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With an IOP Elevation >=30 mm Hg
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With an IOP Elevation of >=10 mm Hg Over Baseline
NCT02374060 (15) [back to overview]	Cumulative Proportion of Eyes With Severe Vision Loss
NCT02374060 (15) [back to overview]	Number of Eyes With Endophthalmitis
NCT02374060 (15) [back to overview]	Number of Eyes With Retinal Tear or Detachment
NCT02374060 (15) [back to overview]	Number of Eyes With Vitreous Hemorrhage
NCT02374060 (15) [back to overview]	Proportion of Baseline Central Subfield Thickness Observed at 24 Weeks
NCT02374060 (15) [back to overview]	Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks
NCT02374060 (15) [back to overview]	Proportion of Eyes With >= 20% Reduction in Macular Thickness (or Normalization Even if <20% Reduction) at 24 Weeks
NCT02374060 (15) [back to overview]	Proportion of Eyes With >= 20% Reduction in Macular Thickness (or Normalization Even if <20% Reduction) at 8 Weeks
NCT02374060 (15) [back to overview]	Proportion of Eyes With Resolution of Macular Edema at 24 Weeks
NCT02381652 (1) [back to overview]	Number of Treatment-Emergent Adverse Events: Cingal 13-02 vs. Cingal 13-01
NCT02519738 (1) [back to overview]	Decrease in Size (mm) of Granulation Tissue
NCT02592629 (1) [back to overview]	Change in Pain Assessment
NCT02595398 (3) [back to overview]	Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks
NCT02595398 (3) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02595398 (3) [back to overview]	Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02637323 (4) [back to overview]	Plasma Drug Concentrations (pg/mL) by Time Pooled Across FX006 Cohorts and TCA IR 40 mg Cohort
NCT02637323 (4) [back to overview]	Plasma Drug Concentrations (pg/mL) by Time Pooled Across FX006 Cohorts and TCA IR 40 mg Cohort
NCT02637323 (4) [back to overview]	Synovial Fluid Drug Concentrations (pg/mL) by Time Point Pooled Across FX006 Cohorts and TCA IR in Synovial Fluid
NCT02637323 (4) [back to overview]	Synovial Fluid Drug Concentrations (pg/mL) by Time Point Pooled Across FX006 Cohorts and TCA IR in Synovial Fluid
NCT02680301 (2) [back to overview]	Efficacy of 0.1% Triamcinolone Containing Wet Wrap as an Ointment or as a Cream Formulation in Patients With Moderate to Severe Atopic Dermatitis
NCT02680301 (2) [back to overview]	Number of Patients Adhering to Treatment Protocol
NCT02762370 (7) [back to overview]	Percent Time Blood Glucose Less Than 70 mg/dl, 70 - 180 mg/dl, 180.1 - 250.0 mg/dl, 250.1 - 350.0 mg/dl, and Greater Than 350.0 mg/dl
NCT02762370 (7) [back to overview]	Change in Average Blood Glucose From Baseline (Hour -48 to Hour -1) to Hour 1 to Hour 48 for FX006 32 mg Relative to TCA IR 40 mg.
NCT02762370 (7) [back to overview]	Change From Baseline for Average Blood Glucose (mg/dL)
NCT02762370 (7) [back to overview]	Change From Baseline for Maximum Blood Glucose: Baseline Average Blood Glucose (Hour -72 to Hour -1) to Maximum Blood Glucose (Hour 1 to Hour 72) for FX006 32 mg Relative to TCA IR 40 mg
NCT02762370 (7) [back to overview]	Glycemic Variability Coeffecient of Variation (CV)
NCT02762370 (7) [back to overview]	Area Under the Effect (AUE) Curves for Average Blood Glucose - FX006 Versus TCA IR
NCT02762370 (7) [back to overview]	Percent Time Blood Glucose Less Than 70 mg/dl, 70 - 180 mg/dl, 180.1 - 250.0 mg/dl, 250.1 - 350.0 mg/dl, and Greater Than 350.0 mg/dl
NCT02767492 (5) [back to overview]	Visual Analog Pain Score
NCT02767492 (5) [back to overview]	Single Alpha Numeric Evaluation (SANE)
NCT02767492 (5) [back to overview]	Lysholm Knee Score
NCT02767492 (5) [back to overview]	Knee Injury and Osteoarthritis Outcome Score (KOOS)
NCT02767492 (5) [back to overview]	Veterans Rand 12 Item Health Survey
NCT02781818 (3) [back to overview]	Patient Rating of Impression of Treatment at Day 14
NCT02781818 (3) [back to overview]	Number of Days to Lesion Resolution in Combined Treatment Arms Compared to the Placebo Arm.
NCT02781818 (3) [back to overview]	Change in Pain From Baseline to Day 5
NCT02877485 (2) [back to overview]	Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray)
NCT02877485 (2) [back to overview]	Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery.
NCT02949024 (5) [back to overview]	CLS-TA Injections
NCT02949024 (5) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02949024 (5) [back to overview]	Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
NCT02949024 (5) [back to overview]	Mean Change From Baseline in Intraocular Pressure
NCT02949024 (5) [back to overview]	Best Corrected Visual Acuity
NCT02952001 (4) [back to overview]	Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
NCT02952001 (4) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity
NCT02952001 (4) [back to overview]	Time to Additional Therapy for Uveitis
NCT02952001 (4) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02980874 (3) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT02980874 (3) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity
NCT02980874 (3) [back to overview]	Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
NCT02996097 (2) [back to overview]	Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS)
NCT02996097 (2) [back to overview]	Mean Change in Composite Patient Score for Patient and Observer Scar Assessment Scale (POSAS)
NCT03002974 (25) [back to overview]	Change in Patient-assessed Pain Intensity in the Index Joint From Baseline at Time Points From 6 Hours to 8 Days for the First Gout Flare Treated in the Study as Measured by 5-point Likert Scale
NCT03002974 (25) [back to overview]	Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS
NCT03002974 (25) [back to overview]	Physician's Assessment of Clinical Signs in Index Joint: Tenderness
NCT03002974 (25) [back to overview]	Median Time to Response
NCT03002974 (25) [back to overview]	The Percent of Patients With at Least One Serious Adverse Event, Including Death
NCT03002974 (25) [back to overview]	Median Time to Resolution of Pain
NCT03002974 (25) [back to overview]	Health Care Resource Utilization Due to a Gouty Arthritis Flare
NCT03002974 (25) [back to overview]	Patient´s Assessment of Global Response to Treatment (5-point Likert Scale)
NCT03002974 (25) [back to overview]	Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
NCT03002974 (25) [back to overview]	Change From Baseline in Short Form (36) Health Survey, Acute Version 2 (SF-36®) Physical Functioning Domain Score
NCT03002974 (25) [back to overview]	Median Time to First Intake of Rescue Medication From First Investigational Drug Administration
NCT03002974 (25) [back to overview]	Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
NCT03002974 (25) [back to overview]	Percent Impairment While Working During Last Week Due to Gout During the First Flare and Subsequent Flares
NCT03002974 (25) [back to overview]	Physician's Assessment of Clinical Signs in Index Joint: Erythema
NCT03002974 (25) [back to overview]	Change From Baseline in Health Related Quality of Life EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
NCT03002974 (25) [back to overview]	Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra
NCT03002974 (25) [back to overview]	The Percent of Patients With at Least One Adverse Event
NCT03002974 (25) [back to overview]	Change From Baseline in the Inflammatory Biomarker C Reactive Protein
NCT03002974 (25) [back to overview]	Change From Baseline in the Inflammatory Biomarker Serum Amyloid A
NCT03002974 (25) [back to overview]	Median Time to Onset of Effect
NCT03002974 (25) [back to overview]	Physician's Assessment of Global Response to Treatment
NCT03002974 (25) [back to overview]	Proportion of Patients With Anti-drug Antibodies (ADA) Against Anakinra
NCT03002974 (25) [back to overview]	Proportion of Patients With Neutralizing Antibodies
NCT03002974 (25) [back to overview]	Serum Concentration of Endogenous Interleukin-1 Receptor Antagonist /Anakinra
NCT03002974 (25) [back to overview]	Physician's Assessment of Clinical Signs in Index Joint: Swelling
NCT03097315 (5) [back to overview]	Mean Intraocular Pressure in the Study Eye
NCT03097315 (5) [back to overview]	Number of Patients With a Grade of 0 in Anterior Chamber Cells in the Study Eye
NCT03097315 (5) [back to overview]	Number of Patients With a Grade of 0 in Anterior Chamber Flare in the Study Eye
NCT03097315 (5) [back to overview]	Number of Patients With a Grade of 0 in Vitreous Haze in the Study Eye
NCT03097315 (5) [back to overview]	Adverse Events
NCT03126786 (2) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity Letter Score
NCT03126786 (2) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT03127137 (1) [back to overview]	Change in Strength in Both Groups After CESI.
NCT03191903 (11) [back to overview]	Change From Baseline in Patient Global Assessment at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in the Evaluator Global Assessment at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in Total WOMAC Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 1 Week (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 3 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Pain Score at 3 Weeks in the Per-Protocol Population
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Physical Function Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	Change From Baseline in WOMAC Stiffness Score at 26 Weeks (ITT Population)
NCT03191903 (11) [back to overview]	OMERACT-OARSI Responder Index at 26 Weeks Post Treatment Comparing the Cingal Group to the TH Group (ITT Population)
NCT03191903 (11) [back to overview]	The Usage of Rescue Medication (Acetaminophen) Through 26 Weeks (ITT Population)
NCT03203447 (3) [back to overview]	Mean Change From Baseline in Best Corrected Visual Acuity
NCT03203447 (3) [back to overview]	Mean Change From Baseline in Central Subfield Thickness
NCT03203447 (3) [back to overview]	Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)
NCT03378076 (2) [back to overview]	Incidence of Treatment Emergent Adverse Events
NCT03378076 (2) [back to overview]	Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
NCT03380026 (3) [back to overview]	Severity of Dermatitis
NCT03380026 (3) [back to overview]	Efficacy of Valchlor vs Valchlor Plus Triamcinolone
NCT03380026 (3) [back to overview]	Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring
NCT03382262 (2) [back to overview]	Total Number of Treatment Emergent Adverse Events
NCT03382262 (2) [back to overview]	Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
NCT03382821 (4) [back to overview]	"The Percentage of Participants Reporting Patient Global Impression of Change Score of 6-7 (Indicating Much Improved and Very Much Improved)"
NCT03382821 (4) [back to overview]	Neck Disability Index-5
NCT03382821 (4) [back to overview]	Percentage of Participants Reporting >6.8 Reduction on the Medication Quantification Scale III
NCT03382821 (4) [back to overview]	The Percentage of Participants With Reduction of 50% or More of Neck and Arm Pain NRS Score
NCT03390036 (8) [back to overview]	Change From Baseline in Patient Global Assessment at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in WOMAC Physical Function Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in WOMAC Pain Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in Total WOMAC Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in WOMAC Stiffness Score at 39 Weeks
NCT03390036 (8) [back to overview]	Change From Baseline in Evaluator Global Assessment at 39 Weeks
NCT03390036 (8) [back to overview]	The Usage of Rescue Medication (Acetaminophen) at Week 39
NCT03390036 (8) [back to overview]	OMERACT-OARSI Responder Rate at 39 Weeks
NCT03463915 (7) [back to overview]	Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire
NCT03463915 (7) [back to overview]	Change From Baseline in Treatment Response as Measured by the Visual Analogue Scale (VAS) for Pain
NCT03463915 (7) [back to overview]	Number of Participants With at Least One Adverse Event
NCT03463915 (7) [back to overview]	Pelvic Floor Distress Inventory (PFDI)
NCT03463915 (7) [back to overview]	Pelvic Pain and Urgency/Frequency (PUF) Questionnaire
NCT03463915 (7) [back to overview]	Sexual Function Measured by the Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR) Questionnaire
NCT03463915 (7) [back to overview]	Overactive Bladder Questionnaire (OAB-q)
NCT03636373 (4) [back to overview]	Patient's Assessment of Response to Treatment
NCT03636373 (4) [back to overview]	Physician's Assessment of Response to Treatment
NCT03636373 (4) [back to overview]	Joint Pain on Numeric Pain Scale
NCT03636373 (4) [back to overview]	Joint Pain Intensity in the Most Affected Joint
NCT03758365 (2) [back to overview]	Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle
NCT03758365 (2) [back to overview]	Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
NCT03797872 (1) [back to overview]	Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study
NCT03895840 (6) [back to overview]	30 Second Chair Standing Test
NCT03895840 (6) [back to overview]	KOOS-PS (Knee Osteoarthritis Outcome Score - Physical Function Short Form)
NCT03895840 (6) [back to overview]	KOOS-QoL (Knee Osteoarthritis Outcome Score - Quality of Life)
NCT03895840 (6) [back to overview]	NRS for Pain
NCT03895840 (6) [back to overview]	Timed Stair Climb
NCT03895840 (6) [back to overview]	40m Fast Paced Walking Test (40m FPWT)
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04115644 (8) [back to overview]	Visual Analog Scale
NCT04216017 (2) [back to overview]	Visual Analogue Scale
NCT04216017 (2) [back to overview]	American Shoulder Elbow Society Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total Score
NCT04231318 (15) [back to overview]	The Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index
NCT04231318 (15) [back to overview]	The Usage of Rescue Medication (Acetaminophen/Paracetamol) at 26 Weeks
NCT04231318 (15) [back to overview]	Change From Baseline in Knee Pain as Measured by Numerical Rating Scale (NRS) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Evaluator Global Assessment (EGA) Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Patient Global Assessment (PGA) Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in Knee Pain as Measured by Visual Analog Scale (VAS) Pain Score
NCT04231318 (15) [back to overview]	Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Stiffness Score
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT04582669 (5) [back to overview]	Percentage of Subjects Reporting Thinning and/or Atrophy of the Skin, Acneiform Lesion(s), Capillary Dilation(s), and Dyschromia When Compared to Baseline.
NCT05438277 (1) [back to overview]	Incidence of a Flare Reaction

Adverse Ocular Outcomes

(NCT00105027)
Timeframe: 12 months

,,,,,

Intervention	events (Number)
	Initiation of IOP-lowering medications	IOP > 35 mm HG	IOP > 10 mm HG above baseline	Laser peripheral iridotomy	Trabeculectomy	Tube shunt	Cataract: lens opacity onset or progression	Cataract surgery	Infectious endophthalmitis	Noninfectious endophthalmitis	Retinal detachment	Iris neovascularization	Retinal neovascularization	Vitreous hemorrhage	YAG capsulotomy	Sector or panretinal photocagulation	Pars plana vitrectomy
BRVO 1 mg Dose Triamcinolone Acetonide	11	2	12	0	0	0	27	0	0	0	1	1	1	1	0	1	0
BRVO 4 mg Dose Triamcinolone Acetonide	57	14	50	1	0	0	38	4	1	0	0	2	3	3	1	4	1
BRVO Standard Care	3	1	1	0	0	0	15	3	0	0	1	1	5	2	1	5	1
CRVO 1 mg Dose Triamcinolone Acetonide	18	5	15	0	0	2	20	0	0	0	0	9	2	4	0	9	2
CRVO 4 mg Dose Triamcinolone Acetonide	32	8	24	1	0	0	25	4	0	0	0	4	2	0	0	3	0
CRVO Observation	7	1	2	0	0	0	12	0	0	0	0	2	4	4	1	5	1

Intervention	um (Median)
CRVO Observation	-277
CRVO 1 mg Dose Triamcinolone Acetonide	-196
CRVO 4 mg Dose Triamcinolone Acetonide	-261
BRVO Standard Care	-224
BRVO 1 mg Dose Triamcinolone Acetonide	-149
BRVO 4 mg Dose Triamcinolone Acetonide	-170

Intervention	letters read (Mean)
CRVO Observation	-12.1
CRVO 1 mg Dose Triamcinolone Acetonide	-1.2
CRVO 4 mg Dose Triamcinolone Acetonide	-1.2
BRVO Standard Care	4.2
BRVO 1 mg Dose Triamcinolone Acetonide	5.7
BRVO 4 mg Dose Triamcinolone Acetonide	4.0

Intervention	Participants (Number)
	Participants who received 1 treatment	Participants who received 2 treatments	Participants who received 3 treatments	Participants who received 4 treatments
Verteporfin + 1 mg Triamcinolone	11	10	9	2
Verteporfin + 4 mg Triamcinolone	12	15	12	2
Verteporfin + Pegaptanib	10	19	5	4

Intervention	Percentage of Participants (Number)
Verteporfin + 1 mg Triamcinolone	59.4
Verteporfin + 4 mg Triamcinolone	63.4
Verteporfin + Pegaptanib	71.1

Intervention	Percentage of Participants (Number)
Verteporfin + 1 mg Triamcinolone	31.3
Verteporfin + 4 mg Triamcinolone	12.2
Verteporfin + Pegaptanib	28.9

Intervention	Percentage of Participants (Number)
Verteporfin + 1 mg Triamcinolone	18.8
Verteporfin + 4 mg Triamcinolone	2.4
Verteporfin + Pegaptanib	23.7

Intervention	mm^2 (Mean)
	Baseline	12 Months	Change from Baseline
Verteporfin + 1 mg Triamcinolone	6.9178	6.8959	-0.0219
Verteporfin + 4 mg Triamcinolone	5.6400	5.8149	0.1749
Verteporfin + Pegaptanib	6.3011	8.6245	2.3234

Intervention	participants (Number)
	Frequency - Missing	Frequency - Better	Frequency - Same	Frequency - Worse	Severity - Missing	Severity - Better	Severity - Same	Severity - Worse
Placebo	1	14	21	4	1	14	16	9
Triamcinolone Acetonide	0	10	13	15	0	15	8	15

Intervention	ears (Number)
	Initial Tympanogram of Type B or C	6 weeks Complete Normalization (Type A)
Placebo	57	20
Triamcinolone Acetonide	55	12

Intervention	Percentage of Eyes (Number)
Focal/Grid Laser Photocoagulation	53
1mg Intravitreal Triamcinolone	34
4 mg Intravitreal Triamcinolone	38

Intervention	Microns (Mean)	Microns (Median)
Focal/Grid Laser Photocoagulation	-175
1mg Intravitreal Triamcinolone	-124
4 mg Intravitreal Triamcinolone	-126
Focal/Grid Laser Photocoagulation	-158
1mg Intravitreal Triamcinolone	-103
4 mg Intravitreal Triamcinolone	-114

Intervention	Microns (Mean)
Focal/Grid Laser Photocoagulation	-139
1mg Intravitreal Triamcinolone	-86
4 mg Intravitreal Triamcinolone	-77

Intervention	Microns (Median)
Focal/Grid Laser Photocoagulation	-131
1mg Intravitreal Triamcinolone	-74
4 mg Intravitreal Triamcinolone	-76

Intervention	Percentage of Eyes (Number)
	>= 15 letters better	10-14 letters better	5-9 letters better	no change, + - 4 letters	5-9 letters worse	10-14 letters worse	>=15 letters worse
1mg Intravitreal Triamcinolone	20	4	17	23	10	9	17
4 mg Intravitreal Triamcinolone	21	16	9	24	6	6	16
Focal/Grid Laser Photocoagulation	26	18	18	21	4	4	8

Intervention	Percentage of Eyes (Number)
	>= 15 letter improvement	14 to 10 letter improvement	9 to 5 letter improvement	same +- 4 letters	5-9 letters worse	10-14 letters worse	>=15 letters worse
1mg Intravitreal Triamcinolone	14	11	14	27	9	6	20
4 mg Intravitreal Triamcinolone	17	11	15	23	6	8	20
Focal/Grid Laser Photocoagulation	18	13	16	24	10	5	14

Intervention	microns (Mean)
	4 Weeks	8 Weeks	17 Weeks	34 Weeks
Anterior Peribulbar Injection of 20 mg Triamcinolone	-27	-38	-50	-45
Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser	-37	-44	-49	-68
Focal Laser Photocoagulation	-10	-27	-30	-54
Posterior Peribulbar Injection of 40 mg Triamcinolone	-47	-29	-24	-31
Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser	-16	-25	-52	-45

Intervention	eyes (Number)
	Eyes that were retreated	Eyes with ≥ 250 central subfield thickness
Anterior Peribulbar Injection of 20 mg Triamcinolone	14	16
Anterior Peribulbar Injection of 20 mg Triamcinolone + Laser	9	13
Focal Laser Photocoagulation	22	26
Posterior Peribulbar Injection of 40 mg Triamcinolone	15	14
Posterior Peribulbar Injection of 40 mg Triamcinolone + Laser	9	11

Intervention	Units on a scale (Mean)
	Pain VAS at Baseline	Pain VAS at 26 weeks
Bupivicaine	57.1	42.9
Hylan G-F 20	60.7	49.8
Triamcinolone	63.2	50.1

Intervention	units on a scale (Mean)
	DASH at Baseline	Dash at 26 Weeks
Bupivicaine	25.7	24.2
Hylan G-F 20	28.8	26.1
Triamcinolone	28.9	27.0

Intervention	Eyes (Number)
Sham+Prompt Laser	72
0.5 mg Ranibizumab+Prompt Laser	91
0.5 mg Ranibizumab+Deferred Laser	74
4 mg Triamcinolone+Prompt Laser	82

triamcinolone acetonide

Description

Cross-References

Synonyms (241)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (8)

Protein Targets (44)

Potency Measurements

Inhibition Measurements

Biological Processes (221)

Molecular Functions (75)

Ceullar Components (46)

Bioassays (100)

Research

Studies (5,624)

Market Indicators

Research Demand Index: 113.77

Study Types

Clinical Trials (357)

Trial Overview

Trial Outcomes

Adverse Ocular Outcomes

Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography

The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit

Changes From Baseline in Best-corrected ETDRS Visual Acuity Score

Number of Participants Requiring Verteporfin Treatment Throughout the Study

Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.

Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12

Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months

Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12

Mean Change From Baseline in Total Area of Lesion at 12 Months

Complete Normalization of Abnormal Tympanometry Considering the Subjects Who Took Additional Treatment as Having Incomplete Resolution

Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment

Number of Subjects With Change in Symptom Frequency and Severity - Plugged Sensation in Ears

Number of Subjects With Change in Symptom Frequency and Severity - Dampened Hearing/Loss Worse Than Usual

Number of Subjects With Change in Symptom Frequency and Severity - Pain in Ears

Number of Subjects With Change in Symptom Frequency and Severity - Popping Sensation in Ears

Per-Ear Treatment Outcome

Number of Subjects With Change in Symptom Frequency and Severity - Fullness or Pressure in Ears

Central Subfield Thickness < 250 Microns at 2 Years

Central Subfield Thickness at 2 Years

Central Subfield Thickness on Optical Coherence Tomography (OCT) at Three Years

Change in Central Subfield Thickness on OCT Baseline to 3 Years

Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.

Change in Visual Acuity From Baseline to 3 Years

Change in Visual Acuity From Baseline to 3 Years

Mean Change in Central Subfield Thickness Baseline to 2 Years

Median Change in Central Subfield Thickness Baseline to 2 Years

Median Change in Visual Acuity Baseline to 2 Years

Overall Central Subfield Thickening Decreased by >=50% Baseline to 2 Years

Percentage of Eyes With a Change in Central Subfield Thickness on OCT <250 Microns From Baseline to 3 Years

Distribution of Visual Acuity Change Baseline to 3 Years

Distribution of Change in Visual Acuity Baseline to 2 Years

Change in Central Subfield Thickening From Baseline Through 34 Weeks

Reduction of ≥ 50% in Retinal Thickening in the Central Subfield From Baseline Through 34 Weeks

Central Subfield Thickness <250 Microns From Baseline Through 34 Weeks

Persistence/Recurrence of Diabetic Macular Edema (DME) Either Retreated or Meeting Criteria for Retreatment at 17 Weeks

Change in Visual Acuity Letter Score From Baseline Through 34 Weeks

Mean Visual Acuity Letter Score at Each Follow-up Visit

Pain Visual Analogue Scale (VAS)

Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire

Central Subfield Thickness < 250 With at Least a 25 Micron Decrease From Baseline to 1 Year

Change in Retinal Thickening of Central Subfield on Optical Coherence Tomography From Baseline to 1 Year

Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year

Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity

Mean Optical Coherence Tomography Retinal Volume at 1 Year

Number of Injections in First Year

Percentage of Eyes Receiving Laser at the 48 Week Visit (%)

Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year

Change From Moderately Severe Non-proliferative Diabetic Retinopathy or Better From Baseline to 1-year

Intervention	microns (Mean)
Sham+Prompt Laser	-102
0.5 mg Ranibizumab+Prompt Laser	-131
0.5 mg Ranibizumab+Deferred Laser	-137
4 mg Triamcinolone+Prompt Laser	-127

Intervention	mm^3 (Mean)
Sham+Prompt Laser	-1.0
0.5 mg Ranibizumab+Prompt Laser	-1.4
0.5 mg Ranibizumab+Deferred Laser	-1.5
4 mg Triamcinolone+Prompt Laser	-1.4

Intervention	Participants (Number)
	Nonfatal myocardial infarction	Nonfatal cerebrovascular accident	Vascular death	Any ATC cardiovascular event
Ranibizumab	1	3	7	11
Sham	3	5	4	10
Triamcinolone	2	1	2	5

Intervention	Eyes (Number)
	Improved by 2 or more levels	Worsened by 2 or more levels
Ranibizumab	46	5
Sham	6	11
Triamcinolone	20	2

Intervention	Letters (Mean)
	Not pseudophakic at baseline	Pseudophakic at baseline
0.5 mg Ranibizumab+Deferred Laser	10	7
0.5 mg Ranibizumab+Prompt Laser	9	8
4 mg Triamcinolone+Prompt Laser	2	8
Sham+Prompt Laser	2	4

Intervention	Letters (Mean)
	≥66 (better than 20/50)	≤65 (20/50 or worse)
0.5 mg Ranibizumab+Deferred Laser	5	13
0.5 mg Ranibizumab+Prompt Laser	6	12
4 mg Triamcinolone+Prompt Laser	1	7
Sham+Prompt Laser	1	5

Intervention	Letters (Mean)
	Moderately severe non-proliferative DR or better	Severe non-proliferative DR or worse
0.5 mg Ranibizumab+Deferred Laser	9	9
0.5 mg Ranibizumab+Prompt Laser	10	8
4 mg Triamcinolone+Prompt Laser	3	5
Sham+Prompt Laser	3	2

Intervention	Letters (Mean)
	Typical/predominantly focal	Neither predominantly focal nor diffuse	Typical/predominantly diffuse
0.5 mg Ranibizumab+Deferred Laser	8	8	10
0.5 mg Ranibizumab+Prompt Laser	8	10	9
4 mg Triamcinolone+Prompt Laser	3	3	5
Sham+Prompt Laser	3	2	3

Intervention	Letters (Mean)
	<400 microns	≥400 microns
0.5 mg Ranibizumab+Deferred Laser	7	11
0.5 mg Ranibizumab+Prompt Laser	7	11
4 mg Triamcinolone+Prompt Laser	3	6
Sham+Prompt Laser	3	3

Intervention	Eyes (Number)
	≥15 letter improvement	14-10 letter improvement	9-5 letter improvement	Same ±4 letters	5-9 letters worse	10-14 letters worse	≥15 letters worse
0.5 mg Ranibizumab+Deferred Laser	52	36	54	35	5	2	4
0.5 mg Ranibizumab+Prompt Laser	57	38	34	38	14	3	3
4 mg Triamcinolone+Prompt Laser	39	22	32	54	12	12	15
Sham+Prompt Laser	43	38	67	86	20	16	23